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Summary 
There is an urgent need for the development of effective antibacterial coatings to 
cope with more and more resistant bacterial strains in medical environments, and 
particularly to prevent nosocomial infections following bone implant surgery. There 
are two main approaches to tackle this important issue: (I) directly prevent bacterial 
infection by the use of antibacterial coatings or (II) indirectly avoid bacteria 
proliferation by enhancing pre-osteoblast attachment, proliferation and 
differentiation in order to get a faster osseointegration of the implant and form the 
protective capsule, which would avoid infection, as fast as possible. 
This thesis presents different approaches for mesoporous titania film (MTF) 
fuctionalization with growth factors and antibiotics. Antibiotics are incorporated to 
the coating alone or by means of complex assembly in polyelectrolyte multilayers 
(PEMs). Also, bioactive ions can boost the proliferation and differentiation 
processes of pre-osteoblasts. They can be directly incorporated to the tiania matrix 
or be complexed on the pore walls that have been previously functionalized with 
carboxylic groups.  
In Chapter 1, MTFs are used for gentamicin loading and delivery, and surface 
functionalization with recombinant human Bone Morphogenetic Protein 2 (rhBMP-
2). MTFs are synthesized by spin coating on top of rounded glass coverslips through 
the evaporation induced self-assembly (EISA) method. The resulting film has a 
thickness of 80 nm with pores of 5.7 nm in diameter connected by necks of 4.2 nm. 
They show a porosity of a 30.7 %, obtained by Environmental Ellipsometric 
Porosimetry (EEP). The elastic modulus the MTFs is of 25.5 ± 5 GPa, which makes 
the coating optimal for bone implants. 
Gentamicin is incorporated in the MTF pores by immersion of the porous materials 
in gentamicin solution while rhBMP-2 is adsorbed electrostatically on top of the 
MTF. Contact angle and X-ray Photoelectron Spectroscopy (XPS) measurements are 
performed to prove gentamicin loading and rhBMP-2 functionalization. An initial 
burst release of gentamicin takes place in physiological media, and the 36 % of the 
total released gentamicin is liberated, followed by a prolonged release that lasts 
weeks. Such a release profile is highly appealing for bone implants where a high 
concentration of antibiotics is necessary during implant surgery while a lower 
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antibiotic concentration is needed until tissue is regenerated. The MTF loaded with 
gentamicin and functionalized with rhBMP-2 are effective against S. aureus 
colonization and the presence of rhBMP-2 enhances MC3T3-E1 pre-osteoblastic cell 
attachment, proliferation and differentiation, which are slowed down when 
gentamicin is present. 
In Chapter 2, polyelectrolyte multilayers (PEMs) based on poly-L-lysine (PLL) and 
complexes of poly (acrylic acid) (PAA) and gentamicin have been fabricated 
applying the layer-by-layer (LbL) technique. The PEM is assembled on top of MTFs. 
Complexes are prepared by mixing PAA and gentamicin solutions in 500 mM NaCl 
at pH 4.5. The most stable complexes are obtained in these experimental conditions. 
The assembly of PLL and the complexes follows an exponential growth allowing a 
high loading of gentamicin in a 4 bilayer PEM. The PEM is stable till pH 13 meaning 
that it does not degrade at physiological pH, besides; there is a continuous release 
of gentamicin at pH 7.4. PEMs show an initial burst release of gentamicin in the first 
6 hours, which liberates 48 % of the total gentamicin, followed by a sustainable 
release lasting over weeks, where around 80 % of the total gentamicin inside the 
PEM is released. PEMs are effective in preventing the proliferation of S. aureus. 
Bacteria grown on top of the PEM is 3 orders of magnitude lower than on glass 
coverslips immersed in gentamicin, used as control. 
In Chapter 3, strontium titanate mesoporous films (SrTiMFs) with 30 % pore 
volume and a 20 % Strontium (Sr) molar content have been prepared by the EISA 
method. The resulting films have a pore diameter of 5.5 nm connected by 
bottlenecks of 3.2 nm and have a thickness of 85 nm. SrTiMFs display a large internal 
surface area available for exchange of Sr. Sr release is followed through Inductively 
Coupled Plasma Mass Spectrometry (ICP-MS) measurements. A 44 % of the Sr inside 
the titania matrix is released in the cell media within the first 8 h.  
SrTiMFs improve attachment of MC3T3-E1 pre-osteoblastic cells, which show larger 
filopodia and more elongated features than cells attached to plain MTFs. Cell 
proliferation and differentiation rates are also largely improved. Overall, Sr 
incorporation in mesoporous titania coatings can lead to an enhanced 
osseointegration at early stages of tissue formation, at day 2 the cell proliferation is 
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64 % higher if compared to cells grown on top of MTFs and the alkaline phosphatase 
(AP) activity is higher from the 5th day of osteogenic cell culture. 
In Chapter 4, inorganic−organic hybrid mesoporous silica and titania thin films with 
covalently bonded carboxylic acid groups are synthesized. Silica films are produced 
in one-step synthesis using carboxylic derivatized alkoxysilanes obtained by 
photochemical radical thiol-ene addition (PRTEA). The organosilanes are 
synthesized by clicking mercaptosuccinic (MSA) or mercaptoacetic (MAA) thioacids 
with vinyltrimethoxysilane (VTMS), using benzophenone as the photoradical 
initiator. Films are synthesized by EISA from a sol containing a mixture of 
tetraethoxysilane and different quantities of the organosilanes, without any further 
treatment after the PRTEA reaction. Titania films are synthesized in two steps; the 
sol is prepared mixing VTMS and the Ti precursor, and after film synthesis, the 
photochemical reaction with the MSA incorporates the carboxylic groups to the 
mesoporous film surface. 
Structural characterization with electron microscopy, porosimetry measurements, 
and Small Angle X-ray Scattering with two-dimensional (2D-SAXS) detection 
confirm mesoporous phases of silica films whose degree of ordering depended on 
the amount of added organosilane. The incorporation of the functional vinyl and 
carboxyl groups is shown by XPS, and the presence of the COOH groups is confirmed 
by Diffuse Reflectance Infrared Fourier Transform Spectroscopy (DRIFTS). The 
availability of the COOH groups for further chemical modification is demonstrated 
by DRIFTS by following the changes in the typical carbonyl IR bands during proton 
exchange and metal complexation. Pb2+ is complexed to silica films, while Sr2+ is 
complexed to titania films. Sr release experiments show a prolonged release of Sr2+ 
lasting a week which enhances proliferation and differentiation processes in the 
MC3T3-E1 pre-osteoblastic cell line. 
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Resumen 
Cada vez hay más cepas bacterianas resistentes a antibióticos y su presencia en 
entornos médicos supone un riesgo cuando los pacientes son sometidos a una 
intervención quirúrgica. Cuando una persona es sometida a una cirugía para la 
sustitución de un hueso por un implante hay riesgo de desarrollar una infección 
nosocomial y no conseguir una buena osteointegración del implante. En estos casos, 
es necesario realizar una segunda cirugía para evitar la proliferación de la infección 
en la zona donde se sitúa el implante, siendo necesaria su sustitución.  
En la actualidad, para evitar infecciones se suministran antibióticos oralmente; su 
mayor desventaja es que la concentración que llega a la zona deseada, en este caso 
el implante, es baja, y en muchos casos no es lo suficientemente alta para evitar la 
proliferación bacteriana. En este marco surge la necesidad de desarrollar 
recubrimientos antibacterianos efectivos. Hay dos rutas principales para conseguir 
una buena osteointegración del implante; (I) evitar la proliferación bacteriana 
empleando superficies antibacterianas, esta sería la forma más directa, y (II) se 
puede evitar de una manera indirecta la infección mejorando la adhesión de pre-
osteoblastos al implante, lo que hará que se forme la cápsula protectora más 
rápidamente evitando así la proliferación bacteriana y consiguiendo una rápida 
proliferación y diferenciación celular. 
Esta tesis presenta diferentes métodos de funcionalización de películas de titania 
mesoporosa mediante el uso de antibióticos y factores de crecimiento. Es posible 
incorporar antibióticos directamente, por inmersión, o también se pueden formar 
complejos con el antibiótico y ensamblar una película basada en multicapas de 
polielectrolitos (PEM, por sus siglas en inglés). Los iones bioactivos pueden 
estimular procesos celulares como la proliferación y diferenciación en pre-
osteoblastos. Estos iones se pueden incorporar a la matriz de titania o complejarse 
en las paredes del film mesoporoso que se ha funcionalizado previamente con 
grupos carboxilo. 
En el Capítulo 1, se utilizan películas mesosporosas de titania para encapsular y 
liberar controladamente gentamicina. La superficie mesoporosa se funcionaliza con 
la proteína morfogenética ósea recombinante humana 2 (rhBMP-2, por sus siglas en 
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inglés). La gentamicina es un antibiótico de amplio espectro que se emplea en 
infecciones serias que han podido ser causadas tanto por bacterias gram negativas 
como positivas; como P. aureginosa, E. Coli o Citrobacter, Estreptococos o 
Estafilococos. La gentamicina es un aminoglucósido y por tanto su mecanismo de 
acción consiste en unirse al ARN ribosomal de la subunidad 30S de los ribosomas 
bacterianos, interfiriendo así en la síntesis proteica. La rhBMP-2 es una proteína 
ósea, y se ha demostrado que promueve la formación ósea y se emplea para 
reconstruir defectos óseos patológicos. 
 Las películas se sintetizan mediante recubrimiento por centrifugación sobre 
cubreobjetos de vidrio a través del método de autoensamblaje inducido por 
evaporación (EISA, por sus siglas en inglés). La película obtenida tiene un espesor 
de 80 nm con poros de 5.7 nm de diámetro conectados por cuellos de 4.2 nm de 
diámetro. Muestran una porosidad del 30.7 %, obtenida por Porosimetría 
Elipsométrica Ambiental (EEP, por sus siglas en inglés). El módulo de elasticidad de 
las películas se midió por nanoindentación, resultando tener un valor de 25,5 ± 5 
GPa, lo que hace que la superficie sea óptima para su uso en implantes óseos. A pesar 
de que las superficies de titania densa muestran un módulo de elasticidad en el 
rango de 100 a 120 GPa, mayor que el de películas mesoporosas de titania, el módulo 
elástico del hueso varía entre 4 y 30 GPa, donde se encuentra el valor de las películas 
mesoporosas. 
La gentamicina se incorpora en los poros por inmersión, mientras que la rhBMP-2 
se adsorbe electrostáticamente sobre la superficie de la película. Mediante medidas 
de ángulo de contacto y Espectroscopía Fotoelectrónica de Rayos-X (XPS, por sus 
siglas en inglés) se prueba la presencia de gentamicina y rhBMP-2. Se observa que 
la liberación de la gentamicina del interior de los poros de la película ocurre en dos 
fases; al inicio un 36 % de la gentamicina encapsulada se libera rápidamente, 
seguida por una segunda fase que ocurre más prolongadamente y que dura semanas. 
Este perfil de liberación resulta óptimo en implantes óseos donde es necesaria una 
alta concentración de antibiótico durante la cirugía y en las horas posteriores, 
viéndose necesaria su disminución cuando el tejido óseo se está formando. Las 
películas en base a titania funcionalizadas con gentamicina y rhBMP-2 han resultado 
ser eficaces contra la colonización por S. aureus. Cuando se sembraron 1,000 
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unidades formadoras de colonias (UFC), éstas no proliferaron, demostrando la 
eficacia de la gentamicina que se libera del interior poroso de la película. La 
presencia de rhBMP-2 mejora la adhesión celular, evaluada con la línea celular pre-
osteoblástica MC3T3-E1, lo que contrarresta el efecto que la gentamicina tiene en la 
proliferación y diferenciación celular. Después de 10 días de cultivo en medio 
osteogénico la diferenciación celular es el doble si se compara con películas 
mesporosas no funcionalizadas. 
En el Capítulo 2, se fabrican multicapas en base a poli-L-lisina (PLL) y complejos de 
ácido poli(acrílico) (PAA) y gentamicina mediante la técnica de ensamblado capa 
por capa (LbL, por sus siglas en inglés). La técnica LbL consiste en la adsorción 
sucesiva de polielectrolitos con carga opuesta mediante interacciones 
electrostáticas. La multicapa se fabrica sobre películas mesoporosas de titania. Los 
complejos se preparan mezclando PAA y gentamicina en 500 mM NaCl a pH 4.5 con 
el objetivo de obtener complejos de tamaño estable. Se necesitan aproximadamente 
2 h para fabricar la multicapa, y los complejos se estabilizan durante 2 h, después de 
mezclar el PAA con la gentamicina. Una vez han transcurrido estas 2 h se comienza 
a fabricar la multicapa. El tamaño de los complejos se mantiene estable durante la 
formación de la multicapa con un tamaño alrededor de 300 nm de diámetro. El 
ensamblado del PLL y los complejos sigue un crecimiento exponencial, observado 
cuando el ensamblado es monitoreado en la Microbalanza de Cristal de Cuarzo con 
monitoreo de la disipación (QCM-D, por sus siglas en ingles), permitiendo una alta 
carga de gentamicina en una PEM de únicamente 4 capas. Las imágenes de 
Microscopía Electrónica de Barrido (SEM, por sus siglas en ingles) y Microscopía de 
Fuerza Atómica (AFM, por sus siglas en ingles) demuestran que la superficie del 
ensamblado es irregular, lo que unido al crecimiento exponencial observado por 
QCM-D, da lugar a asociar este tipo de crecimiento a un crecimiento por “islas” 
descrito previamente en otros trabajos. Hasta pH 13 la PEM es estable, sin embargo, 
a pH fisiológico la gentamicina se libera. El 48 % de la gentamicina total es liberada 
en las 6 primeras horas, dando lugar después a una liberación paulatina del 80 % 
que dura más de un mes.  
Para estudiar la actividad de la gentamicina liberada de la multicapa se siembran 
1,000 UFC de S. aureus sobre las multicapas y sobre los sustratos control, que 
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consisten en cubreobjetos de vidrio sumergidos en gentamicina. Se incuban las 
bacterias durante 24 h y posteriormente se despegan las que se han adherido y se 
siembran sobre placas de agar, para proceder al conteo visual de las UFC después de 
dejarlas crecer una noche (aproximadamente 18 h). Las multicapas sintetizadas son 
eficaces para prevenir la proliferación de la S. aureus, en comparación con el control, 
la cantidad de bacterias que crecen sobre la multicapa son 3 órdenes de magnitud 
inferior. 
En el Capítulo 3, se preparan películas mesoporosas de titanato de estroncio 
(SrTiMFs) con un 30 % de volumen poroso y un contenido molar de estroncio (Sr) 
del 20 %. Las películas presentan un diámetro de poro de 5,5 nm conectados por 
cuellos de 3,2 nm y tienen un espesor de 85 nm. Los SrTiMFs muestran una gran 
área superficial interna disponible para el intercambio de Sr. Los espectros 
obtenidos en diferentes zonas de la película por Microscopía Electrónica de Barrido 
por Transmisión (STEM, por sus siglas en inglés) han demostrado que el Sr se 
encuentra distribuido homogéneamente en la estructura de titania y no se observan 
agregados o islas de Sr. 
La liberación del estroncio se monitorea mediante mediciones de Espectrometría de 
Masas de Plasma Acoplado Inductivamente (ICP-MS, por sus siglas en inglés). Los 
resultados indican que en las 8 primeras horas el 44 % del Sr que contenía la película 
es liberado al medio celular. Después de las 8 horas, se observa que más Sr se libera, 
pero en cantidades inferiores, y debido a que no se ha liberado el 100 % se espera 
que haya una liberación más lenta y paulatina. 
Los SrTiMFs mejoran la adhesión de pre-osteoblastos mostrando una mayor 
filopodia, se observa que las células están más alargadas, si se compara con células 
cultivadas sobre sustratos de titania que no contienen estroncio.  Las tasas de 
proliferación y diferenciación celular también mejoran gracias a la presencia de 
estroncio. En general, la incorporación de Sr en los recubrimientos de titania 
mesoporosa puede dar lugar a una más pronta osteointegración en las etapas 
tempranas de formación de tejido óseo. En el segundo día, la proliferación celular es 
en un 64% mayor, comparada con la proliferación celular sobre sustratos sin 
estroncio, y la actividad de la alcalina fosfatasa también es mayor después del quinto 
día de cultivo en medio osteogénico. 
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En el Capítulo 4, se sintetizan películas híbridas de sílice inorgánica-orgánica 
mesoporosa y de titania con grupos funcionales de ácido carboxílico 
covalentemente unido a las paredes de los poros. Las películas de sílice se fabrican 
en un solo paso utilizando alcoxisilanos derivados de ácidos carboxílicos obtenidos 
mediante la reacción clic de adición radicalaria tiol-eno iniciada fotoquímicamente 
(PRTEA, por sus siglas en inglés). Los organosilanos se preparan mediante una 
reacción clic entre tioácidos mercaptosuccínicos (MSA, por sus siglas en inglés) o 
mercaptoacéticos (MAA, por sus siglas en inglés) y el viniltrimetoxisilano (VTMS, 
por sus siglas en inglés). Las películas se sintetizan mediante EISA a partir de una 
solución que contiene una mezcla de tetraetoxisilano y diferentes cantidades de 
organosilanos. Las películas de titania se obtienen en dos pasos; el sol se prepara 
mezclando VTMS y el precursor de Ti, y después de la síntesis de la película, se 
somete la película a una reacción fotoquímica con MSA para incorporar los grupos 
carboxilo en la superficie porosa de la película.   
Las películas se caracterizan mediante microscopía electrónica, mediciones de 
porosimetría y Dispersión de Rayos-X de Ángulo Pequeño con detección 
bidimensional (2D-SAXS, por sus siglas en inglés). El grado de ordenamiento de las 
películas de sílice depende de la cantidad de organosilano agregado en la síntesis. 
La incorporación de los grupos vinilo y carboxilo funcionales se muestra mediante 
XPS, y la presencia de los grupos COOH se confirma mediante Espectroscopia de 
Transformada de Fourier de Infrarrojo por Reflectancia Difusa (DRIFTS, por sus 
siglas en inglés). La disponibilidad de los grupos COOH para la modificación química 
se demuestra mediante DRIFTS siguiendo los cambios en las bandas IR típicas de 
carbonilo durante el intercambio de protones y la complejación de metals. Para 
películas de sílice se estudia la complejación de Pb2 +, y para películas de titania Sr2 
+.  
La liberación del estroncio se estudia por ICP-MS, mostrando una liberación 
prolongada de Sr que dura una semana, beneficiando así los procesos de 
diferenciación y proliferación de pre-osteoblastos. Se observa una mejora en la 
proliferación a 3 día de cultivo y la diferenciación celular se mejora después de 15 
días de cultivo en medio osteogénico. Estos resultados se obtienen comparando con 
la proliferación y la diferenciación celular sobre películas de titania mesoporosa 
sumergidos en SrCl2.   
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Este capítulo muestra la posibilidad de sintetizar películas mesoporosas con grupos 
funcionales disponibles para la complejación de iones bioactivos, como pueden ser 
el magnesio o el calcio, que también ayudan en procesos celulares relacionados con 
la regeneración de hueso. 
En general, se ha demostrado la versatilidad de las películas mesoporosas de titania 
para mejorar la osteointegración y evitar la proliferación bacteriana.  Los materiales 
mesoporosos son muy versátiles siendo posible modificar la estructura mesoporosa 
y la orientación de los poros cambiando el surfactante empleado para la síntesis. 
También se puede modificar el espesor cambiando los parámetros de velocidad de 
centrifugación o inmersión y, por último, también es posible sintetizar películas 
híbridas mesoporosas, pudiendo obtenerse así películas con diversas 
funcionalidades. Modificando la síntesis de las películas mesoporosas, varía la 
concentración de moléculas que quedan atrapadas en el interior de la estructura 
porosa. Además, el área superficial interna disponible para el intercambio iónico 
también se puede ampliar.  
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I. INTRODUCTION 
Biomaterials are widely used with the aim to enhance the longevity and the life 
quality of human beings. They are used in different parts of the human body as 
replacement implants for knees, dental structures or hips, as artificial valves for the 
heart or for stents in blood vessels, to cite a few examples.[1–5] 
Bone grafting is one of the most commonly used surgical methods to augment bone 
regeneration in orthopaedic procedures.[6] Over two million bone grafting 
procedures are performed annually worldwide, which is the second most frequent 
transplantation in humans right after blood transfusion.[7] Among all clinical 
available grafts, autologous bone is still being considered as the gold standard since 
all necessary properties required in bone regeneration in term of osteoconduction, 
osteoinduction and osteogenesis are combined.[8] However, there is a limited supply 
and alternative to autologous grafting,  synthetic bone substitutes have been largely 
developed during the past decades.[9] 
Professor Themistocles Glück (1853–1942) from Berlin implanted the first artificial 
knee in 1890 and manufactured and implanted the first artificial hip in 1891 as well. 
The ivory head was fixed to the bone with a nickel plate and screws.[10] With the 
introduction of Vitallium® interposition implant (Co-Cr-Mo alloy), the American 
surgeon Marius Smith Petersen (1886–1953) achieved the first predictable and 
lasting results after an arthroplasty.[11] In this period surgeons experimented with 
real bone-joint replacements from various materials. The implant from the brothers 
Robert (1901–1980) and Jean Judet (1905–1995) from Paris achieved the greatest 
popularity.[12] Until this moment the prosthesis for hip replacement were made 
entirely of polymethilmehacrylate (PMMA) and frequently broke, this implant was 
afterwards reinforced with the introduction of a steel rod, but they still prone to 
fatigue fractures and loosening.[13,14] The called Judet hip prosthesis was introduced 
in 1948 to a patient, and the particularity of this implant was that to reconstruct the 
femoral head, an acrylic femoral head was used. This implant holds the current 
world record in the implant in vivo durability (51 years).[12] Artificial knees were 
developed in the same period but they were less successful if compared to hip 
implants. The reason for the inferior results was probably not in the implants itself 
but resulted from an inadequate surgical technique.  
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The modern concept of low-friction hip arthroplasty was developed in the 1970s 
using polyethylene in the cup, stainless steel in the femoral head and stem, and 
polymethyl methacrylate (PMMA) as bone cement (John Charnley, 1911-1982).[15] 
Charnley’s total hip arthroplasty has a long and well-established record with long-
term survival in more than 90 % of patients over 60 years of age.[16] Contemporary 
principles of mechanical axis balance and the importance of joint stability evolved 
only in the mid-1980s. Further development of the implants was based on the 
introduction of new materials, different ways of fixation, advances in implant design, 
properties and coatings, and new, less invasive surgical techniques. Today there is a 
very extensive list of materials used for production of artificial joints.[17]  
Synthetic implants 
Besides a vast number of available materials, ceramics, titanium and its alloys or 
polymers are the most used materials for orthopedic implants.[18–20] A classification 
of the different type of materials used for implants can be done based on the biologic 
response that they elicit once implanted.[21] The material can be biotolerant, those 
materials that form a thin fibrous tissue interface; bioinert, typically oxides that 
integrate well into bone and do not cause a reaction with the host; and bioactive 
materials.[21,22] These last ones have been proven to promote tissue regeneration by 
interacting with the bone.[22] The materials classified by their biologic response are 
summarized in Table I-1.  
 
 
 
 
 
 
 
 
Biodynamic 
activity 
Chemical composition 
Metals Ceramics Polymers 
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Biotolerant 
 
Gold  
Co-Cr alloys  
Stainless steel 
Niobium  
Tantalum 
  
Polyethylene  
Polyamide 
Polymethylmethacryl
ate 
Polytetrafluroethylen
e 
Polyurethane 
 
Bioinert Commercially pure 
titanium  
Titanium alloy (Ti-
6AL-4U) 
Al oxide  
Zirconium oxide 
 
 
Bioactive  Hydroxyapatite  
Tricalcium 
phosphate  
Bio glass  
Carbon-silicon 
 
Table I-1. Implant materials classification by the biologic response they exhibit after 
implantation.[21]  
The properties and therefore the design and composition of a material for an 
implant is application-driven.  Mechanical properties, the resistance to corrosion 
and wear as well as osseointegration and biocompatibility are some of the 
properties the biomaterial should exhibit when selecting a candidate for bone 
replacement.[20] Depending on the type of bone, the modulus of elasticity varies 
between 4 to 30 GPa.[23] The implant should exhibit high tensile and compressive 
strength to prevent fractures and be functionally stable. An increase in the hardness 
of the implant leads to a decrease in wear, which prevents fracture of the 
implants.[21] Regarding the surface properties of the implant, is quite important the 
wettability, the more hydrophilic is the surface, the better osteoblast adhesion have 
been proved.[24] Many works have also shown the importance of the roughness of 
the surface in order to improve the cell and tissue response.[25,26]  
The material cannot be toxic and does not have to cause any inflammatory or allergic 
reactions in the body, thus the success depends on how the human body reacts after 
the implantation.[20]  The low wear and the corrosion resistance ensure the longevity 
of the material. Such resistance suppress the release of non-compatible metal ions 
into the body which cause allergic or toxic reactions.[27] Since the implant loosening 
is often the cause of the weak surface compatibility with adjacent bone or other 
tissues, the surface characteristics of the implant are of fundamental importance 
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having a direct impact on osseointegration.[28] Figure I-1 shows a scheme of the 
properties that must be taken into account for the design of a biomaterial for an 
implant.  
 
Figure I-1. Properties that a biomaterial should display to be a good candidate for its use in 
an implantable device.  
Titanium implants 
The increased use of titanium and its alloys as biomaterials is a result of  their 
superior biocompatibility and excellent low corrosion properties.[29,30] Since the 
role of an implant is the replacement of the bone, it needs to mimic the biological 
environment and mechanical properties of the bone. Although currently used 
commercial titanium implants satisfies the required mechanical properties with a 
Young’s modulus within the range of 100 and 120 GPa,[31] the chemical instability 
and deformations of protective oxide layer usually results in poor osseointegration. 
Surface deformations of the protective layer  liberate metal ions forming Lewis Acids 
and lowering the pH in the implant environment.[32] The acidic environment formed 
at the implant surface favors bacterial infection and causes immunogenic response 
which can lead to an aseptic loosening of the implant.[33]   
IMPLANTABLE 
BIOMATERIALS
Surface 
properties
Wettability
Roughness
Biocompatibility
Corrosion 
resistance
Bulk properties
Modulus of 
elesticity
Tensile and 
compressive 
strength
Hardness
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Figure I-2. Schematic diagram of an artificial hip joint (left) and knee implant (right).[34] 
Many elements such as Ag, Cu, Fe or Zn form alloys with titanium, enhancing the 
stability of the implant in physiological media.[21] Among all titanium materials and 
titanium based alloys, the most used materials in biomedical field are the 
commercially pure titanium and the Ti-6Al-4V alloy. One of the most common 
applications of titanium alloys is as artificial hip joints that consist of an articulating 
bearing (femoral head and cup) and stem,[35] where metallic cup and hip stem 
components are made of titanium.  They are also often used in knee joint 
replacements, which consist of a femoral and tibial component made of titanium and 
a polyethylene articulating surface.[35] 
Most metals and alloys that resist well against corrosion are in the passive state. 
Metals in the passive state have a thin oxide layer on their surface, the passive film, 
which separates the metal from its environment.[36] Typically, the thickness of 
passive films formed on these metals is about 3-10 nm [35] and they consist of metal 
oxides. The natural oxide is amorphous and it is known that protective and stable 
oxides on titanium surfaces are able to provide favourable osseointegration. The 
stability of the oxide depends strongly on the composition structure and thickness 
of the film.[37] Because of the presence of an oxide film, the dissolution rate of a 
passive metal at a given potential is much lower than that of an active metal. It 
depends mostly on the properties of the passive film and its solubility in the 
environment.[38] 
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Surface engineering can play a significant role in extending the performance of 
orthopaedic devices made of titanium several times beyond its natural capability. 
The main objectives of surface treatments mainly consist of the improvement of the 
tribological behaviour, corrosion resistance and osseointegration of the implant. 
There are coatings for enhanced wear and corrosion resistance by improving the 
surface hardness of the material that can be applied by different surface 
modifications techniques such as surface oxidation, physical deposition methods 
like ion implantation and plasma spray coatings, as well as thermo-chemical surface 
treatments such as nitriding, carburizing and boriding.[39,40] 
As previously mentioned, one of the main drawback of titanium implants is the high 
risk of bacterial infection, thus the aseptic loosening, which leads to the need of 
perform a second surgery to replace the infected implant.[41] 
Revision surgery and implant infection 
Even with the development of prophylactic antibiotic therapies, environmental 
control and improvements in surgical techniques, the incidence of infection varies 
between 1 – 2 % in primary arthroplasties and 3.5 – 5 % in revision surgeries.[42,43] 
The main risk factors associated with infection in knee arthroplasty are a previous 
surgery, advanced age, female gender, rheumatoid arthritis, obesity, diabetes and 
immunodeficiencies.[44] The post-implantation surgical trauma weakens the local 
defense system, raising the risk of infection, if prolonged requires further surgical 
interventions to replace the implant.[41] The revision surgery, however, is less 
successful than the initial surgery because of higher risk of trauma and longer bone 
healing period.[45] Once the implant is exposed into physiological conditions  a 
protein layer can be formed on the surface, making feasible bacterial colonization 
and in the worst case the biofilm formation,[46,47] which acts as a protecting layer 
against the host defence and bactericidal agents. Therefore, it remains highly 
challenging and critical to avoid the infection just after the implantation surgery.[47]  
To treat the infection, if there is still no need to replace the implant, the infection 
focus has to be removed surgically and then the patient is treated for a long time 
with antibiotics.[48] The classification of the infection, used to determine the 
required treatment, differentiates infections developed early ( < 3 months), 
intermediate (3 – 24 months) and late ( > 24 months), classification proposed by 
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Zimmerli et al.[49] Early and intermediate infections are usually acquired during 
prosthetic implantation, whereas late infections results from haematogenous 
spread of the focus at a distance.[49,50] 
Two-thirds of the infections in orthopaedic implants are caused by Staphylococcus 
pathogens and they also are the responsible for two of the major bone infections: 
arthritis and osteomyelitis, which suppose the inflammatory destruction of joints 
and bones.[51] More specifically Staphylococcus aureus and Staphylococcus 
epidermidis account together for two out of three infections in orthopaedics.[51]  
Nosocomial infections are the ones associated with healthcare acquired in an 
hospital.[52] Staphylococcus aureus is an important nosocomial pathogen, able to 
cause a variety of human disease conditions. It can often be found as a commensal 
and a transient or persistent part of the resident flora of the skin and anterior nares 
in a large proportion (20 – 50 %) of the human population. However, when 
cutaneous/mucous barriers are breached, severe and at times life threatening 
infections can develop. Nosocomial infections by S. aureus are particularly frequent 
in immunocompromised and severely debilitated patients, and prevail in the 
presence of indwelling medical devices. Treatment of S. aureus infections is often 
complex, namely due to the emergence of methicillin-resistant S. aureus (MRSA) 
strains and resistance to other classes of antibiotics. Because of its pathogenic 
potential and complexity of its treatment, MRSA has received more attention than 
its methicillin-sensitive counterpart (MSSA). MRSAs are resistant to β-lactam 
antibiotics (oxacillin, penicillin and amoxicillin), including third generation 
cephalosporins, streptomycin, tetracycline and sulfonamides; and upon exposure to 
vancomycin and other glycopeptide antibiotics, certain MRSA strains become less 
susceptible to these antibiotics. S. aureus possesses several cell-surface adhesive 
molecules that facilitate its binding to the bone matrix. Binding involves a family of 
adhesins that interact with extracellular matrix (ECM) components and these 
adhesins have been termed microbial surface components recognizing adhesive 
matrix molecules (MSCRAMMs). Specific MSCRAMMs are needed for the 
colonization of specific tissues and for the adhesion to biomaterials and to the ECM 
proteins deposited on the biomaterial surface. Particular MSCRAMMs include 
fibrinogen-binding proteins, elastin-binding adhesin and collagen-binding adhesin. 
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A number of these adhesins have already been thoroughly investigated and 
identified as critical virulence factors implicated in various phases of infection, 
including early colonization, invasion, tissue localization and cell internalization.[53–
55] In recent years, the polysaccharide intercellular adhesin (PIA) has been found in 
many S. aureus strains, and is required for biofilm formation and bacterium-
bacterium adhesion.[56] This adhesin is responsible for the production of the 
extracellular polysaccharide matrix that develops the biofilm. It is known that once 
the biofilm is formed, the bacteria within the biofilm are protected from 
phagocytosis and antibiotics.[55]  
S. aureus produces virulence factors to facilitate disease progression, and rapidly 
develops antimicrobial resistance. The cell-surface virulence factors include the 
MSCRAMMs as receptors in the human host, other surface proteins, polysaccharide 
intercellular adhesin and capsular polysaccharides. The cell-surface MSCRAMMs 
typically are produced during exponential growth phase. The role of these various 
virulence factors is to provide nutrients required for survival in the host, and 
microbial cell protection from the host immune system during lesion formation. The 
secreted virulence factors, typically produced during the post-exponential and 
stationary phases, include a large group of exoenzymes, such as proteases, glycerol 
ester hydrolase and nucleases that make nutrients available to the 
microorganism.[55] 
A large body of works has been dedicated to the development of proper coatings for 
titanium implants, which make the surface antibacterial and avoid bacterial 
adherence. Due to the diversity of bacterial ecosystems the coatings should be 
tailored to tackle the different bacteria. On the other hand, tissue integration might 
also be taken into account. It has been demonstrated that the growing and 
proliferating cells on the surface of the implant can suppress bacterial proliferation. 
Although post-implementation supply of antibiotics to the patients can prevent 
infection, the low drug concentration at the target site remains as major 
disadvantage.[41]  
Gentamicin, cephalothin, amoxicillin, tobramycin or vancomycin are some of the 
most used antibiotics due to their broad antibacterial spectra.[57–61] Nonantibiotic 
organic antimicrobial agents can also be used because of the risk of drug resistance 
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when antibiotics are used.[41,62,63] Inorganic materials such as silver have also been 
proposed as an attractive dopant for titanium implants since it exhibits a broad 
antibacterial spectrum. However, silver compromises the activity of osteoblasts and 
epithelial cells.[64,65] The treatment of the implants with UV irradiation or by 
changing the surface crystallinity leads usually to alteration of physicochemical 
properties, allowing thus the decreases in the bacterial activities.[66] Bioactive 
polymers coatings, such as chitosan are also investigated because they can reduce 
bacterial adhesion.[67] Interestingly, the use nitric oxide has also been proposed as it 
inhibits the growth of a wide variety of bacteria.[68] Nitric oxide augments the 
antimicrobial ability of the immune system thus it loaded into xerogels for 
subsequent release.[69] Still, the combination of nitric oxide with titanium implants 
remains unproven. 
Paying special attention to the antibiotics, aminoglycosides as gentamicin or 
tobramycin, penicillins, glycopeptides like vancomycin, teracyclines or rifamycins 
are the drugs that have been used to give antibacterial properties to implants.[70] 
Aminoglycosides bind to the bacterial 30S ribosomal subunit. Ribosomes are the 
protein factories of cells. They are composed of two subunits in bacteria, a 30S and 
a larger 50S. By binding to the ribosome, aminoglycosides inhibit the translocation 
of tRNA (transcriptional) during translation and leaving the bacterium unable 
to synthesize proteins necessary for growth. Although the eukaryotic cells of 
humans also have ribosomes, these cellular protein factories differ in size and 
structure from the ribosomes of prokaryotes. That is why aminoglycosides do not 
interfere with protein synthesis in human cells. The mechanism of action of the 
aminoglycosides is shown in Figure I-3. Especially important is gentamicin, which 
is used for serious infections caused by either gram positive or negative bacterial 
strains, as P. aeruginosa, E. coli or Citrobacter, Streptococcus and Staphylococcus 
species.[71] This broad-spectrum antibiotic contains five amino groups which gifts 
the molecule with a positive charge in acidic environment because the pKa of the 
amino groups range in between 5.5 and 9.[72–74] Figure I-4 shows the gentamicin 
molecule.  
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Figure I-3. Mechanism of action of aminoglycosides to inhibit bacterial protein synthesis. 
The aminoglycosides bind irreversibly to the rRNA (ribosomal RNA) in the 30S subunit of 
bacterial ribosomes. They interfere with the translation reducing the rejection rate for tRNA 
(transcriptional RNA) that are not matches for the codon, leading to a misreading of the 
aminoacids, interfering with the protein synthesis.[75] 
 
 
Figure I-4. Chemical formula of  the Gentamicin molecule.[76] 
Layer-by-Layer technique for supramolecular structure deposition 
The build-up of multilayer films of polyelectrolytes using the layer-by-layer 
technique (LbL) was demonstratesby Decher et al.[77] The LbL technique is based on 
the alternative deposition of oppositely charged polyelectrolites on top of charged 
surfaces, this process is shown in a scheme in Figure I-5.[78–80]  The assembly is 
driven by attractive electrostatic interactions and entropy considerations.[81,82]  
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Figure I-5. Layer-by-layer assembly method. Alternatively, positively and negatively 
charged molecules are adsorbed one after the other on a substrate. This process can be 
repeated n times to a final film thickness.[83] 
This technique is a powerful strategy for non-covalent modification of charged 
surfaces. Is an easy and reliable method for surface engineering and has many 
potential applications in diverse areas such as optoelectronics, nanofiltration, tissue 
engineering or devices such as carriers for drug delivery.[79,84–86] 
Significant research has been done using the LbL technique to produce 
polyelectrolyte multilayers (PEMs) films combining a diversity of components. 
Biopolymers such as proteins and nucleic acids, lipids, and inorganic particles have 
been introduced in the fabrication of multilayer films.[87,88] For biosensing purposes 
or multistep catalysis, research has been conducted in the incorporation of enzymes 
to the LbL films.[78]  Möhwald et al.[89] extended the deposition of thin films of PEMs 
on top of colloidal particles, instead of using planar surfaces. As the LbL assembly 
was proven to work on colloidal particles, the use of sacrificial templates for the LbL 
assembly allowed the fabrication of empty capsules retaining the size and the shape 
of the original colloidal template. Capsules based on PEMs have been fabricated 
aiming a controlled release and targeting.[89] 
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PEMs assembled by the LbL process can be also considered as a special case of 
polycation/polyanion complex formation. Due to the step-wise assembly of 
polycations and polyanions, the film has a layered structure. However, the layers are 
not fully stratified, as there is a certain degree of interdigitation among them due to 
the free space within a deposited polyelectrolyte layer, which gets filled when more 
layers are deposited.[90]  
PEMs result to be very stable. They cannot be easily removed unless one of the 
components loses charges by means of a change in pH , or when a specific ion or 
surfactant interacts with the polymers weakening the electrostatic interaction 
between the PEs.[91,92] Only at very high ionic strength the films can be partially 
erased.[93] 
Due to a wide range of PEs available to assemble multilayer films, as well the ability 
to tailor their properties by varying the deposition conditions, PEMs are being 
incorporated into a variety of biological applications. Their use includes coatings to 
either promote or prevent cell adhesion, and more importantly in directing or 
maintaining cellular phenotypes.[94] In addition to electrostatic interactions, 
multilayer films have been assembled from DNA strands using complimentary base 
pairing,[95] by click chemistry utilizing covalent bonding,  and through hydrogen 
bonding to create degradable multilayers for drug release applications.[96,97] 
PEMs have been assembled from synthetic as well as naturally occurring 
polymers.[80,98,99] Synthetic PEMs have been assembled from cationic PEs such as 
poly (allylamine hydrochloride) (PAH), poly (diallyldimethylammonium chloride) 
(PDAC) and poly-L-lysine (PLL) and anionic PEs such as poly (acrylic acid) (PAA) 
and sulfonated polystyrene (SPS).[94,100,101] PEMs have also been fabricated from 
naturally occurring PEs such as, polypeptides, polysaccharides, DNA, and 
proteins.[102–106] 
A self-assembled PEM can grow in a linear or exponential manner (Figure I-6).[99,102] 
Linear growth typically occurs when the PEs are highly charged and do not diffuse 
freely throughout the PEM. Highly charged PEs exhibiting linear growth include 
cationic PAH and anionic SPS, to name some.[99] On the other hand, exponential 
growth occurs in the presence of weak PEs as PLL, alginate (ALG), and poly-(lactide-
co-glycolide) (PLGA).[102,103,107,108] In a few cases, linear growth in the presence of 
Introduction 
23 
 
weak PEs has also been observed.[109] To explain the exponential growth of PEMs 
three models can be found in the literature;[110] the first one is called the ‘Diffusion 
Model’. This model states that the exponential PEM growth is largely due to the 
diffusion of at least one PE through the film, resulting in an exponentially increasing 
thickness, as additional bilayers are added to the film.[108,111–113] The ‘Dendritic 
Model’ is also used to describe the exponential growth of PEMs and is based on the 
well-known tendency of PE to from brushes when are in contact with oppositely 
charged structures.[110,114,115] Lastly, the ‘Island Model’ is proposed which states that 
the first PE only coats part of the surface forming ‘islands’. Then, further adsorption 
steps continue growing the initially formed islands increasing the available surface 
area showing an exponential growth of the formed PEM.[110,116] Researchers have 
exploited the two different modes of growth within the same PEM to create distinct 
regions within a multilayer. [117] 
 
Figure I-6. Scheme of the thickness increase in PEMs following a linear or exponential 
growth as function of the number of polyelectrolyte bilayers assembled. 
Polyamine acids facilitate the attachment of cells and proteins to solid surfaces in 
biological applications. In cell cultures normal attachment, growth, and 
development of many cell types are dependent on attachment factors and 
extracellular matrix components. α-Polylysine is a synthetic polymer, which can be 
composed of either L-lysine or D-lysine. "L" and "D" refer to the chirality at lysine's 
central carbon. This results in poly-L-lysine and poly-D-lysine respectively.[118] PLL 
is commonly used to coat tissue culture ware as an attachment factor and has a pKa 
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of 10.5.[119] It improves cell adherence which is based on the interaction between 
the positively charged polymer and negatively charged cells or proteins.[120] 
PAA is a synthetic high-molecular weight polymer of acrylic acid. In a water solution 
at neutral pH, PAA is a weak anionic polymer with a pKa of 3.9,[119] i.e. many of the 
side chains of PAA will lose their protons and acquire a negative charge. This makes 
PAA PE, with the ability to absorb and retain water and swell many times their 
original volume.[121] 
 
Figure I-7. a) Poly-L-lysine and b) Poly (acrylic acid) monomer chemical structure. 
PEMs assembled through the LbL technique can retain a high drug concentration, 
which creates new opportunities for the release of therapeutic molecules in a 
localized manner.[122] Drug reservoirs are constructed by exploiting the 
characteristic diffusivity associated only with exponentially growing PEMs, not 
normally observed under linear growth.[117] Assembly conditions modulate the 
mechanical properties of PEMs. Drug reservoirs take advantage of exponentially 
grown PEMs in which bioactive molecules are incorporated. Due to the higher 
diffusivity associated with such regions, bioactive molecules can easily diffuse, 
thereby providing a means for localized delivery at high concentration.[107] 
In order to fabricate films entailing a small positively charged biomolecule, such as 
an antibiotic (Gentamicin for example), these could be assembled at the place of 
polycations in the PEM. Although gentamicin sulfate, positively charged, can be 
assembled in LbL multilayers by alternating deposition with negatively charged 
polyelectrolytes,[123,124] its weak charge leads to low concentrations of drug loading 
and a low structural stability of the film that causes degradation.[122] 
Mesoporous titania 
Several surface modification techniques have been proposed to achieve a good 
interaction between titanium implants and bone tissue.[125] Since rougher surfaces 
promote bone and implant interlocking the coating of implant surface with 
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mesoporous film become an attractive method to improve bioactivity of the 
implant.[126,127]  
 
Figure I-8. Schematic representation of a titanium implant recovered with a mesoporous 
film used for knee and hip implants. [128,129] 
The IUPAC classification defines three types of mesoporous materials depending on 
the pore size. Thus, microporous materials exhibit pores < 2nm, while the pore size 
between 2 and 50 nm corresponds to mesoporous materials. The macroporous 
materials have pores larger than 50 nm.[130] Mesoporous materials can be found in 
the form of powder, nanoparticles or films, and the framework composition can be 
organic, inorganic or metallic.[131]  
Mesoporous titania is obtained through the sol-gel process assisted by a surfactant 
as structure-directing agent. The synthesis of material with homogenous pores 
requires highly controllable experimental conditions since the titania precursors 
(titanium alkoxides and titanium tetrachloride) undergo rapid hydrolysis and 
condensation leading to the rapid TiO2 precipitation without forming 
mesopores.[131] Several methods have been developed for the synthesis of films of 
which the Evaporation-Induced Self-Assembly (EISA) is considered the most 
convenient to prepare mesoporous TiO2 films (MTFs),[132] where TiCl4 is the most 
used titanium source.[131]  
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The EISA process was first reported by Brinker and Ozin and was originally designed 
for the preparation of mesostructured silica thin films.[133,134] The solute (precursor) 
is dispersed in a solvent (usually alcohol), first, colloidal particles are formed and 
the called sol is formed. The colloidal particles aggregate to form a 3D network, 
called gel. In the sol-gel process the two most important reaction that occur are the 
hydrolysis and the condensation, leading to the formation of M-OH-M or M-O-M 
bridges.[135]  
Amphiphilic surfactants have the ability to self-assemble into a variety of structures. 
The surfactants have the natural ability to organize into different shapes and at a 
certain concentration, called Critical Micelle Concentration (CMC) the surfactants 
assemble into spherical micelles. The inorganic phase then undergoes condensation 
around the surfactant phase, called Liquid Crystal Templating (LCT) mechanism. 
The elimination of the surfactant molecules leads to the formation of the 
mesoporous material.[135] 
For a mesoporous thin film formation, by the EISA process, a solution containing the 
surfactant, the metal alkoxide or salt, the alcohol, water and often acid are mixed. At 
the beginning the surfactant concentration is lower than CMC, and the solution can 
be casted on a substrate through spray, spin or dip coating and the evaporation of 
the alcohol starts and the surfactant and the metal oxide concentrations start to 
increase. Due to the surfactant concentration increase the self-assembly of the 
organic-inorganic hybrid leads to a Liquid Crystal (LC) phase. Micelles are formed 
when the CMC is reached and an organized LC phase is formed, where the inorganic 
network is not still fully condensed, this phase is called Tuneable Steady State (TSS). 
In the TSS water and solvent molecules are in equilibrium with the environment and 
the duration of this state depends on the relative humidity (RH). Finally, the 
template is removed to give the porosity to the film and get a full condensation of 
the inorganic network. The film undergoes a calcinations process in a temperature 
range of 300 - 550 °C to remove the surfactant.[135] This process is shown 
schematically in Figure I-9. 
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Figure I-9. Evaporation Induced Self-Assembly (EISA) process scheme.  
Chemical functionalization of mesoporous titania 
The progress in the fabrication of mesoporous materials was accompanied with the 
development of novel strategies to incorporate organic functional groups within the 
pores. There are two main synthesis routes; the post-grafting (post-
functionalization), where the functional groups are incorporated to the porous 
matrix after the material is fabricated through vapour deposition or solution 
impregnation, and the co-condensation (one-step approach), where in one step the 
functionalization is achieved. In the post-grafting method, to achieve the 
functionalization, new bonds are formed between the Si-OH or M-OH groups that 
are in the surface react with the functionalizing agent. The co-condensation method 
requires the mixing of inorganic and functionality-containing precursors.[136,137] 
While the former method is relatively easy to implement, the latter method is time-
efficient and both the functionalization and condensation take place simultaneously. 
Usually organosilanes are used for the co-condensation approach, which can be 
mixed with titanium precursors to obtain mixed and functionalized mesoporous 
films. However, some of the functional groups will remain entrapped inside the 
network, remaining unavailable for further reactions.[138]  
Many different organic moieties have been incorporated to the pore surface, such as 
mercaptoalkyl, aminoalkyl, phenyl, glycidyl, vinyl, cyanoalkyl, and alkyl 
groups.[139,140] Functionalization with carboxylic groups has been less explored than 
other functional groups. There is a need to perform two steps for the 
functionalization due to the lack of suitable commercial reagents. This is the reason 
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why there is a lack of reported methods that allow the incorporation of COOH 
functional groups. Nevertheless, several methodologies have been described to 
achieve the incorporation of the COOH group into silica powders (SBA-15, MCM 
type, SiO2 nanoparticles) by co-condensation or post-grafting.[140] These strategies 
include: modification of a NH2-functionalized surface with succinic acid, co-
condensation or post-grafting with an aqueous solution of carboxyethylsilanetriol, 
or grafting of an organosilane bearing an ester group that results in a free carboxylic 
moiety after a hydrolysis step.[140] Another possible approach is the use of cyanide 
to carboxylic methods, wherein the COOH group is obtained after hydrolysis of the 
−CN group with sulphuric acid using hard experimental conditions: high 
temperature and long reaction times.[141] Liu et al. have shown successful 
incorporation of carboxylic groups into mesoporous thin films through a co-
condensation method, applying the cyanide to carboxylic conversion in a two-step 
method.[142] Despite some works can be found about co-condensation strategies for 
chemical functionalization of silica based mesoporous films and particles, no reports 
can be found in literature about chemical functionalization of titania based 
mesoporous structures. 
The functionalization with carboxyl groups brings a pH-dependent switch-ability to 
the pore surface, whose adsorption capability or catalytic activity can be varied by 
changing the solution acidity. This also brings the possibility to anchor 
biomolecules, such as proteins, antibodies, or folic acid to the COOH groups and can 
also be used as ligands for metal complexation in decontamination or detection 
processes.[141,143,144] Carboxylic groups could also be used to entrap bioactive ions, 
allowing a sustainable release of entrapped ions. 
Pores as reservoirs for drug delivery 
A typical implant replacement intervention requires the prescription of antibiotics 
to minimize the risk of the failure of implant integration and infectional 
responses.[145] To decrease the amount of drugs dosage, the local and controllable 
drug delivery becomes an alternative scenario to increase implant adaptation. By 
this mean, the delivery of the drugs occurs in an specific site of the human body 
where the local amount of drug and his release can be regulated.[146] 
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The goal of any drug delivery  vehicle is to provide therapeutic amounts of drug to 
the proper site in the body to achieve promptly and to maintain desired drug 
concentration.[147] Delivery of drugs by means of the so called controlled release 
technology began in the 1970s and has continued to expand rapidly.[148] Various 
drug delivery systems, such as liposomes, micelles, emulsions, polymeric 
micro/nanoparticles have shown great promise in controlled and targeted drug 
delivery. Among these systems porous materials are emerging as a new category of 
host/guest systems.[149–152] 
As expected, a large surface area and large pore volume enable mesoporous 
materials to act as drug reservoirs. The most important requirement for 
mesoporous coatings is that they must have the ability to load and release drugs. 
The substrate has to be able to hold the drug and deliver it gradually in the specific 
target site.[153] The dose of the drug and the necessary release time vary on the 
application.  Drug release from porous carriers may be complete within 10 min or 
be incomplete after several hours or days. Solvent polarity and surface properties 
play an important role in the adsorption and release of drugs from porous 
carriers.[154,155] Adsorption is the accumulation of concentration of substances at a 
surface or interface; the phenomenon by which the molecules of gas, vapour and 
liquid spontaneously concentrate at a contacting surface without undergoing 
chemical reaction, thereby forming a surface or interfacial layer. 
The advantage of using MTFs is their tuneable pore size and films thickness that 
translates to a well-controlled amount of drug to be loaded.[156] Typical loading is 
performed through capillary action by immersing the templates in a concentrated 
drug solution. The release profiles have an initial burst release and a decreasing tail 
distribution, which is lower due to the pore interconnection and the presence of 
necks, making the molecules to get entrapped inside the film and making slower 
their release. Although the period just after the implantation is the most critical 
stage that brings the high risk of infection, the antibacterial properties of the implant 
should remain for longer time until the complete integration of the implant.[46,157] 
Bone remodeling process 
To ensure the implant integration in the human body is important to understand 
how the bone is remodelled and behaves in order to perform in vitro experiments 
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and be sure about the biocompatibility and the osseointegration capability of the 
implantable material. 
The skeleton is a very dynamic tissue and remains in a constant repairing of 
mechanical microdamage. The cell forming actions are the processes that ensure the 
secure integrity of the skeleton resorption during the exchange of old bone with new 
bone. These processes are regulated by local and systemic factors that maintain the 
subtle balance between the resorption and bone formation, avoiding the excessive 
bone loss or gains, which may cause risk of fracture or compression syndromes. 
Osteoclasts, osteoblasts and osteocytes take part in those processes.[158] The process 
of remodelling commences by osteoclastic resorption that forms a lacuna with a 
depth between 40 and 60 µm leading to completed refilling of lacuna with new 
bone.[159,160] Many transcription factors are involved in the osteoblast 
differentiation process, which are derived from mesenchymal cells differentiating 
from progenitors into proliferating pre-osteoblasts, osteoblasts and osteocytes or 
bone-lining cells. Runt-related transcription factor 2 (Runx2) is essential for cell 
differentiation and it regulates the expression of diverse genes.[161] Alkaline 
phosphatase (AP) and type I collagen are expressed once osteoblast are 
differentiated and they are important for bone matrix synthesis and the 
mineralization process.[162] Mature osteoblasts differentiate to osteoclasts, whose 
objective is to break down bone tissue, so a balance is found between new bone 
formation and resorption. Osteocytes are a type of osteoblasts that get entrapped in 
the bone matrix and form the so-called osteoid, a non-mineralized organic part of 
the bone.[158] All this process is shown schematically in Figure I-10.  
 
Figure I-10. Bone remodeling cycle. Bone surface is resorted by osteoclasts and pre-
osteoblast differentiate to osteblasts for new bone formation and osteocyte differentiation. 
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The underlaying surface is of major importance because it defines the proper bone 
cells attachment to form focal adhesions. Through the focal adhesions, cells interact 
with the surrounding and mediate a bidirectional signaling. Integrins play a major 
role in the process through bounding to the actin cytoskeleton inside the cell and to 
the substrate outside the cells.[163] Growth and differentiation of pre-osteoblasts are 
regulated by transcription factors activity and gene and protein expression, which 
are activated due to the mechanotransducive signaling the integrins mediate.[164] 
As previously mentioned, it is well known that cell proliferation allows fast implant 
integration in the tissue (osseointegration), avoiding bacterial growth. Implant 
surface modifications can enhance the interactions that occur with the biological 
fluids and cells and accelerate osseointegration. Many bioactive coatings have been 
reported. For example, calcium phosphate coatings have been shown to increase the 
biochemical interlock between bone and implant materials. Similarly, collagen 
coating promotes osseointegration.[165–167] Also, the use  of growth factors can 
enhance osteoblast growth, proliferation and differentiation, as has been 
demonstrated in the case of bone morphogenetic protein 2 (BMP-2).[168],[169]  
Bone morphogenetic proteins regulate growth, differentiation, chemotaxis, and 
apoptosis, and play pivotal roles in the morphogenesis of a variety of tissues and 
organs.[170] They are members of the transforming growth factor-β (TGF-β) 
proteins, which includes a large families of growth and differentiation factors.[171] 
Whereas the BMPs are multifunctional proteins, implantation of the osteogenic 
BMPs such as BMP-2 and BMP-7 at an osseous site results in bone and cartilage 
formation. In vivo, these BMPs act primarily as differentiation factors, turning 
responsive mesenchymal cells into cartilage- and bone-forming cells. This is 
supported by many in vitro studies showing that the BMPs turn on specific markers 
of the osteoblast or chondroblast phenotype in a number of cells.[172]  
The activity of BMPs is tightly controlled at many levels. Outside the cell, soluble 
inhibitory proteins can bind certain BMPs and inhibit their binding to cell surface 
receptors. It has been found that BMPs can up-regulate the expression of some of 
these inhibitors, suggesting a negative feedback loop that limits the activity of BMPs. 
A number of negative regulators of BMP action exist within the nucleus. All of these 
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regulatory mechanisms together cause the bone-induction process to be controlled 
tightly and self-limiting.[173,174]  
Recombinant human BMP-2 (rhBMP-2) induces the expression of osteocalcin, a 
bone specific protein[172] and induces expression of the osteoblast lineage markers. 
BMP-3, the most abundant BMP in adult bone, is an antagonist of osteogenic 
BMPs.[175] BMP-3 inhibits BMP-2 mediated induction of Msx2, a gene that provides 
instructions for producing a protein that is necessary for proper development of 
cells and tissues throughout the body, and blocks BMP2-mediated differentiation of 
osteoprogenitor cells into osteoblasts. 
BMPs bind to two types of receptors termed as Type 1 and Type 2 receptors, 
required for signal transduction.[176] The overall structures of Type 1 and Type 2 
receptors, named as BMPR-I and BMPR-II respectively, are similar. They have a 
short extracellular domain with some conserved cysteine residues, a single 
transmembrane domain, and an intracellular domain containing a serine/threonine 
kinase motif. Even BMPs can interact directly with BMPR-I, signal transduction for 
BMPs require both receptors, because BMPs in the first moment BMPs interact with 
BMPR-II, because this is the specific receptor, which facilitates afterwards the 
interaction with BMPR-I, that is in charge of mediating the signals inside the cells to 
activate Smad proteins.[173,177–179] Smad proteins are also part of the TGF-β 
superfamily, and are very important to regulate cell development and growth.[180] 
Once inside the cell membrane, the Smads are phosphorylated by Type 1 receptor 
kinase so they can be transported to the cell nucleus and the accumulation of these 
complexes in the nucleus leads to the regulation of transcriptional responses.[181] All 
the process described above is schematically shown in Figure I-11.  
Introduction 
33 
 
 
Figure I-11. BMP pathway to induce bone formation. 
Bioactive ions 
Bone surface chemistry has a large influence on proper and fast osseointegration. 
Human bone mineral consists of various ion-substituted apatites, thus, the use of 
bioactive elements is being developed to induce the ability of bone formation.[182] 
Several ions have been shown to be capable of inducing osteoblast precursor 
differentiation through growth factor signalling pathways, or to stimulate other 
processes in support of bone tissue growth. These ions include boron (B3+), calcium 
(Ca2+), cobalt (Co2+), copper(II) (Cu2+), fluoride (F–), lithium (Li+), magnesium 
(Mg2+), niobium (Nb5+), phosphate (PO43–), silicate (Si4–), silver (Ag+), strontium 
(Sr2+), vanadium (V5+), and zinc (Zn2+). Compared with protein growth factors, the 
advantages of using such ions to induce bone tissue repair are manifold, including 
lower cost, greater simplicity, higher stability, and more efficacy at low 
concentrations.[183] Table I-2 summarized the main effects observed for the 
mentioned ions. 
Ion Effects and in vivo main results References 
 
Boron  
(B3+) 
• Promote osteogenic differentiation through enhanced 
ALP activity and increased expression of osteogenic 
gene markers, improved mineralization, proliferation 
and adhesion. 
[184–186] 
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• Scaffolds comprising nanogels combined with boron-
containing mesoporous bioactive glass showed 
improved bone tissue formation in critical-sized rat 
femur defects 
 
Calcium 
(Ca2+) 
• Increased adhesion, proliferation, and differentiation 
of osteoblasts. 
• Titanium implants modified with Ca2+ demonstrated 
elevated bone density and osseointegration after 12-
weeks post implantation in a sheep tibia model. 
[187–189] 
 
Cobalt 
(Co2+) 
• Downregulates some osteogenic markers and reduces 
proliferation of osteoblasts; also stimulates osteoclast 
activity; is important in angiogenesis. 
• Cobalt-treated implants had improved 
vascularization in mouse models. 
[190,191] 
 
Copper(II) 
(Cu2+) 
• Borate bioactive glass scaffolds doped with 3 wt% 
CuO demonstrated improved angiogenesis and bone 
formation in rat calvarial defects after 8 weeks. 
[192–195] 
 
 
Fluoride  
(F–) 
• Fluoride promotes proliferation, increases 
mineralization, upregulates osteogenic marker genes, 
and modulates apoptotic processes. 
• Fluoride-substituted apatite containing 0.48 wt% F 
showed increased rate of bone formation 2 weeks 
post implantation in rats. 
[183,196–198] 
 
 
Lithium 
(Li+) 
• Increases proliferation, cementogenic differentiation 
and ALP activity. 
• Local application of Li2CO3 accelerated bone 
regeneration by promoting osteoblastogenesis and 
inhibiting osteoclastogenesis in male Wistar rats. 
[199,200] 
 
Magnesium 
(Mg2+) 
• Increases expression of collagen and matrix 
mineralization; increases spreading. Decreases 
osteoclast differentiation, increases cell adhesion to 
biomaterial surfaces. 
• Enhances osseointegration by increasing bone-to 
implant contact. 
[201–204] 
 
Niobium 
(Nb5+) 
• Has been shown to stimulate osteoblast activity, 
promote mineralization, and control cytotoxicity in 
bone tissue cultures; combined with HA, it can 
increase calcification, ALP activity, and osteoblast 
function. 
• Ti-Nb alloy demonstrated osseocompatibility and 
osseointegration at 2, 4, and 12 weeks post 
implantation in female beagle dogs. 
[198,205] 
 
Phosphate 
(PO43–) 
• Induces apoptosis in osteoclasts and inhibits 
osteoclast differentiation and bone resorption 
activity. 
• P is involved in osteoblast differentiation and ECM 
mineralization. 
[206–209] 
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Silicon 
(Si4–) 
• Can induce osteoblast differentiation and collagen I 
production and promotes osteogenesis and 
angiogenesis. 
• In female Sprague–Dawley rats, dietary silicon. 
Influences bone growth through modulation of 
turnover of collagen and sialic acid-containing ECM 
proteins. 
[183,196] 
 
Silver  
(Ag+) 
• Has antimicrobial actions when used in tissue culture. 
Furthermore, exposure of bone progenitor cells to 
silver based nanoparticles accelerated osteogenesis. 
[183,210,211] 
 
 
Strontium 
(Sr2+) 
• Increases expression of Runx-2, BMP-2, OCN, OPN, 
BSP, and Col1, ALP activity and matrix mineralization. 
Enhances attachment, proliferation, and 
differentiation in osteoblastic cells; reduces osteoclast 
activity. 
• Promotes bone formation, remodeling and 
osseointegration by increasing the bone-to-implant 
contact. 
[204,212–216] 
 
 
Vanadium 
(V5+) 
• In vitro studies demonstrated its pro-osteogenic 
function without significant cytotoxicity. 
• Known to be more highly concentrated in bone tissue 
in vivo, suggesting that it has a role in osteogenesis; 
enhanced angiogenesis and chondrogenesis, and 
promoted mineralization 3–4 weeks post fracture in 
male Wistar rats.  
[210,217,218] 
 
 
Zinc  
(Zn2+) 
• Increases proliferation, expression of type I collagen, 
Runx-2, BSP, and OCN, ALP activity in enhanced. 
• Increases bone formation, BMD, bone mineral content 
growth, osseointegration, peri-implant osteogenesis, 
bone-to-implant contact. However, it can also 
unfavorably increase bone resorption. 
[219–226] 
 
Table I-2. Summary of the effects of various ions on bone regeneration. 
Calcium has a variety of roles in cells and living systems, from intracellular 
molecular signalling to macroscale structural properties. This ion is especially 
important in bone tissue, because it is one of the two most essential components of 
mineralized bone matrix, along with phosphate. Moreover, the hydroxyapatite that 
forms the inorganic phase of bone tissue contains approximately 99% of the calcium 
in the body, acting as a storage reservoir for the mineral. Calcium can be leached 
from, or deposited into, existing bone matrix to maintain calcium homeostasis in the 
body. This bone calcification system is important in the formation of mature bone 
and during bone reparation. Therefore, it is imperative to maintain the extracellular 
concentration of calcium in bone tissue.[227] Furthermore, cellular calcium signalling 
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is a key process in the formation and repair of bone. Calcium can stimulate the 
proliferation of mesenchymal precursor cells, as well as mature bone cells,[228] 
through a process dependent on the production of nitric oxide (NO). This allows for 
appropriate numbers of bone growth precursor cells to be generated and recruited 
to the injury site in the context of bone tissue regeneration. In the context of bone 
regeneration applications, the calcium ion is of great importance. In vitro studies 
have shown that moderate extracellular calcium concentrations are optimal for 
osteoblast proliferation and extracellular matrix (ECM) mineralization.[229] 
Furthermore, recent research has demonstrated that loading of calcium into bone 
repair scaffolds promotes the adhesion, proliferation, and differentiation of 
osteoblast-like MG63 cells in vitro.[188] This observation, keeping in mind the general 
importance of calcium in bone formation and cellular signaling, gives support to the 
idea of using calcium ions to promote bone regeneration in medical applications. 
Magnesium is the fourth-most abundant element in the human body, of which 
approximately half is stored in bone tissue. [230] It is an essential cation for many 
physiological functions, including enzymatic reactions involved in energy 
metabolism and synthesis of proteins, lipids, and nucleic acids.[184] Numerous 
studies have shown a correlation between magnesium deficiency and 
osteoporosis.[210] Pure magnesium corrodes too quickly in physiological pH and 
produces excessive hydrogen gas; therefore, efforts to use the metal itself in 
orthopaedic applications have been impeded.[230] However, there have been several 
studies focused on complementing biomaterials with Mg2+ that have shown Mg2+ 
supplementation to increase cellular adhesion via an integrin-mediated mechanism, 
spreading, proliferation, ALP activity, matrix mineralization, and osteogenic 
differentiation in vitro as well as enhance osseointegration in vivo.[203,204,231] 
Silicon, commonly existing as the silicate ion (Si4–) in vivo, has an essential role in 
bone-forming metabolic processes. Silicon concentrations are elevated during early 
bone calcification, inducing hydroxyapatite precipitation into the matrix.[183] Si ions 
have been widely used to modify hydroxyapatite, which is also a used biomaterial 
for bone replacement. In addition, the presence of Si ions speeds the remodeling. 
Silicon also has a role in modulating the homeostasis of collagen and other ECM 
proteins in bone matrix; the ion induces osteoblast differentiation as well as 
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collagen I production in human osteoblast cells.[232] In addition, silicon is able to 
induce angiogenesis and vascularization.[147] 
Zinc is an essential trace element required for many cellular catalytic, structural, and 
regulatory processes and is critical for normal growth, immunological functions, and 
neurological health.[233,234]  Zinc is further recognized as an antioxidant and anti-
inflammatory agent that might have significant therapeutic benefits against several 
chronic diseases, such as cancer, neurodegeneration, atherosclerosis, and 
immunological disorders. It has long been known that zinc is required for bone 
growth and development and that its deficiency can lead to many kinds of skeletal 
abnormality in fetal and postnatal development, including bone growth retardation, 
abnormal mineralization, and osteoporosis.[234,235] At a cellular level, zinc exerts a 
dual mode of action by supporting both osteoblastogenesis and suppressing 
osteoclastogenesis. Zinc can enhance osteogenesis through inducing collagen 
synthesis, ALP activity, and mineralization of bone nodules. In osteoblast-like 
MC3T3-E1 cells, this is mediated by Runx2 expression, the master gene of 
osteogenesis and, in mesenchymal stem cells.[219,220,236] 
Strontium is structurally, physically, and chemically similar to calcium and, thus, has 
been studied extensively in the context of bone regeneration. Strontium is a strong 
bone-seeking trace element, of which approximately 98% is localized in human 
bone tissue.[237] In recent years, strontium has been recognized as a treatment for 
osteoporosis in the form of strontium ranelate. In vitro, the drug as a dual mode of 
action, by both decreasing bone resorption and increasing bone formation.[238] Over 
time, this has shown to translate into an increase in osteoblast surfaces, mineral 
apposition rate, trabecular and cortical bone formation, bone mineral density 
(BMD), and ultimately, lower risk of fracture.[239]  
Strontium itself promotes osteogenic differentiation of MSCs by upregulating the 
expression of osteoblast marker genes, such as Runx2, OCN, osteopontin (OPN), bone 
sialoprotein (BSP), and type 1 collagen, and increasing ALP activity and matrix 
mineralization.[212] Strontium also upregulates the expression of endogenous BMP-
2;[213] however, when used in conjugation with free rhBMP-2, a Sr-rhBMP-2 complex 
is rapidly formed that undermines the binding capability of rhBMP-2 to its receptor. 
As a result, the BMP/Smad signaling pathway is suppressed, decreasing the 
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efficiency of in vitro and in vivo rhBMP-2 induced osteogenesis.[182] Strontium has 
also widely been used to enrich biomaterials such as various kinds of calcium 
phosphate, bioactive glass, bone cement, and metallic implant. The presence of Sr2+ 
in these structures enhanced the proliferation and osteogenic differentiation in 
osteoblastic cells, and inhibited osteoclast activity in vitro.[214,240] In vivo, Sr2+ 
incorporation promotes bone formation, remodeling and osseointegration. Studies 
have shown Sr2+ to lead to an increase in the bone-to-implant contact, peri-implant 
bone volume, and push-out force.[204,241] Additionally, a recent study investigated 
the potential benefits of a combined ionic therapy using a cobalt- and strontium-
doped bioglass, making use of the osteogenic effect of strontium and the angiogenic 
effect of cobalt, in the regeneration of functional bone tissue.[241] This highlights the 
potential therapeutic applications of combining multiple ions into bone tissue 
regeneration implants to exploit the different actions of different ions. 
Shi et al. have shown that strontium can be incorporated into the titanium implant 
surfaces to subsequently release the bioactive ion and enhance implant 
osseointegration.[242] High surface of MTF coatings enable high interaction surface 
of the implant with the surrounding. Importantly, it is possible to incorporate 
strontium or calcium into the MTF during the synthesis process simply by adding 
ionic salts to the sol.[243] By this way the ions will be incorporated to the titania 
matrix forming titanates with an enhanced biological activity. As for now the 
incorporation of 0.2 x 10-3 : 1 of Sr : Ti relation in moles has been achieved.[243] 
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II. AIM AND OBJECTIVES OF THE THESIS 
This PhD dissertation aims at the design and fabrication of mesoporous titania thin 
films with controlled pore size and chemical functionalization for potential use as 
coating in titanium implants. Mesoporous coatings offer the advantage that they 
display pores that can be filled with drugs and molecules promoting cell growth and 
with antibacterial properties that can be beneficial for the bone regeneration. In 
addition, in mesoporous materials the active surface of the coating is largely 
increased due to their porosity. Pores will be used here for the encapsulation and 
sustainable release of antibiotics.  The large surface area of the porous materials will 
provide a means to enhance the delivery of bioactive ions. In addition, the 
mesoporous coatings will be engineered with bioactive molecules and self-
assembled films of antibiotics.  
The general aim comprises the following specific objectives: 
Objective 1 
To design and fabricate functional mesoporous titania films (MTFs) loaded 
with antibiotic molecules such as gentamicin and its subsequent controlled 
release. Drug release will be assessed through fluorescent emission measurements 
at different time periods. The impact of the antibiotic release will be evaluated by 
studies of S. aureus proliferation on top of the film. In addition, recombinant human 
Bone Morphogenetic Protein 2 (rhBMP-2) will be assembled on top of the MTFs. The 
impact of rhBMP-2 on MC3T3-E1 pre-osteoblastic cell line proliferation and 
differentiation will be evaluated. 
Objective 2 
To fabricate a multilayer coating through the layer-by-layer technique using 
as building blocks poly-L-lysine (PLL) and complexes of gentamicin and poly 
(acrylic acid) (PAA) to achieve a stable film capable of releasing gentamicin in 
a time window of weeks. Optimal gentamicin concentrations and ionic 
strength/pH conditions will be found to obtain stable complexes with the highest 
possible loading of gentamicin. The release of antibiotics and effectiveness of the 
PEM will be evaluated studying the proliferation of S. aureus on top of the film. 
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Objective 3 
To synthesize mesoporous films comprising strontium titanates and evaluate 
their potential for enhancing osseointegration. A new fabrication method will be 
evaluated that comprises the film formation from a heterogeneous precursor 
mixture containing titanium precursor and strontium chloride as well as a structure 
directing agent. By spin coating and taking advantage of the evaporation induced 
self-assembly (EISA) method SrTiO3 mesoporous films will be fabricated. The 
release of strontium ions from the film will be studied and their capability to 
promote MC3T3-E1 pre-osteoblast cell proliferation and differentiation for the 
improvement of osseointegration of titanium implants will be evaluated. 
Objective 4 
To fabricate mesoporous titania films functionalized with carboxylic groups 
capable of complexing and releasing Sr+2 for enhanced osseointegration. A   
one step co-condensation approach will be developed to synthesize mesoporous 
silica films with carboxylic groups, and then the synthesis will be extended to the 
functionalization of titania films. A two-step synthetic pathway is followed to obtain 
a versatile titania mesoporous system that can be functionalized with different 
bioactive ions. The presence of carboxylic groups will be evaluated by selective 
complexation of bioactive ions; lead and strontium for silica and titania films, 
respectively. The main purpose of this chapter is to enhance cell osseointegration in 
implants by means of the release of strontium ions complexed to carboxylates in the 
pore walls of the coating. 
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III. MATERIALS AND METHODS 
Materials 
All the mesoporous films based on titania are prepared in glass coverslips of 14 mm 
in diameter and 0.13 - 0.16 mm of thickness from Thermo Scientific through spin 
coating. Silica based mesoporous films are prepared in glass slides of 0.8 – 1 mm of 
thickness from Thermo Scientific through dip coating. 
For the titania film synthesis Titanium (IV) Chloride (≥ 99.0%, TiCl4), 
tetraethoxysilane (TEOS, 98 %), Brij 58 and Pluronic F127® were purchased from 
Sigma Aldrich (Madrid, Spain) and Absolute Ethanol (≥ 99 %, EtOH) from Scharlau. 
For chemical and biomolecular functionalization of the mesoporous films 
Mercaptosuccinic acid (MSA, 97 %), Mercaptoacetic acid (MAA, 97 %), 
Vinilmethoxisilane (VTMS, 98 %), Benzophenone (Ph2CO, 99 %), Strontium chloride 
hexahydrate (SrCl2 x 6H2O), recombinant human Bone Morphogenetic Protein -2 
(rhBMP-2) and Gentamicin Sulphate were also purchased from Sigma Aldrich 
(Madrid, Spain). Pb(NO3)2 and methanol were purchased from Merck.  
For LbL coatings Poly (acrylic acid) solution Mw = 100 kDa and Poly – L –lysine  0.01 
% with Mw = 150 – 300 kDa were also purchased from Sigma Aldrich (Madrid, 
Spain). 
To study the gentamicin release 2 – mercaptoethanol, Boric Acid and O – 
phtaldehyde were purchased from Sigma Aldrich and the 2 – propanol was 
purchased from Fisher Scientific. 
Phosphate buffered saline (PBS) in tablets, Sodium dodecadocyl sulphate (SDS), 
Nitric acid (HNO3) and Sodium hydroxide (NaOH) were purchased from Sigma 
Aldrich. Sodium chloride (NaCl), Calcium nitrate (Ca(NO3)2) and hydrochloric acid 
(HCl) were purchased from Fisher Scientific.  
All the buffers and solutions were filtered through the 0.2 μm filters (Fisher, Madrid, 
Spain) and degassed in bath sonicator prior to its use. The Falcon polystyrene tissue 
culture plates were purchased from Fisher Scientific (Madrid, Spain). Nanopure 
water used in preparation of all the dilutions and buffers was produced with a 
Diamond UV water purification system (Branstead International, IA, Iowa, USA). 
Methods 
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The main techniques and methods used are described below, and more specific 
methods are presented in the experimental part of each chapter. 
Spin coating and dip coating 
The spin coating technique uses centrifugal forces created by a spinning substrate 
to spread a coating solution over the desired surface to cover. Is important the 
amount of liquid used and it should be dispensed in the proper location with the 
help of a syringe or a pipette used manually or with an automated pumping 
system.[244] 
The setup consists of a sample holder or a stage, a motor and a controller used to 
spin the sample at a specific velocity and for a determined time. The solution is 
dispensed just at the beginning of the spinning process while the spin speed starts 
to accelerate to spread the liquid over the surface to cover it. During the spin time 
the solution is spread across the substrate and the excess will be forced off. The spin 
velocity will determine the coating thickness because while the spin speed 
decreases, the lower amount of solution would be forced off.[244]  
For the mesoporous films synthesized by spin coating for this research work, 30 µL 
are dispensed in the glass substrates. The acceleration time is set at 0 to reach the 
velocity of 68 rpm as soon as possible and the sample is spinning at this velocity for 
30 seconds. The SCC-200 spin coater from Novocontrol Technologies is used. 
In dip coating technique, the substrate where the glass slide is withdrawn vertically 
to the sol.[245] Thickness and uniformity are sensitive to the conditions the substrate 
is withdrawn, and the faster the velocity the thicker is the film deposited.[246]  
A withdrawal speed of 3 mm s-1 is used to deposit the films synthesized by dip 
coating onto glass slides.  
X-Ray photoelectron spectroscopy (XPS) 
X-Ray photoelectron spectroscopy is a surface analysis technique. It is used to 
measure the elemental composition, the empirical formula and chemical and 
electronic state of the elements within a material.[247] The basic principle of XPS lays 
in photoelectric effect described by Einstein.[248] In XPS experiment, kinetic energy 
is measured from electrons that are emitted from the surface as schematically 
shown in Figure III-1. A soft X-ray irradiation is used to excite the core electrons. A 
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bound electron adsorbs the photon, converting some of its energy into kinetic 
energy (KE). The electron leaves the atom and some of its energy is used to 
overcome the Coulomb attraction of the nucleus, reducing its KE by its initial state 
binding energy (BE). At the same time the outer orbitals readjust, lowering the 
energy of the final state that is being created and giving this additional energy to the 
outgoing electron. XPS is very surface sensitive technique as atoms emit photons 
from few top atomic layers. A photoelectron spectrum is recorded by counting 
ejected electrons over a range of electron kinetic energies. Peaks appear in the 
spectrum from atoms emitting electrons of a particular characteristic energy. 
 
Figure III-1. Schematic representation of XPS. A core electron is excited with X-ray source, 
a photoelectron is ejected from the atom for a value of the binding energy, the kinetic energy 
and the work function of the spectrometer.  
Experiments were performed with a SPECS Sage HR 100 spectrometer equipped 
with a 100 mm mean radius PHOIBOS analyzer and a nonmonochromatic X-ray 
source (Mg Kα line of 1253.6 eV energy and 250 W), placed perpendicular to the 
analyzer axis and calibrated using the 3d5/2 line of Ag, with a full width at half 
maximum of 1.1 eV. The selected resolution for high resolution spectra was 15 eV of 
pass energy and 0.15 eV per step. All measurements are made in an ultrahigh 
vacuum chamber at a pressure of around 8 × 10−8 mbar. An electron flood gun is 
used to neutralize the charging. Measurements are conducted directly on the films, 
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which are previously washed with absolute ethanol and cut into samples of 1 cm × 
1 cm. The analysis of spectra is done with CasaXPS 2.3.15dev87 software. Satellite 
removal and Shirley background subtraction are applied. Binding energies were 
calibrated assigning to the C 1s C−C peak 285 eV, and peaks were fitted with 
Gaussian−Lorentzian line shapes to determine the atomic percentages of elements 
present in the films.  
Atomic force microscopy (AFM) 
Atomic force microscopy is a high resolution scanning technique used to measure 
local properties of a surface using a probe. A cantilever with a sharp tip at its end is 
used for the scanning. When the tip is brought into proximity of a sample surface, 
forces between the tip and the sample lead to a deflection of the cantilever according 
to Hooke's law. In most cases a feedback mechanism is employed to adjust the tip-
to-sample distance to maintain a constant force between the tip and the sample.[249]  
There are two imaging modes; static or contact mode and a variety of non-contact 
or “tapping” modes, where the cantilever vibrates at given frequencies. In contact 
mode, the tip drags across the sample surface, and while the tip scans the surface, 
the topography of the surface induces a vertical deflection of the cantilever. A 
feedback loop maintains this deflection at a pre-set load force and uses the feedback 
response to generate a topographic image. Close to the surface of the sample, 
attractive forces can be quite strong, causing the tip to “snap-in” to the surface.  
In tapping mode, AFM maps topography by lightly tapping the surface with an 
oscillating probe tip. The cantilever is driven to oscillate up and down at or near its 
resonance frequency by a small piezoelectric element mounted in the AFM. The 
interaction of forces acting on the cantilever when the tip comes close to the surface, 
Van der Waals forces, dipole-dipole forces or electrostatic forces, among others, 
cause a decrease in the oscillation amplitude as the tip gets closer to the sample. The 
height is adjusted to maintain the oscillation amplitude and scan over the 
sample.[250] 
Images are obtained using a Nanowizard II AFM (JPK, Berlin, Germany). Images are 
acquired in air. The tapping mode is used with the tip TESP-V2 (Bruker, AFM 
probes) which has a spring constant of 40 N m−1 and a resonant frequency in the 
range 280 – 320 kHz. Average roughness  𝑅𝑎 calculation, which gives the deviation 
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in height, is done by applying Equation III-1.  𝑧̅ is the arithmetic average height 
calculated from an image described as a matrix with 𝑁 lines and 𝑀 columns and each 
height value 𝑧 is associated to an (𝑥, 𝑦) coordinate.[250] 
𝑹𝒂(𝑵, 𝑴) =  
𝟏
𝑵
 ∑(𝒛(𝒙, 𝒚) −  ?̅? (𝑵, 𝑴)) 
𝑵
𝒙=𝟏
 Equation III-1 
Phase images need to be obtained with the tapping mode of the AFM and they 
represent the phase lag of the oscillation frequency of the cantilever when interacts 
with the sample. The greater the phase lag is the brighter is going to be the pixel and 
the smaller the phase lag, the darker the pixel. Chemical and physical properties of 
the material such as viscoelasticity, friction or adhesion impact on the phase shift 
and the tip experiences attractive and repulsive forces when it interacts with the 
surface.[250] 
Nanoindentation 
Nanomechanical tests were performed using a triboindenter (Hysitron –TI-950), 
equipped with a Berkovich tip and a 2D - axis transducer. Values of Hardness (H) 
and Elastic Modulus (Er) were extracted from nanoindentation tests.  
Measurements were performed 10 times using partial load-unload function and 
Oliver-Pharr method.[251]  Measurements were performed after 120 seconds of drift 
correction and shallow calibration (5-30 nm) of the indenter on commercially 
available fused quartz (69.6 GPa).  
Small-angle X-ray scattering (SAXS) 
Small-angle X-ray scattering is a small-angle scattering technique by which 
nanoscale electronic density differences in a sample can be quantified. This means 
that it can determine nanoparticle size distributions, resolve the size and shape of 
macromolecules, determine pore sizes and characterize distances of partially 
ordered materials. This is achieved by analysing the elastic scattering behaviour of 
X-rays when travelling through the material, recording their scattering at small 
angles, typically 0.1 - 10°. It belongs to the family of small-angle scattering (SAS) 
techniques along with small-angle neutron scattering, and is typically done using 
hard X-rays with a wavelength of 0.07 - 0.2 nm. Depending on the angular range in 
which a clear scattering signal can be recorded, SAXS is capable of delivering 
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structural information of dimensions between 1 and 100 nm, and of repeat 
distances in partially ordered systems of up to 150 nm.[252]  
In a SAXS instrument a monochromatic beam of X-rays is brought to a sample from 
which some of the X-rays scatter, while most simply go through the sample without 
interacting with it. The scattered X-rays form a scattering pattern which is then 
detected at a detector which is typically a 2-dimensional flat X-ray detector situated 
behind the sample perpendicular to the direction of the primary beam that initially 
hit the sample. The scattering pattern contains the information on the structure of 
the sample. 
2D- Small angle X-Ray scattering (2D-SAXS) patterns were obtained at the Austrian 
SAXS beamline at the Elettra synchrotron (Trieste, Italy), using a 1.54 Å (8 keV) 
incidence X-ray beam. The sample was placed at 82.88 cm from a pixel detector 
(Pilatus1M) on a rotation stage, which allowed to set the glancing angle between the 
incident radiation and the sample to 3°.[253] The samples were prepared onto 
coverslips to allow measurements in Laue geometry. The angular scale of the 
detector was calibrated with Ag-behenate as the reference pattern. 
Confocal laser scanning microscopy (CLSM) 
Confocal laser scanning microscopy is an optical imaging technique with increased 
resolution and depth selectivity. The key feature of confocal microscope is in ability 
to acquire in-focus images from selected depths. Images are acquired point-by-point 
and reconstructed with a computer, allowing three-dimensional reconstructions of 
topologically complex objects. The quality of the image is greatly enhanced over 
simple microscopy because image information from a confocal microscope is 
constructed as one depth level at a time. In effect, the CLSM achieves a controlled 
and highly limited depth of focus.[254]  
Fluorescence images of stained pre-osteoblasts presented in this thesis were 
acquired on a Zeiss LSM 510 confocal microscope (Carl Zeiss, Göttingen, Gremany). 
Scanning electron microscopy (SEM) and Transmission electron 
microscopy (TEM) 
The base of the electron microscopy is the use of electrons to excite a sample and 
obtain an image. The SEM is used for surface imaging and with the TEM electrons 
are transmitted through the specimen to form an image. Incident electrons interact 
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with the sample and they can suffer different transformation, but we are focused on 
secondary electrons and transmitted electrons, detected by SEM and TEM, 
respectively. As secondary electrons have a low energy, only the electrons which are 
in the surface of the sample are able to get out from the sample, so these are the 
electrons we are going to measure. In the SEM, the electrons interact with atoms in 
the sample, producing signals that can be detected and contain information about 
the surface topography and composition. The electron beam is scanned in a raster 
scan pattern, and the beam's position is combined with the detected signal to 
produce an image. The most common SEM mode is detection of secondary electrons 
emitted by atoms excited by the electron beam.[255]  
Electrons are very small and can be deflected by hydrocarbons or gas molecules, in 
both cases, to avoid electron deviation a vacuum environment is needed to use the 
electron beam. The illumination source is an electron gun where a cathode 
(filament) is used as electron source generated by thermal emission. Electron 
microscope lenses are electromagnetic and a wrapping of copper wire makes up the 
magnetic field, which is the essence of the lens. The condenser lenses gather the 
electrons to focus the illumination onto the specimen and to reduce spherical 
aberrations. In the TEM, the objective lens is used to focus and magnify the image 
and the objective aperture is used to enhance the contrast of the image, and finally 
the projector lenses further magnify the image, which is projected into the 
phosphorous screen.[256] 
In Chapter 1 and Chapter 3 film surfaces were visualized with a Field Emission 
Scanning Electron Microscopy (FE SEM) Carl Zeiss NTS Supra 40 at the Advanced 
Microscopy Centre FCEN-UBA in second electron imaging (SEI) detection mode. In 
Chapter 1, to visualize film thickness and pores inside the film a transversal cut is 
done and images were taken with a Dual Beam SEM/FIB Helios 450S 
microscope (FEI, Netherlands) at 5 and 10 kV acceleration voltages.  In Chapter 3, 
to visualize the synthesized polyelectrolyte multilayer (PEM), a SEM of type JEOL 
JSM-6490LV has been used. Sample has been cut with a diamond tip and Pt-Au has 
been sputtered in the preparation chamber GATAN ALTO1000. 
TEM images were collected with TEM JEOL JEM-1400PLUS microscope equipped 
with a Gatan US1000 CCD camera. Films samples were prepared on copper grids 
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with a carbon film purchased from EM Resolutions. The films were scratched and a 
deposited on top of the grid with a 5 µL drop of ethanol. In  Chapter 3 and  Chapter 
4 Energy Dispersive X-ray (EDX) measurements have been performed. A JEOL JEM-
2100F UHR TEM operated at 200 kV in Scanning Transmission Scanning Microscope 
(STEM-BF) equipped with an EDX detector (EDXS, Oxford INCA systems) was used 
for the semi-quantitative analysis of the film composition at different areas on the 
surface. INCA and Origin 8.5 software were used for the analysis of the experimental 
data. 
Inductively coupled plasma mass spectrometry (ICP-MS) 
An Inductively coupled plasma mass spectrometry combines a high-
temperature ICP source with a mass spectrometer. The ICP source converts the 
atoms of the elements in the sample to ions. These ions are then separated and 
detected by the mass spectrometer. Argon gas flows inside the concentric channels 
of the ICP torch. The RF load coil is connected to a radio-frequency (RF) generator. 
As power is supplied to the load coil from the generator, oscillating electric and 
magnetic fields are established at the end of the torch. When a spark is applied to the 
argon flowing through the ICP torch, electrons are stripped off of the argon atoms, 
forming argon ions. These ions are caught in the oscillating fields and collide with 
other argon atoms, forming an argon discharge or plasma.[257] 
The sample is typically introduced into the ICP plasma as an aerosol, either by 
aspirating a liquid or dissolved solid sample into a nebulizer or using a laser to 
directly convert solid samples into an aerosol. Once the sample aerosol is introduced 
into the ICP torch, it is completely desolvated and the elements in the aerosol are 
converted first into gaseous atoms and then ionized towards the end of the 
plasma.[257] Once the ions enter the mass spectrometer, they are separated by their 
mass-to-charge ratio.[257] 
To measure the strontium amount released (Chapter 3 and 4) samples have been 
prepared in 5 % HNO3. Iridium (Ir) was used as internal standard to calibrate the 
equipment. To quantify the amount of strontium, SrCO3 solutions have been 
prepared at 1, 5, 10, 25, 50, 100 and 200 ppb for the calibration curve using the Sr 
reagent for ICP from Inorganic Ventures. To get accurate results the curve was 
forced to the blank. The calibration curve for strontium is: y = 1.01 x – 0.85, where y 
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is the measured intensity (a.u.) and x the strontium concentration (ppm) and has an 
R2 of 0.999. Measurements have been performed at a ICP-MS iCAP Q from Thermo 
Fisher.   
Quartz crystal microbalance with dissipation monitoring 
Quartz Crystal Microbalance with Dissipation monitoring (QCM-D) is a real-time, 
nanoscale technique for thin film formation, interactions and reactions. A QCM 
sensor consists of a thin quartz disc between a pair of electrodes. The sensor can be 
excited to oscillate at its resonance frequency by the application of an alternating 
voltage. The resonance frequency depends on the total oscillating mass of the sensor 
and sensor surface adhering layers, including coupled water. The frequency 
decreases when a thin film is attached to the sensor. If the film is thin and rigid the 
decrease in frequency is proportional to the mass of the film.[258] 
QCM-D is used in Chapter 3 of the thesis for the In situ monitoring of the poly-L-
lysine (PLL) Mw 150-300 kDa and poly (acrylic acid) (PAA) Mw 100 kDa and 
gentamicin complex films assembly and to study the film stability. An E4 QCM-D 
from Q-Sense, Goteborg, Sweden was used. The LbL assembly was performed on 
QSX 303 SiO2 quartz crystals (Q-sense) by alternating the PLL at a 1 mg mL-1 and the 
complex (1 mg mL-1 PAA and 0.3 mg mL-1 gentamicin) at pH 4.5 in NaCl 500 mM 
monitoring the decrease of the resonance frequency. Once the frequency value 
stabilized, the polymer solution has been replaced by NaCl 500 mM (pH 4.5) til a 
plateau was reached. This procedure has been repeated til the desired number of 
layers were deposited. 
Ellipsometry and environmental ellipsometric porosimetry (EEP) 
Ellipsometry measures a change in polarization as light reflects or transmits from a 
material structure. The polarization change is represented as an amplitude ratio, Ψ, 
and the phase difference, Δ. The measured response depends on optical properties 
and thickness of individual materials. Thus, ellipsometry is primarily used to 
determine film thickness and optical constants.[259] 
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Figure III-2. Geometry of an Ellipsometric measurement.[260] 
Data analysis proceeds as follows: After a sample is measured, a model is 
constructed to describe the sample. The model is used to calculate the predicted 
response from Fresnel’s equations which describe each material with thickness and 
optical constants. If these values are not known, an estimate is given for the purpose 
of the preliminary calculation. The calculated values are compared to experimental 
data. Any unknown material properties can then be varied to improve the match 
between experiment and calculation.[259] 
The film thickness is determined by interference between light reflecting from the 
surface and light traveling through the film. Depending on the relative phase of the 
re-joining light to the surface reflection, interference can be defined as constructive 
or destructive. The interference involves both amplitude and phase 
information. The film thickness affects the path length of light traveling through the 
film, but the index determines the light waves’ velocity and refracted angle. Thus, 
both contribute to the delay between surface reflection and light traveling through 
the film. Both refractive index 𝑛 and dielectric constant 𝑘 must be known or 
determined along with the thickness to get the correct results from an optical 
measurement.[259] 
EEP measures the change of the optical properties and thickness of the materials 
during adsorption and desorption of volatile specie. The amount of adsorptive 
inside of pores is calculated from the measured change of the optical characteristics 
of the porous film during the vapour adsorption/desorption. There are several 
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methods for performing these calculations based on various equations (Lorentz–
Lorenz, Newton–Laplace, Bragg–Pippard, etc). The optical characteristics of the 
dense part of the porous media and of the liquid adsorptive are used in these 
calculations. The various equations give similar results, however, the Lorentz–
Lorenz equation is more widely used.[259] 
The technique is based on analysis of the hysteresis loops that appear due to the 
processes of capillary condensation and desorption of a vapour out of porous 
adsorbents. The hysteresis loops appear because the effective radius of curvature of 
condensed liquid meniscus is different during the adsorption and desorption 
processes. The adsorptive vapour condenses in pores even if the vapour pressure P 
is less than the equilibrium pressure of a flat liquid surface P0. Dependence of the 
relative pressure P/P0 on the meniscus curvature is described by the Kelvin 
equation 
1
𝑟1
+  
1
𝑟2
=  − 
𝑅 𝑇
𝛶 𝑉𝐿
𝑙𝑛 (
𝑃
𝑃0
) 
Equation III-2 
where 𝛶 and 𝑉𝐿 are surface tension and molar volume of the liquid adsorptive, 
respectively. The principal curvature radii 𝑟1 and 𝑟2 define pore sizes. In the case of 
cylindrical pores, 𝑟1 = 𝑟2 and  
(
1
𝑟1
+  
1
𝑟2
) =  
2
𝑟𝑘
 
Equation III-3 
The radius 𝑟𝑘 is often termed the Kelvin radius. If the radius of a cylindrical pore 
is 𝑟𝑝, then 𝑟𝑝 = 𝑟𝑘  + 𝑡 , where 𝑡 is the thickness of the layer already adsorbed on the 
pore walls. Values of 𝑡 are obtained from the data for the adsorption of the same 
adsorptive on a nonporous sample having a similar surface.[261]  
Ellipsometry allows us to measure both the refractive index and the film thickness 
𝑑. In this case the adsorptive volume in pores can be calculated as  
𝑉𝑎𝑑𝑠 =  
𝑉𝑚
𝛼𝑎𝑑𝑠 · 𝑑𝑡
(𝐵1𝑑1 −  𝐵0𝑑0) 
Equation III-4    
 
where 𝑉𝑎𝑑𝑠 is the volume of the liquid adsorptive in the pores, 𝐵0 and 𝐵1 are the 
volume polarizability of the film before and after adsorption, 𝑑0 and 𝑑1 are the film 
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thickness before and after adsorption, respectively, 𝑉𝑚 is the molecular volume of 
the adsorptive and 𝛼𝑎𝑑𝑠 is the polarizability of the adsorptive molecule.[261] 
For titania films in all chapters the measurements were performed in a M2000 VASE 
from Woollam ellipsometer. Ellipsometric and EEP measurements of mesoporous 
silica films in Chapter 4 were performed in a SOPRA GES5A ellipsometer, using 
samples previously washed with absolute ethanol and dried. Film thickness and 
refractive index values were obtained from the ellipsometric parameters Ψ and Δ 
under dry air flux containing variable water vapour pressure 𝑃; 𝑃/𝑃0was varied 
from 0 to 1 (𝑃0 being the saturation water vapour pressure at 25 °C). Water volume 
adsorbed at each value 𝑃/𝑃0  was determined by modelling the obtained refractive 
index according to a three-component (water−air−oxide) Bruggeman effective 
medium approximation. Adsorption−desorption isotherms were obtained by 
plotting the water volume adsorbed by the porous film at each 𝑃/𝑃0. The pore size 
distribution was obtained from the isotherms using the Kelvin equation, taking into 
account the water contact angle in the film.[262]  
Contact angle goniometer 
Contact angle goniometer measurements are essential for understanding the 
wetting characteristics of an analysed surface. The contact angle (CA) is defined as 
the angle made by a sessile drop of liquid (𝑙) in contact with a solid (𝑠) surface and 
is measured according the Young’s equation (Equation III-5) from the side of the 
liquid as seen in Figure III-3.[263] Analysing the CA when a drop of water is placed 
on a surface information about the degree of hydrophobicity or hydrophilicity of 
almost any kind of surfaces can be obtained. [264] 
𝛾𝑠𝑣 = 𝛾𝑠𝑙 −  𝛾𝑙𝑣 𝑐𝑜𝑠𝜃 Equation III-5 
 
Figure III-3. Vector representations of Young’s equation on a sessile drop for measuring 
Young’s contact angle.[265]  
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One of the most common techniques used to measure CA is by goniometry, where 
basically the CA is measured by an image of the drop adsorbed on the specimen’s 
surface. After imaging, a tangent is drawn along the solid-liquid interface and the CA 
is measured from the drop profile. Young’s model is applied only to systems with 
smooth and homogeneous surfaces. For rough and heterogeneous surfaces have 
been established modifications to the Young’s model.  
The Wilhelmy plate technique developed by Neumann is widely used to determine 
the advancing and receding contact angles and therefore the surface free energy of 
analysing surfaces.[266] Contact angle measurements were performed in a Drop 
Shape Analyser – DSA100 from Kruss and a Ramé-Hart 190 CA equipment. 
Dynamic light scattering (DLS) 
Dynamic light scattering is a powerful technique for probing soft matter particles 
mainly at the sub-micron region. DLS is based on the time-resolved measurement of 
the scattered intensity, I(t) produced by particles suspended in a liquid undergoing 
the Brownian motion. The Brownian motion is correlated with the scattered light 
therefore the larger the particle, the slower the Brownian motion will be; the 
diffusion due to Brownian motion of the particles is obtained by recording the rate 
at of fluctuation of the intensity of the scattered light. Subsequently small particles 
display more rapid scattered light intensity fluctuation in contrast with large 
particles. Further information about the random fluctuations in a time-resolved 
manner is provided by the autocorrelation function (Equation III-6).  
𝑔 (𝑡) =
〈𝐼 (𝑡 + 𝑡0)  ×  𝐼( 𝑡0)〉
〈𝐼〉2
 
Equation III-6 
 
For large particles the correlation of the signal takes more time to decay while for 
small particles the correlation decreases rapidly as a consequence of the movement 
of the particles.  
𝐷 =
𝑘𝐵𝑇
6𝜋𝜂𝑅𝐻 
 
Equation III-7 
 
According to Stokes-Einstein equation (Equation III-7) the particle size is given in 
terms of hydrodynamic radius which is defined by the diameter of a sphere that has 
the same translational diffusion coefficient as the particle8. Where 𝐷 is the diffusion 
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coefficient, 𝑘𝐵 is Boltzmann’s constant, 𝑇 is the temperature, 𝜂 is the viscosity of the 
medium and 𝑅𝐻 is the hydrodynamic radius of the analysed particle.[267]  
Measurements were performed in a Zetasizer Nano ZS from Malvern. 
Gentamicin detection 
One of the major problems related to the use of gentamicin, and all aminoglycoside 
antibiotics, in the laboratory is the limited means of quantifying the drug. Since 
gentamicin absorbs ultraviolet and visible light poorly and the molecule lacks 
fluorophores, no direct spectrophotometric or fluorometric method can be applied. 
Therefore, its detection often requires derivatisation.[268] 
Boric acid (0.4 M) is dissolved in distilled water; the pH is adjusted to 10.4 with 
potassium hydroxide solution. O-phthaldialdehyde (OPA) reagent is prepared 
according to following procedure: 0.2 g of OPA is dissolved in 1 mL of methanol and 
the solution is mixed with 19 mL of a 0.4M boric buffer. Then, 0.4 mL of 2-
mercaptoethanole is added and the pH was adjusted to 10.4 with the potassium 
hydroxide solution. This reagent is kept in the dark at 4 ◦C until its use the following 
day. The samples and the 2-propanol are mixed in 1:1 proportion in volume and 
vortexed. Then, the OPA reagent is added in the same proportion and the solution is 
vortexed again.[268,269] For 15 min, prior to measurement, the solutions are heated 
at 60 °C to catalyze the reaction. All the reagents were purchased from Sigma 
Aldrich, except the 2-propanol, which is from Fisher. 
The formed fluorescent complex has its maximum absorption at 340 nm and the 
emission at 455 nm was collected at a Thermo Scientific™ Varioskan™ Flash 
Multimode Reader. 
The gentamicin calibration curve was performed from 0 to 4 µg mL-1 containing 7 
points, prepared by triplicate. The calibration curve can be described with the 
following equation; y = 6.49 + 21.26 x where y is the emission of the OPA-gentamicin 
complex at 455 nm and x is the gentamicin concentration in µg mL-1 and has an R2 
of 0.997.  
Diffuse Reflectance Infrared Fourier Transform Spectroscopy (DRIFT) 
A Fourier Transform Infrared (FTIR) Spectrometer is an instrument which 
acquires broadband near Infrared (NIR) to far Infrared (FIR) spectra.   A FTIR is a 
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method of obtaining infrared spectra by first collecting an interferogram of a 
sample signal using an interferometer, and then performing a Fourier Transform 
(FT) on the interferogram to obtain the spectrum.[270]  
An FTIR is typically based on The Michelson Interferometer Experimental Set. The 
interferometer consists of a beam splitter, a fixed mirror, and a mirror that 
translates back and forth, very precisely. The beam splitter is made of a special 
material that transmits half of the radiation striking it and reflects the other half. 
Radiation from the source strikes the beam splitter and separates into two beams. 
One beam is transmitted through the beam splitter to the fixed mirror and the 
second is reflected off the beam splitter to the moving mirror. The fixed and 
moving mirrors reflect the radiation back to the beamsplitter. Again, half of this 
reflected radiation is transmitted and half is reflected at the beam splitter, 
resulting in one beam passing to the detector and the second back to the 
source.[271] 
DRIFT is a surface localized FTIR spectroscopy, since it can provide both chemical 
and structural information for all types of solid surfaces. When infrared radiation 
reaches a sample surface, one or several processes can occur: light can be adsorbed, 
reflected from the surface, or it can penetrate the sample before being scattered. If 
scattering centers, which are fibers in the case of ACM, are randomly oriented, the 
phenomenon is isotropic and generates a diffuse reflectance. The scattered light is 
then collected and relayed to the IR detector, where the absorption by chemical 
groups is revealed.[272] 
Optical Path Difference (OPD) is the difference between the two beams travelling 
through the two arms of an interferometer. Interferogram is the name of the 
signal format acquired by an FT-IR spectrometer. It is usually significantly more 
complex than a single sinusoid, which would be expected if only a single 
wavelength of light was present. The X-axis of the interferogram represents the 
optical path difference. Each individual spectral component contributes a single 
sinusoid with a frequency inversely proportional to its wavelength to this signal. 
This leads us to the definition of the unit of spectral measurement: the 
wavenumber (cm-1), denoted as n. A wavenumber represents the number of full 
waves of a particular wavelength per cm of length (typically in vacuum, where the 
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index of refraction n=1). The advantage of defining the spectrum in wavenumbers 
is that they are directly related to energy levels. A spectral feature at 4,000 cm -
1 spectral location represents a transition between two molecular levels 
separated by twice the energy of a transition with spectral signature at 2,000 cm -
1.[270] 
Once an interferogram is collected, it needs to be translated into a spectrum 
(emission, absorption, transmission, etc.). The process of conversion is through 
the Fast Fourier Transform algorithm.[270] 
In this work FTIR and DRIFT spectroscopy measurements were performed in a 
Nicolet Magna 560 instrument, equipped with a liquid N2-cooled MCT-A detector. 
X-Ray Reflectrometry (XRR) 
XRR studies allow determining porosity of porous films.[273] Measurements were 
performed on a Panalytical Empyrean X-ray diffractometer with an incident beam 
of Cu Kα radiation at 1.54 Å and an incident angle of 1°. A divergence slit of 0.38 mm 
and a mask of 10 mm were used for the measurements. Film thickness was 
determined from the Kiessigfringes in the reflectogram. The reflectivity critical 
angle θc (the angle at which the reflected intensity is half the total external 
reflection) allows determining the electronic density (ρe) of the film by using 
Equation III-8; 
𝜌𝑒 =
𝜋 
𝜆2𝑟𝑒 
𝜃𝑐
2 Equation III-8 
where re is the classical radius of the electron (2.813 × 10–6 nm). Taking into account 
Equation III-8, the films porosity can be estimated from XRR data by measuring the 
change in the critical angle (and thus, in the thin film density) when the relative 
humidity (RH) changes from ~5 % (i.e. the pores are full of air) to ~90 % (i.e. the 
pores are filled with water). For that purpose, XRR measurements were made with 
the films placed inside a controlled humidity chamber. Considering that the increase 
in film density is only due to the presence of water, the water volume fraction 
(Fv(H2O)) within the film was determined from the measured electronic densities 
using Equation III-9. In this case, the Fv(H2O) calculated is equivalent to the porosity 
(P) of the material. 
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𝑃 = 𝐹𝑣(𝐻2𝑂) =  
𝜌𝑒  (𝑓𝑖𝑙𝑚 +  𝐻2𝑂)  −  𝜌𝑒( 𝑓𝑖𝑙𝑚) 
𝜌𝑒(𝐻2𝑂)
 
 
Equation III-9 
 
where ρe(film + H2O) is the electronic density of water-filled film (measured at high 
RH), ρe(film) is the electronic density of the film (measured at  low RH) and the 
ρe(H2O) is the water electronic density. 
Cell culture and assays 
In this part, the cell culture methods and several assays to determine the 
osseointegration and antibacterial capacity of the substrates are explained.  
MC3T3-E1 pre-osteoblastic cell line 
The MC3T3 cell line comes from mouse (Mus musculus) calvaria bone. They are 
adherent pre-osteoblasts with fibroblastic morphology and with the ability to 
differentiate to osteoblasts. For the experiments the MC3T3-E1 cell line from Sigma 
Aldrich is used.  
MC3T3-E1 cell culture 
Cells are preserved in cryotubes with culture medium containing 10% glycerine at 
liquid N2 at 196 °C. They are defrozen in 37 °C water bath, transferred to a centrifuge 
tube containing full culturing medium and centrifuged at 150 x g for 5 minutes. The 
cell pellet is resuspended in the full medium and dispensed in a culture flask. They 
are cultured in supplemented α-Minimum Essential Medium (α-MEM, Sigma 
Aldrich) with 10 % Fetal Bovine Serum (FBS, Sigma Aldrich) and 1 % of antibiotics 
(Penicillin-Streptomycin, Sigma Aldrich), referred as full culturing medium. They 
are kept at 37 °C and in a 5 % CO2 atmosphere.  
When cells reach 80 % confluence they are replicated. Using trypsin cells are 
detached from the culture bottle and around the 15-20 % of the detached cells are 
transferred to a new bottle. In this way, cells are always kept in the exponential 
growth phase. Cells are used for experiments til 15 passages to keep the genetic 
integrity of the cell line.  
Actin cytoskeleton and focal adhesion staining  
The actin cytoskeleton is composed of actin polymers and various associated 
proteins. It mediates a diversity of essential biological functions in eukaryotic cells. 
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The organization of the actin cytoskeleton is tightly regulated both temporally and 
spatially. Actin polymers are super organized into a filamentous network that is 
mediated by actin side binding or cross-linking proteins. A disruption of normal 
regulation may lead to cell transformations that have been shown to contain less F-
actin and exhibit atypical coordination of F-actin levels to the cell cycle.[274] 
Focal adhesion and adherent junctions are membrane-associated complexes that 
serve as nucleation sites for actin filaments and as cross-linkers between the cell 
exterior, plasma membrane and actin cytoskeleton. The function of focal adhesions 
is structural, linking the ECM on the outside to the actin cytoskeleton on the inside. 
Focal adhesions consist of integrin-type receptors that are attached to the 
extracellular matrix and are intracellularly associated with protein complexes 
containing vinculin (universal focal adhesion marker), talin, α-actinin, paxillin, 
tensin, zyxin and focal adhesion kinase (FAK). 
To confirm cell adhesion to the substrates Confocal Laser Scanning Microscopy 
(Zeiss LSM510) observations were performed after F-actin, focal adhesions and 
nucleus labeling with actin cytoskeleton and focal adhesion staining kit (FAK100, 
Millipore). Briefly, after reaching the 80% confluence, cells are trypsinized and 
resuspended in fresh medium to a final cell density of 3 × 104 cells mL-1. 1 mL of cell 
suspension is added into each well of 24 multi well cell culture plates. After culturing 
for 2, 24 and 48 h, cells are first permeabilized with 0.1 % Triton-X100 (Sigma-
Aldrich) for 4 min at room temperature. Then, cells are incubated in dilute anti-
vinculin primary antibody for 1 h at room temperature, followed by three times 
wash for 5−10 min each with wash buffer (PBS with 0.05% Tween-20 (Sigma 
Aldrich)), followed by 1 h further incubation with a fluorescein isothiocyanate 
(FITC)-conjugated secondary antibody and tetramethylrhodamine (TRITC)-
conjugated Phalloidin at room temperature. After three times rinsing with wash 
buffer, cells are incubated with 4,6-diamidino-2-phenylindole (DAPI) for 3 min at 
room temperature, followed by a three times wash.  
MC3T3-E1 cell proliferation 
After reaching 80 % confluence, cells are trypsinized and resuspended in fresh 
medium to a final cell density of 2.5-3 × 104 cells mL-1. 1 mL of cell suspension is 
added into each well of 24 well cell culture plates. A cell proliferation colorimetric 
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assay is conducted with the Cell Counting Kit-8 (CCK-8) (Sigma Aldrich) containing 
WST-8[2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H-
tetrazolium, monosodium salt], a nontoxic dye used for continuous cell culturing. 
Colorimetric analysis is performed at a certain time periods of cell culturing, in days 
scale, as noted in each of chapter. For this assay, the cells cultured on the samples 
are refreshed with 10 % v/v of CCK-8 containing medium. After 2 hours of 
incubation at 37 °C, aliquot of 150 µL is placed into 96 well cell plate. Optical density 
of reaction solution was acquired using a plate reader (GENios Pro, Tecan) equipped 
with a 450 nm filter. The statistical ANOVA analysis was done in Origin 8.5 software. 
Fisher’s tests were performed to determine statistically significant differences with 
a p < 0.05. 
MC3T3-E1 cell differentiation 
MC3T3-E1 cell line behaves similar to primary calvarial osteoblasts and exhibit high 
levels of osteoblast differentiation after growth in ascorbic acid and inorganic 
phosphate. They form a well mineralized extracellular matrix (ECM) after 10 days 
of osteogenic culture.[275]   
For cell differentiation the full medium is additionally supplemented with 50 µg mL-
1 of L- ascorbic acid and 2mM of β-glycerophosphate, both purchased from Sigma 
Aldrich. 
 
 Alkaline phosphatase activity 
Alkaline phosphatase (AP) is an important component in hard tissue formation, 
highly expressed in mineralized tissue cells. The AP in hard tissue formation serves 
as a marker for osteogenic activity has and it occurs at an early step in the 
mineralization process. Proliferating osteoblasts show AP activity in the stage of 
extracellular matrix maturation, being greatly enhanced during in vitro bone 
formation. AP activity is therefore a feasible marker for differentiating and 
mineralizing osteoblastic formation.[276]  
For AP quantification cells are seeded with a density of 5 x 104 cell mL-1 in a 24 
multiwell dish. After 4 days of growth cells are cultured in osteogenic medium for 
20 days following the differentiation during time.  
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The AP is quantified with the StemTAG™ Alkaline Phosphatase Activity Assay Kit 
from Cell Biolabs Inc. The AP catalyzes the conversion of p-Nitrophenyl Phosphate 
(pNPP) to p-Nitrophenol (pN). p -Nitrophenol is a bright yellow-colored compound 
which has maximum absorbance at 405 nm. The rate of increase in absorbance from 
pNPP (colorless) to pN (color) is directly proportional to the AP enzyme activity in 
the serum sample. Following the indications of the fabricant, a calibration curve 
with pN at concentrations ranging from 0.5 mM to 0.9766 µM is performed. The 
calibration curve to know the total amount of pN is obtained from 10 points ranging 
from and is y = 0.04 + 7.51 x  where y is the absorbance at 405 nm and x is the pN in 
mM with an R2 of 0.999.  
Cells are cleaned twice with PBS and lysated with 250 µL lysis buffer for 10 minutes 
at 4 °C. The solution has to be spin down at 12.000 g for 10 minutes and the 
supernatant must be kept. 1 : 1 relation in volume of cell lysate and pNPP are 
incubated for 15 minutes at 37 °C. To stop the reaction the same proportion in 
volume of 1 X stop solution is added and shacked for 30 seconds. 
A Bradford assay is performed to quantify the protein quantity in the lysate and 
normalize the results. 1 part of protein sample is mixed with 30 parts of the Bradford 
Reagent, which consists of a dye, Brilliant Blue G that forms a complex with proteins, 
shifting the absorption maximum from 465 to 595 nm. Bovine serum albumin (BSA), 
from Sigma, is used as protein standard, and a calibration curve is performed with 5 
points ranging from 1 to 2 mg mL-1 of BSA. The calibration curve is y = 0.37 + 0.13 x  
where y is the absorbance at 595 nm and x is the total amount of protein in mg mL-1 
with an R2 of 0.983. 
The absorbance measurements were performed at a Thermo Scientific™ Varioskan™ 
Flash Multimode Reader and the statistical ANOVA analysis was done in Origin 8.5 
software. Fisher’s tests were performed to determine statistically significant 
differences with a p < 0.05. 
Staphilococcus aureus  
Staphilococcus aureus is by far the most common pathogen found in surgical 
wounds, which can cause surgical site infections.[277] Is a gram positive spherical 
bacteria belonging to the Staphylococci group.  
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The used S. aureus strain RN4220 is from Iñigo Lasa’s Laboratory at Instituto de 
Agrobiotecnología, UPNA-CSIC Gobierno de Navarra. This strain is resistant to 
erythromycin.  
S. aureus culture  
S. aureus is cultured in Luria-Bertani (LB) broth from Lennox with 10 µg mL-1 
erythromycin (Sigma Aldrich) overnight at 37 °C under constant shaking at 200 rpm.  
S. aureus growth on surfaces 
After 24 h of growth in LB Broth, the bacteria are centrifuged at 2,500 rpm for 5 
minutes and washed in 10 mM PBS with 150 mM NaCl (pH 7.4) three times. The 
optical density is adjusted to 0.257 at 600 nm with an UV-VIS Varian Cary 50 
spectrophotometer, estimated to give 3 x 108 CFU mL-1. The bacteria solution is 
diluted in LB Broth with 10 μg mL-1 erythromycin (Sigma Aldrich) at a concentration 
of 1,000 CFU mL-1 and 1 mL is seeded onto the substrates placed each of them in a 
well of a 24 well dish. Bacteria is cultured for 24 h at 37 ˚C and then rinsed three 
times with 10 mM PBS to remove non-attached bacteria. After incubation, images 
are taken in the transmission mode in a Cell Axio Observer Micrsocope. To detach 
the adhered bacteria, samples are vortexed at 30,000 rpm for 1 minute inside sterile 
50 mL centrifuge tubes with 10 mL of 10 mM PBS. Dilutions are done in PBS to 
culture 100 μL onto sterile LB Agar (Lennox) with 10 μg mL-1 erythromycin. The 
plates are placed into an incubator at 37 ˚C to allow colonies to grow until visual 
counting is possible (approximately 18 hours). 
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IV. CHAPTER 1 
MTFs with embedded Gentamicin 
and surface modified with rhBMP-2 
 
 
1.1. Motivation 
Since bone and joint inflammatory problems account for 50 % of chronic diseases in 
developed countries,[19] there is an urgent demand for mechanically-resistant and 
bone-compatible orthopaedic implants.[278–280] Implants often fail, requiring 
additional surgery and implant replacement, which is costly and compromises the 
health of the patient. A major reason for the failure of implants is the development 
of bacterial infections at the site of implant. During bone surgery, the surface of the 
implants is susceptible to bacterial infections that can lead to the formation of a 
biofilm and to a compromised immune response at the site of the implant. Aseptic 
loosening of the implants following surgery can result in the premature failure of 
the implant due to poor osseointegration.[281,282] Staphylococcus aureus is among the 
most common bacteria causing implant associated infections and is considered to 
be a major, virulent pathogen that colonizes and infects both hospitalized patients 
with decreased immunity and healthy immunocompetent people.[283,284] Skin and 
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mucous membranes are excellent barriers against local tissue invasion by S. aureus, 
but if any of them is breached due to trauma or surgery, bacteria can enter the 
underlying tissue, creating its characteristic local abscess lesion.[285,286] Antibiotics 
are normally locally administered at the implant site, which effectively avoids the 
formation of bacterial colonies during surgery. However, there is a risk of bacterial 
colonization during the time bone tissue is being regenerated, which last several 
weeks, until the protective capsule is formed and especially after surgery when the 
osseointegration processes has started. To ensure the successful implant 
adaptation, the rational supply of antibiotics is needed and can be achieved by 
coating the implant surface with antibiotics-loaded polymer coatings such as 
polyelectrolyte multilayers, brushes or hydrogels.[287–290] However, the main 
challenge is to obtain a localized supply of the antibiotics with a two-phase release 
profile. An initial burst release at short times is highly desirable as during surgery 
and at the initial phase of bone formation the risk of bacterial infection is larger, but 
at the same time a slow release lasting weeks is also required while the capsule is 
getting regenerated. 
Coating the implant surface with mesoporous film is an attractive method to 
improve biocompatibility of Ti implants, as rougher surfaces promote bone and 
implant interlocking.[291–293] Mesoporous materials have an ordered, homogenous 
distribution of interconnected pores whose diameters are in the 2–50 nm 
range.[131,294–300]  Titania can be synthesized as a mesoporous material without 
compromising its mechanical properties,[301] which are fundamental for bone 
replacement. Mesoporous titania can be used for drug loading by soaking 
mesoporous in a drug solution and once drugs are entrapped their release is slowed 
by the necks that interconnect the mesopores.[302,303] Atefyekta et al.[304] have 
studied the loading and release of gentamicin, vancomycin and daptomycin from 
mesoporous titania films (MTFs) of pore sizes ranging from 4 to 7 nm, but the 
release of the antibiotics from the MTFs has been shown to occur within the first 80 
minutes, which is not desirable for implants, where an initial burst release followed 
by a prolonged one is needed.[304] 
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This chapter shows that the loading of mesoporous titania film with antibiotics and 
its surface functionalization with growth factors improve the antibacterial 
properties of the titania and promote the pre-osteoblasts proliferation and 
differentiation. Gentamicin was used to load mesoporous titania films of 80 nm in 
thickness and 5.7 nm in pore diameter, prepared by spin coating through the 
evaporation-induced self-assembly method. In contrast to previous studies, while 
36 % of the gentamicin is released within the first 6 hours gentamicin release 
prolongs over 35 days. The antibacterial properties of the mesoporous titania were 
further enhanced by immobilizing a growth factor - the recombinant human bone 
morphogenetic protein 2 (rhBMP-2) - on the surface of the film, favouring cell 
attachment and growth. While the antibacterial action of the gentamicin-loaded 
MTF was tested against S. aureus, the proliferation, adhesion, and differentiation 
assays were performed with the MC3T3-E1 pre-osteoblastic cell line.  
1.2. Experimental section 
1.2.1. MTF synthesis and characterization 
For the sol preparation Titanium (IV) Chloride, Ethanol Absolute, Pluronic F127® 
and nanopure water (H2O) were mixed in a molar proportion of TiCl4 : EtOH : F-127 
: H2O = 1 : 40 : 0.005 : 10. The titania precursor is prepared first, adding the TiCl4 to 
the EtOH under vigorous stirring and leave till drops to room temperature. The F-
127 is homogenized under stirring in water and then the titania precursor is added.  
The sol is left stirring for 10 minutes to obtain a homogenous solution.  Ti dense 
films, without pores, are also synthesized, simply by mixing the same reagents in the 
same order except the surfactant. 30 μL previously mixed with EtOH in a volume 
proportion of sol : EtOH = 2 : 1, are spin coated and then placed for 30 minutes in an 
humidity chamber with a controlled relative humidity of 50 %, obtained with 
saturated Calcium Nitrate, Ca(NO3)2, solution in water. They are afterwards 
subjected to a thermal treatment: 30 minutes at 60 ˚C and another 30 minutes at 
130 ˚C. Finally, they are calcinated; first, heating up with a ramp of 1 ˚C min-1 and 
then, keeping them at 350 ˚C for 2 h. Ti dense films are treated in the same way. 
The porous structure was confirmed through TEM imaging and after performing a 
transversal cut of the film, the inner part of the film was observed with the SEM. 
Films thickness and pore size are calculated and analysing the 2D-SAXS pattern the 
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ordering of the mesoporous structure is evaluated. The value of the Elastic Modulus 
(Er) is extracted from nanoindentation tests. 
1.2.2. rhBMP-2 and Gentamicin functionalization and characterization 
A drop of 100 μL of rhBMP-2 (pI 9.15) at concentrations of 10 μg mL-1 and 100 μg 
mL-1 in PBS 10 mM was adsorbed for 1 hour on top of MTFs previously cleaned by 
immersing in absolute ethanol for 30 minutes, 15 minutes in distilled water, dried 
with N2 gun and sterilized for 1h under UV light. After rhBMP-2 adsorption films 
were immersed in gentamicin sulfate solution at 0.2 mg mL-1 in distilled water for 
24 hours and prior to its use films were immersed once in water and left to dry in 
air. 
Water contact angles were measured for different rhBMP-2 concentrations 
adsorbed on MTFs. Three different films at different rhBMP-2 concentrations and 
with/without gentamicin were measured. The presence of sulphur was confirmed 
by XPS atomic composition analysis. AFM images were obtained for samples without 
any functionalization, with rhBMP-2 100 mg mL-1 and films with rhBMP-2 100 mg 
mL-1 and gentamicin.   
1.2.3. Gentamicin release study 
MTFs were immersed for 24 h in 0.2 mg mL-1 gentamicin in water. Then they were 
immersed in water once to remove the exceed of gentamicin and left to dry in air. 
Samples were placed in a well of a 24 multiwell dish. 1 mL of PBS 10 mM was added 
to each well containing the samples and the PBS was removed and replaced for each 
measurement. The release was measured at 30 minutes, 1, 2 and 6 hours and 2, 3, 6, 
7, 10, 21, 28 and 35 days. Experiment was performed in triplicate. 
1.2.4. MC3T3-E1 cell bioactivity experiments 
Cell adhesion was evaluated in MTFs, films functionalized with gentamicin, 10 and 
100 ng mL-1 rhBMP-2 and films dually functionalized. Cell adhesion was evaluated 
after 2 h, 1 and 2 days after cells were seeded onto samples.  
Cell proliferation was followed for 2 h, 1, 2 and 4 days on top of glass, Ti dense 
substrates, MTFs and MTFs with 10 and 100 ng mL-1 rhBMP-2 and dually 
functionalized films.  
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AP was quantified at 2, 5, 10 and 20 days of cell culture in osteogenic medium, the 
differentiation was evaluated for MTFs, MTFs with 100 ng mL-1 rhBMP-2 and dually 
functionalized films. 
All samples were prepared under sterile conditions and dried in air prior to its use. 
Samples are prepared in triplicate. 
1.2.5. Antibacterial study 
MTFs were functionalized with gentamicin and dually functionalized MTFs were 
prepared with 100 ng mL-1 rhBMP-2 and gentamicin. As control MTFs were used. 
Samples were prepared in triplicate for the experiment.  Films were dried in air and 
placed in wells of 24 multiwell dishes.  
Detached bacteria were diluted in 10 mM PBS; for samples with gentamicin the 
dilutions were 1/1, 1/10 and 1/100, and for MTFs 1/10,000, 1/100,000 and 
1/1,000,000.  
1.3. Results and discussion 
1.3.1. MTF synthesis and functionalization with rhBMP-2 and gentamicin  
The porous structure of the MTFs was confirmed by TEM and SEM characterization 
(Figure IV-1a and IV-1b). The insert in Figure IV-1a shows the SAXS pattern of the 
MTF. The elliptic shape of the pattern suggests the presence of multiple domains of 
locally ordered pores.[138] Calculated interplanar distances show an interpore 
distance of 11.5 nm and 3.9 in the (-110) and (110) planes, respectively. The 
contraction due to the calcination process at 350 °C is of 65 %, as calculated from 
differences in the interpore distances at (-110) and (110) planes.[305] From the 
analysis of water adsorption-desorption isotherms (Figure IV-1d) obtained by 
Environmental Ellipsometric Porosimetry (EEP), it can be concluded that the MTF 
has a porosity of 30.7 %, and a pore size of 5.7 nm in diameter connected by necks 
of 4.2 nm in diameter. The calculated film thickness from the EEP measurements is 
of 80 nm, a value which is in agreement with the thickness of around 90 nm obtained 
from the SEM image of the transversal cut of the MTF (Figure IV-1c). 
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Figure IV-1. Mesoporous titania film (MTF) structural characterization by electron 
microscopy, 2D-SAXS and EEP. a) TEM image, insert; 2D-SAXS pattern, b) SEM image of the 
surface, c) SEM image of a transversal cut and d)  EEP of water vapour adsorption and 
desorption. 
Nanoindentation measurements, Figure IV-2, show an elastic modulus of 25 ± 5 
GPa, smaller than the elastic modulus for dense titanium surfaces, which is ranged 
between 100 and 120 Gpa.[31] Nevertheless, this value  is in agreement with the 
range of elastic modulus for bone, which lays between 4 and 30 GPa depending on 
bone type,[23] and also with the  values previously reported for porous titania 
films.[306] 
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Figure IV-2. Nanoindentation studies performed on mesoporous titania films. a) Shows the 
partial-load/unload vs displacement curve used for the tests and b) the results of the 
analysis of each unload section for Elastic modulus (Er). 
MTFs are functionalized with rhBMP-2 and loaded with gentamicin. The 3D 
structure of the BMP-2 has a size of around 7 nm x 3.5 nm x 2.5 nm,[307] which does 
not allow the molecule to enter inside the mesoporous structure and it will remain 
in the surface of the films. To confirm the presence of both rhBMP-2 and gentamicin, 
the atomic percentage of S/Ti is obtained through high resolution XPS spectra in the 
spectral range of Sulphur (S) and Titanium (Ti) (Figure IV-3). As gentamicin 
sulphate is used, the S is used as an indirect marker to ensure the presence of 
gentamicin. The peak corresponding to S 2p3/2 is more pronounced in the MTF 
loaded with antibiotic, coated with protein or both loaded and coated, as compared 
to the bare MTF. Because first the rhBMP-2 is adsorbed on top of the MTF and then 
the film is immersed in gentamicin for a day, it could be the case that the rhBMP-2 
desorbs from the titania surface during the loading. Although there is no S in the 
bare MTF, a S/Ti atomic relative percentage of 0.41 ± 0.09 % is obtained, which 
corresponds to the noise of the equipment. When the MTF is loaded with gentamicin 
the S/Ti relative percentage increases to 2.03 ± 0.09 %. If the MTF is functionalized 
with rhBMP-2 without gentamicin loading the S/Ti increases to 3.44 ± 0.99 %. The 
S/Ti ratio for the MTFs functionalized with rhBMP-2 and loaded with gentamicin is 
the lowest: 1.48 ± 0.32 %. The loss in S content could be a consequence of the 
incorporation of gentamicin after the rhBMP-2 is adsorbed on top of the MTF; 
however, the calculated standard error is high. Additional proof of the loading and 
functionalization were obtained from contact angle measurements. Figure IV-4 
shows the changes in contact angle of water following rhBMP-2 functionalization 
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and gentamicin loading. Bare MTF has a contact angle of 13.4 ± 0.30° (Figure IV-
4a). When the MTF is loaded with gentamicin or functionalized with rhBMP-2 the 
contact angle changes to 73.15 ± 1.07 ° (Figure IV-4b) and 72.47 ± 2.60 ° (Figure 
IV-4c), respectively. For the MTF functionalized with rhBMP-2 and loaded with 
gentamicin the contact angle increases to 90.95 ± 2.19 ° (Figure IV-4d). Moreover, 
gentamicin loading was proven by release experiments and by measuring the 
antibacterial properties of the MTF after loading.   
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Figure IV-3. XPS high resolution spectra of Titanium (Ti) and Sulphur (S) and S/Ti atomic 
percentage calculation on top of each graph for each film. a) Ti and b) S of MTF, c) Ti and d) 
S of MTF with gentamicin, e) Ti and f) S of MTF with 100 ng mL-1 rhBMP-2 and g) Ti and h) 
S of MTF with 100 ng mL-1 rhBMP-2 and gentamicin substrates.  
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Figure IV-4. Contact angle measurements. a) Bare MTF b) MTF with gentamicin, c) MTF 
with 100 ng mL-1 rhBMP-2 and d) MTF with 100 ng mL-1 rhBMP-2 and gentamicin. 
MTFs show a smooth topography as confirmed by AFM imaging (Figure IV-5a, IV-
5b and IV-5c), with a roughness of around 190 pm. When the protein is deposited 
on top of the MTF, the roughness increases to 250 pm, meaning that the surface loses 
homogeneity and confirming the presence of rhBMP-2 (Figure IV-5f). The height 
profile shows singularities with a few nm in thickness, which are not observed in the 
bare MTF. Phase image also confirms the presence of a different material on top of 
the MTF (Figure IV-5e); when the height changes also a phase shift is detected. 
When the MTF functionalized with rhBMP-2 is loaded with gentamicin some rhBMP-
2 is loosed from the surface (Figure IV-5g) and the roughness decreases to 210 pm 
(Figure IV-5i). The presence of proteins is indicated in the image by blue arrows.  
MTFs with embedded Gentamicin and surface modified with rhBMP-2                          Chapter 1 
73 
 
 
Figure IV-5. AFM images (height, phase and height section) of MTF, MTF with 100 ng mL-1 
rhBMP-2 and MTF with 100 ng mL-1 rhBMP-2 and loaded gentamicin. a) height, b) phase 
and c) section of MTF substrates, d) height, e) phase, f) section of MTF with 100 ng mL-1 
rhBMP-2 substrate, showing an increase in the height, and g) height, similar to MTF with 
100 ng mL-1 rhBMP-2 sample, h) height and i) section image of MTF with 100 ng mL-1 
rhBMP-2 and loaded with gentamicin. 
1.3.2. Gentamicin release from MTFs 
The release profile of the gentamicin is plotted in Figure IV-6. There is a fast release 
at initial times; within the first 6 h around the 36 % of the total gentamicin liberated 
is released. This initial burst release is required to avoid bacteria adhering and 
infecting the implant during surgery, which is known to be the riskiest period for 
infection. After the burst release a second slower and prolonged release takes place. 
Release is evaluated up to 35 days, where a plateau is reached and this second 
release profile is within the time frame required for the implant to be integrated in 
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the tissue and for the formation of the protective fibrous capsule.[308] This second 
release step suggests that gentamicin is retained inside the pores interacting with the 
titania surface. Angelomé el al.[309] have shown that hydroxyl groups in dialcohols can 
be incoporated into MTFs by complexation of  Ti(IV) centers present in the pore 
surface.[309] Moreover, they have demonstrated that the dialcohols can be released in 
aqueous solution at specific pH values. Thus, gentamicin can be anchored to the titania 
surface through oxo bridges due to the presence of three hydroxyl groups in the 
molecule, which would explain the slow release of gentamicin from the MTF. 
The obtained results on gentamicin liberation are significantly different from 
Atefyekta et al.[304], where a fast release of gentamicin takes place in around 80 min 
from mesoporous titania with pore sizes similar to ours. However, their mesoporous 
titania films are less ordered and 200 nm thick, twice as thick as the ones presented 
in this chapter. It is possible that the pores in the synthesized MTFs are more 
interconnected and with narrowed necks and this causes that only the 36 % of 
gentamicin is released fast as gentamicin is more difficulted to leave the pore mesh. 
In the work by Atefyekta et al.[304] the authors have recognized that the release was 
fast and the methodology that they used to measure the antibiotic release could also 
be a reason for the differences observed in the present chapter.  Atefyekta et al.[304] 
have measured gentamicin loading and release by Quartz Crystal Microbalance with 
Dissipation (QCM-D) from MTF deposited on top of a QCM-D crystal. Both upload 
and release were measured from variations in the frequency of the crystal and for 
the release studies the authors apply a continuous flow of PBS at a flux of 50 mL min-
1, which is a relatively high flux and should trigger a faster liberation of gentamicin. 
Besides, in this work, the release was performed in static conditions. 
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Figure IV-6. Release profile of gentamicin from MTF. Region I shows the burst release (the 
insert is a zoom of region I) and region II the sustainable release. The release is followed up 
to 35 days by emission measurements at 455 nm. 
 
 
 
 
 
 
 
 
 
1.3.3. Biocompatibility and bioactivity evaluation  
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Initial cell adhesion on biomaterials plays a key role on cell proliferation, migration 
and differentiation. The focal adhesions (FA) and extracellular matrix (ECM) 
interactions involve integrins that bind different ECM proteins with the external end 
and cytoskeleton via adapter proteins such as talin, α-actinin, filamin and vinculin. 
FAs are based on this integrin-adapter protein−cytoskeleton complex. Osteoblasts 
anchor on a substrate via integrin receptors, which are involved in processes named 
as “outside-in-signaling” and “inside-out-signaling” between the ECM and the cell. 
These pathways involving integrins can regulate subsequent cell adhesion, 
migration, proliferation, and differentiation.[310,311] 
The MC3T3-E1 osteoblast precursor cell line is used to evaluate adhesion to the 
functionalized MTFs. Figure IV-7, IV-8 and IV-9 show confocal laser scanning 
microscope images of the cells cultured on the bare MTFs, MTFs functionalized with 
rhBMP-2 and MTFs functionalized with rhBMP-2 and gentamicin, respectively. The 
actin filaments (F-actin) are stained with phalloidin, red fluorescence in the second 
row and vinculin is stained with FITC, green fluorescence in the first row. The 
nucleus is stained with DAPI and is represented in blue in the merge images (third 
row), where all the labeled cell parts are shown. From the F-actin images can be seen 
that cultured cells in the three substrates exhibit a similar size and a well-arranged 
cytoskeleton with distinctive stress fibers inside the cytoplasm, especially at the 
border of the cells. However, cell shape is different after 48 h of culture (third 
column). When the MTF was modified with rhBMP-2 (Figure IV-8) cell shape was 
more elongated if compared with cells cultured 48 h on the bare MTFs (Figure IV-
7) or rhBMP-2 and gentamicin (Figure IV-9).  This cell shape and higher filopodia 
[312] means that cells were interacting better when rhBMP-2 is present on the 
surface. FA allow cells to interact with the surrounding environment; vinculin can 
interconnect signals in the focal adhesions and is a key regulator.[313,314]  In the 
images of vinculin staining (first row) in all substrates lots of green spots can be 
found.  After 2 h of cell incubation on the substrates (first column) focal adhesions 
can also be perfectly distinguished, meaning that cells adhere well to the substrates 
from initial times, which will later improve cell proliferation.[310,313]  
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Figure IV-7. CLSM images of vinculin (first row), actin (second row), the merge of the actin, 
the vinculin and the nucleus (third row) and the zoom of the merge image (fourth row) at 
2h (first column), 24h (second column) and 48h (third column) of growth of MC3T3-E1 cell 
line on MTFs substrates at 63x. 
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Figure IV-8. CLSM images of vinculin (first row), actin (second row), the merge of the actin, 
the vinculin and the nucleus (third row) and the zoom of the merge image (fourth row) at 
2h (first column), 24h (second column) and 48h (third column) of growth of MC3T3-E1 cell 
line on MTF with 100 ng mL-1 rhBMP-2 substrates at 63x. 
MTFs with embedded Gentamicin and surface modified with rhBMP-2                          Chapter 1 
79 
 
 
 
 
 
 
Figure IV-9. CLSM images of vinculin (first row), actin (second row), the merge of the actin, 
the vinculin and the nucleus (third row) and the zoom of the merge image (fourth row) at 
2h (first column), 24h (second column) and 48h (third column) of growth of MC3T3-E1 cell 
line on MTF with 100 ng mL-1 rhBMP-2 and gentamicin substrates at 63x. 
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During the thesis glass substrates, dense titanium substrates or MTFs are used 
indistinctly as controls for experiments with cells. In Figure IV-10 is shown that any 
of them is suitable for MC3T3-E1 pre-osteoblast proliferation. MC3T3-E1 pre-
osteoblasts are cultured for 1, 2 and 7 days on glass, dense titanium and MTF 
substrates. As seen there is no significant difference on cell density for the evaluated 
time periods and any of the three substrates are used as controls from now on. 
 
Figure IV-10. Proliferation of MC3T3-E1 pre-osteoblasts cultured on Glass, Ti dense and 
MTF substrates for 1, 2 and 3 days.  
To study the influence of the rhBMP-2 on cell proliferation, cells are cultured in 
substrates coated with rhBMP-2. The deposition of rhBMP-2 on the MTF was 
performed from solutions with 10 and 100 ng mL-1 rhBMP-2 concentration. Results 
are plotted in Figure IV-11. After 7 days, the culture is confluent, meaning that the 
surface is completely covered by cells forming a monolayer, and no difference can 
be distinguished between the MTF functionalized with rhBMP-2 and the bare MTF 
control. Within the first day cells proliferate at the same rate and cell density is the 
same for the three evaluated substrates. After 2 days of culture, substrates with 100 
ng mL-1 of rhBMP-2 show an enhanced cell proliferation rate if compared with cells 
cultured on MTFs and MTF with 10 ng mL-1 rhBMP-2 (p < 0.05). After 4 days of 
culture, same differences are maintained, but cell density is also higher when 
rhBMP-2 concentration is low (10 ng mL-1) if compared with MTFs. As previously 
seen in Figure IV-8, cells are more expanded and showing higher filopodia in 
presence of rhBMP-2. When the interaction of cells with a substrate is better it is 
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known that proliferation is also improved.[310,313] If MTFs are loaded with 
gentamicin and functionalized with rhBMP-2, differences are observed regarding 
the proliferation rates of MC3T3-E1 cells on films only functionalized with rhBMP-
2.  At day 2, between samples with rhBMP-2 or samples with rhBMP-2 and loaded 
with gentamicin there is no difference on cell density and in both cases the density 
is higher if compared with cell density on bare MTFs. If cells are cultured for 4 days, 
there is a difference between samples without and with gentamicin. After 4 days of 
cell culture, for the MTF with rhBMP-2 loaded gentamicin, the cell proliferation rate 
is not as high as without gentamicin, and the proliferation rate decreases in a 46 % 
with a value comparable to bare MTFs. 
 
Figure IV-11. Proliferation of MC3T3-E1 pre-osteoblasts cultured on MTF, MTF with 10 ng 
mL-1 rhBMP-2, with 100 ng mL-1 rhBMP-2 and with 100 ng mL-1 rhBMP-2 and gentamicin 
substrates for 2 h, 1, 2 and 4 days. * means that the difference is statistically significant (p < 
0.05) 
Alkaline phosphatase is one of the gene markers in the early stage of osteogenic 
differentiation.[162] Figure IV-12 shows the AP activity of cells cultured on the MTFs, 
MTFs with rhBMP-2 and MTFs with rhBMP-2 and gentamicin. After cells reach 
confluence, they are differentiated for 20 days and AP activity is measured at 
different steps to evaluate differences in differentiation rates. At day 2 and day 5 of 
differentiation there is no difference between the evaluated substrates and at day 
20 all cells are differentiated and is not possible to see any difference among 
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substrates as well. Only at day 10 of cell culture in osteogenic medium differences 
can be seen. For MTF coated with rhBMP-2, with or without gentamicin, the 
differentiation is more than the double of the differentiation on bare MTFs. This 
result was expected as the effectiveness of rhBMP-2 in promoting pre-osteoblast 
differentiation has been demonstrated in  a large number of works.[168,315–317]  
 
Figure IV-12. Alkaline phosphatase activity after 2, 5 10 and 20 days of MC3T3-E1 pre-
osteoblastic cell culture in osteogenic medium on MTF, MTF with 100 ng mL-1 rhBMP-2 and 
MTF with gentamicin and 100 ng mL-1 rhBMP-2 substrates. * means the difference is 
statistically significant (p < 0.05) 
1.3.4. Evaluation of the antibacterial properties of the rhBMP-2 and 
gentamicin functionalized MTFs 
The evaluation of the antibacterial capacity of MTF loaded with gentamicin and 
rhBMP-2 functionalized is performed by incubating S. aureus for 24 h on top of the 
films.  Figure IV-13a shows CFU grown on the LB agar plates. Green ticks mean 
bacteria have grown on the agar plates and CFU counting is possible and red crosses 
means that S. aureus has not grown.  4.75 x 106 ± 5.8 x 105 CFU are counted for MTF, 
in Figure IV-13b a zoom of CFU grown on agar plates after growing in MTF is shown. 
However, when the MTF contains gentamicin, with or without rhBMP-2, bacteria are 
not grown, as can be seen in the zoom in Figure IV-13c.  Figure IV-13d and IV-13e 
show a cell observer image of S. aureus grown for 24 h on top of the MTF and the 
MTF functionalized with rhBMP-2 and loaded with gentamicin, respectively. The 
bare MTF surface is completely covered by the bacteria; the image shows black dots 
which are the coccus. The surface of the gentamicin loaded film shows very few dots, 
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so some bacteria attach but are not alive, as seen in the agar plate culture, where no 
CFU are found. 
 
Figure IV-13. CFU counting after S. aureus growth on agar plates for 24h and cell observer 
images of S. aureus growth on MTF and MTF functionalized with rhBMP-2 and gentamicin. 
a) Three samples with cultured S. aureus for 24 h on LB agar plates. S. aureus cultured in 
1/10,000 dilution for MTF and 1/1 dilution for MTF with 100 ng mL-1 rhBMP-2 and 
gentamicin and MTF with gentamicin. b) Zoom of Sample 1 of agar plates with cultured S. 
aureus on MTF, c) Zoom of Sample 1 of agar plates with cultured S. aureus on MTF with 
rhBMP-2 and gentamicin and cell observer images of 24 h of growth of S. aureus on d) MTF 
and d) MTF with rhBMP-2 and gentamicin substrates. 
1.4. Conclusions and perspectives 
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Highly mesoporous titania films with a 30.7 % porous volume have been shown here 
to encapsulate gentamicin in the porous matrix to an extent that the films display 
antibacterial properties. At physiological pH, the release of gentamicin in 10 mM PBS 
shows a two-step release profile. The porous structure of the titania results in an 
initial burst release of gentamicin within the first 6 h with a liberation of around the 
36 % of the total released gentamicin. The burst release is followed by a slow release 
of the remaining gentamicin that lasts over weeks. This release profile fits with the 
initial requirements of avoiding the formation of bacteria colonies on the implant 
while surgery is conducted, releasing most of the gentamicin during first hours, 
while the rest of the gentamicin is released in lower doses for a period lasting weeks 
avoiding infection while the tissue is being reconstituted.  
MTFs functionalized with rhBMP-2 improve MC3T3-E1 cell adhesion and 
proliferation. However, when the MTF is also loaded with gentamicin, proliferation 
rate is diminished but still is comparable to the proliferation rate for bare MTFs. Cell 
differentiation is not affected by the presence of gentamicin, and when MTFs are 
functionalized with rhBMP-2 the differentiation rate increases at day 10 to the 
double of the rate of cells cultured onto MTFs. 
The efficacy of the functionalized substrates against S. aureus bacterial infection is 
shown seeding 1,000 CFU of bacteria on the gentamicin loaded MTFs. Bacteria do 
not proliferate, hinting the potential of the gentamicin loaded MFT for avoiding S. 
aureus infections.  
Overall, this chapter shows the potential of mesoporous titania for antibiotic loading 
and delivery for avoiding bacterial infection. The release profile of gentamicin 
matches with the requirements of a burst release during operation and immediately 
after followed by a sustainable release of gentamicin until the bone tissue is 
reconstituted. The additional modification of the MTF with rhBMP-2 has a positive 
effect on proliferation and cell adhesion that seems to overcome negative effects 
from gentamicin on pre-osteoblasts. The versatility of the mesoporous substrates 
has been shown; it is possible to tune the mesoporous structure by changing the 
surfactant used for the synthesis, and film thickness can also be tuned in order to 
modify the number of loaded molecules inside the film. Also, many different types 
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of molecules can be entrapped inside the film or adsorbed on the top, giving 
different functionalities to the substrate. 
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V. CHAPTER 2 
Antibacterial PEMs based on PLL 
and PAA-gentamicin complexes 
 
 
 
2.1. Motivation 
The widespread nature of bacterial infections and their increasing resistance to 
antibiotics has led to the development of antibacterial coatings in multiple medical 
settings, especially on bone implants.[70] The surface of implants is susceptible to 
numerous bacterial infections mainly because of the formation of a surface biofilm 
and the compromised immune response at the implant/tissue interface.[318] Once a 
biofilm is formed, it protects adherent bacteria from the host defence system and 
bactericidal agents via several mechanisms.[47,319,320] The biofilm becomes a source 
of pathogens and infections, being the cause of so called nosocomial 
infections.[48,124,321] Nosocomial infections are secondary to the main condition of 
the patient, and can have lethal consequences following operations such as bone 
replacement or open heart surgery.[322–324] Because biofilms can form on almost any 
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material present in a surgery room, prevention of their formation can be 
fundamental for patient survival. 
 The encapsulation of antibiotics in polymer matrixes is an attractive approach for 
the fabrication of antibacterial coatings. These coatings are usually made out of 
hydrogels, layer-by-layer (LbL) assemblies, polymer brushes or porous polymer 
scaffolds.[70,223,325–333] A major drawback of the encapsulation of antibiotics in 
polymer films is the difficulty in achieving a slow release of antibiotics. In addition, 
often the coating degrades accompanied by liberation of the antibiotics all at once, 
or at a rate faster than required.[70,334] 
The LbL technique has been used for the engineering of scaffolds and implants to 
assemble growth factors and other molecules that facilitate tissue regeneration or 
enhance cell adhesion.[335–341] Molecular complexes, stable colloidal aggregates of 
molecules bound by week interactions, have also been employed as building blocks 
for the fabrication of PEMs. For example, Romero et al.[342] have shown that 
complexes of alginate and the antiTNF-α antibody can be assembled in LbL, while 
the direct assembly of the antibody does not result in stable layers because of the 
weak charge of antiTNF-α. 
Recently, Moskowitz et al.[124] proposed an antibacterial coating with an initial burst 
release of gentamicin followed by slow release. The coating was formed by a 
tetralayer unit containing gentamicin sulphate, poly acrylic acid (PAA) and a 
synthetic poly(β-amino ester) (Poly 1), combined as PAA/Poly 1/PAA/Gentamicin. 
Gentamicin is a frequently used antibiotic, an aminoglycan displaying three primary 
amine groups, which can interact with PAA through electrostatic interactions and 
hydrogen bonding. The entire film comprised 200 tetralayers, achieved over 5 days 
using an automated fabrication method.[124] 
In this chapter, a simple method for the fabrication of antibacterial coatings 
employing the LbL technique is proposed (Figure V-1). Using PAA-gentamicin 
complexes as building blocks with poly-L-lysine (PLL), a coating in just a few 
assembly steps with enough gentamicin loading to exhibit antibacterial properties 
is assembled.  The obtained results are particularly appealing for the development 
of antibacterial coatings to prevent acquisition of nosocomial infections in various 
medical settings. 
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2.2. Experimental section 
 
Figure V-1. A) Scheme of the formation of gentamicin and PAA complexes in 500 mM NaCl 
at pH 4.5. B) LbL assembly of PLL and PAA-gentamicin complexes. The LbL assembly was 
performed in 500 mM NaCl at pH 4.5 in 4 steps: 1) 15 min incubation of 100 µL drop of 1 
mg mL-1 PLL, 2) removal of the PLL that has not been adsorbed by dipping the substrate in 
500 mM NaCl pH 4.5, 3) 15 min incubation of 100 µL drop of PAA-gentamicin complexes 
and 4) removal of the complexes that have not been adsorbed by dipping the substrate in 
500 mM NaCl  pH 4.5. This cycle is repeated 4 times. C) Scheme of PEMs showing 4 bilayers 
of PLL/PAA-gentamicin complexes grown on top of titania films. 
2.2.1. Poly (acrylic acid) and gentamicin complex preparation and 
characterization 
PAA and gentamicin complexes were prepared by mixing PAA and gentamicin 
sulfate at different ionic strengths: 2 M, 500 mM and 10 mM NaCl and H2O. 
Complexes were prepared with PAA 1 mg mL-1 and with different concentrations of 
gentamicin, preparing complexes with 0.1, 0.25, 0.3 and 0.45 mg mL-1 of gentamicin.  
The growth of the complexes was followed measuring the size by dynamic light 
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scattering immediately after complex preparation, after 2 h and after 4 h. In all cases 
measurements were repeated 10 times. For TEM imaging, a drop of 5 µL of the 
complexes was deposited on a TEM grid, left for 5 min on the grid to ensure that the 
complexes were deposited, cleaned 3 times with drops of distilled water and 
incubated for 5 min with a 5 µL drop of ammonium molybdate ((NH4)2MoO4, Sigma 
Aldrich) at 20 ng mL-1 pH 6.7, finally the grid was cleaned three times with water 
drops. 
2.2.2. Poly (acrylic acid) and gentamicin complexes and poly-L-lysine 
multilayer preparation and characterization 
PEMs have been fabricated by means of the LbL technique on top of MTFs (synthesis 
described in Chapter 1). The titania was first cleaned with absolute ethanol and 
dried at 100 °C. The PAA-gentamicin complexes and PLL solutions were prepared in 
500 mM NaCl at a pH of 4.5. A drop of 100 µL with PLL 1 mg mL-1 was left incubating 
on titania for 15 min at room temperature, then it has been removed and rinsed 3 
times with 500 mM NaCl pH 4.5. Then, the same volume of PAA-gentamicin complex 
was deposited on the surface left 15 min, removed and the surface rinsed again 3 
times as before. The alternating assembly of PLL and the complexes has been 
repeated 4 times to obtain a multilayer of 8 layers. Films were synthesized in sterile 
conditions to study their antibacterial capacity. Samples were dried in air for AFM 
measurements and previous to their use for the experiments on gentamicin release.  
To visualize the PEM, SEM images of a transversal cut have been taken and by AFM 
imaging surface roughness was calculated. PEMs were washed with with nanopure 
water and left to dry at room temperature.  
2.2.3. QCM-D Measurements 
The assembly of PLL/PAA-gentamicin complexes multilayers was monitored via 
QCM-D, Q-Sense E4 system. The LbL assembly was performed on QSX 303 SiO2 
quartz crystals. The PLL and the complexes are injected to the 4-sensor chamber 
with the help of a peristaltic pump and left under incubation for at least 10 min. For 
each deposition the solution was fluxed until frequency was stabilized, then a 
rinsing step of at least 10 min with NaCl 500 M (pH 4.5) took place. Experiments 
were conducted at 23 °C and the flux velocity of the solution was 100 µL min-1. 
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To study the stability of the multilayer under different pH conditions the multilayers 
were exposed in the QCMD chamber to NaCl 500 mM solutions with pHs ranging 
from 5 to 13. The solutions were fluxed at 5.77 µL min-1. Fluxing solutions have been 
changed once frequency reaches a plateau. 
2.2.4. Gentamicin release study 
Gentamicin release was studied by placing the samples in a 24 multiwell dish. 1 mL 
of 10 mM PBS was added to the wells with the sample. The release has been 
measured at 30 min, 1, 2, 6, 28, 55 h and 3, 6, 7, 10, 21, 28 and 35 days. The PBS was 
removed for each measurement from the well and replaced with fresh PBS solution. 
2.2.5. Antibacterial study 
PEMs were dried in air and placed in 24 multiwell dishes. Round coverslips of 16 
mm of diameter were immersed for 24h in gentamicin 0.3 mg mL-1 in water and 
cleaned by immersing the samples one time in distilled water, this samples were 
used as control. Samples were prepared in triplicate. Dilutions were made in PBS; 
for samples with the PEM coating the dilutions were 1/1 and 1/10, and for glass 
controls 1/1,000 and 1/10,000. 10 µL of each dilution was placed in LB Agar plates 
for overnight incubation. Visual counting of the CFU has been performed and an 
average and the standard error were calculated. 
 
 
 
 
 
 
 
 
 
 
2.3. Results and discussion 
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2.3.1. PAA-gentamicin complex synthesis and characterization 
PAA-gentamicin complexes were prepared by mixing PAA and gentamicin solutions 
(Figure V-1A) at different gentamicin and NaCl concentrations at pH 4.5. At this pH 
the amines of gentamicin are largely protonated and positively charged since the 
pKa for amino groups in gentamicin are in the range of 5.5 and 9. It can also be 
expected that carboxylate groups from PAA are to a large extent deprotonated and 
negatively charged as the pKa for PAA is 3.9.[74,119] It is found that a pH of 4.5 is 
optimal to favour the formation of complexes of PAA and gentamicin. Salt 
concentration is tuned to obtain the most stable complexes with the highest 
gentamicin concentration. As observed by Dynamic Light Scattering measurements, 
DLS, (Figure V-2), without salt (Figure V-2a) or with 10 mM NaCl (Figure V-2b), 
complexes start to form with 0.1 mg mL-1 of gentamicin, but they do not show a 
stable size when the concentration of gentamicin is 0.25 mg mL-1 or higher. In both 
cases the size of the complexes increases by more than 100 % after 4 h. In water, for 
0.45 mg mL-1 gentamicin, complexes start to precipitate after 4 h. However, DLS also 
shows smaller complexes present in solution that do not precipitate. With 500 mM 
NaCl, complexes start to form with at least 0.3 mg mL-1 of gentamicin, but if the 
concentration of gentamicin is increased to 0.45 mg mL-1 the size of the complexes 
is not stable, changing with time (Figure V-2c). After 4 h the size of the complexes 
is 3 times larger than their size measured immediately after preparation. At high salt 
concentration (2 M) the formation of complexes is suppressed (Figure V-2d).  
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Figure V-2. Changes in the hydrodynamic diameter of PAA-gentamicin complexes over time 
for different NaCl and gentamicin concentrations at pH 4.5. DLS measurements of 
complexes measured immediately after being prepared, and at 2 and 4 h after preparation. 
Complexes were prepared with 0.1, 0.25, 0.3 and 0.45 mg mL-1 gentamicin in a) H2O, b) 10 
mM, c) 500 mM and d) 2 M NaCl. 
 
Antibacterial activity of the coating can be enhanced with larger gentamicin content 
and larger gentamicin concentration leads to larger and more unstable complex size. 
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The largest gentamicin concentration that leads to complexes with relatively stable 
size within the 2 hours that the layer-by-layer assembly lasts has been proved to be 
0.3 mg mL-1. the evolution of the hydrodynamic diameter of the complexes over time 
has been monitored using constant gentamicin concentration (0.3 mg mL-1) and 
varying salt concentration (0 – 2 M) (Table V-1). At high salt concentration (2 M), 
the formation of complexes is suppressed. The resulting hydrodynamic diameter of 
~30 nm corresponds to free PAA of 100 kDa under the same NaCl and pH conditions. 
At low salt concentration (10 mM), the size of the complexes is relatively large, 
>1500 nm, leading to the precipitation after 4 hours. It has been found that at 500 
mM of NaCl the complexes maintained their size (120-300 nm), during the first 4 
hours after formation. More detailed analysis of size distributions revealed the 
presence of two peaks of 25 and 180 nm, just after mixing both components (Figure 
V-3a). After 2 h the smallest peak disappears while the second peak shifts to higher 
values and is narrower, meaning that the larger complexes increase their size at the 
expense of the smaller ones. At 4 h, the peak is slightly shifted to higher sizes and 
seems to continue to narrow, but it is considered that the size distribution has 
practically not changed from 2 to 4 h after assembly of the complexes, which is the 
time when the PEM is assembled. On contrary to DLS analysis, TEM characterization 
of the sample two hours after mixing shows the presence of small and large 
complexes ranging from 60 to 350 nm in diameter (Figure V-3b), suggesting that 
the scattering intensity of the small complexes at 2 h is shielded by the much larger 
scattering of the large complexes. Overall, for the further experiments the complexes 
that were prepared with 0.3 mg mL-1gentamicin and 500 mM of NaCl were selected. 
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 Hydrodynamic diameter (± SD) 
Ionic Strength 0 h 2 h 4 h 
H2O 382.1 ± 80.8 nm 774 ± 147 nm 831.6 ± 143.6 nm 
NaCl 10 mM 596.3 ± 102.6 nm 1121 ± 171.1 nm 1570 ± 229.3 nm 
NaCl 500 mM 177.7 ± 48.7 nm 276.3 ± 72.5 nm 293 ± 59.3 nm 
NaCl 2 M 29.67 ± 5.8 nm 30.13 ± 8.8 nm 33.74 ± 11.5 nm 
Table V-1. Time evolution of the hydrodynamic diameter of PAA-gentamicin complexes 
prepared with 0.3 mg mL-1 gentamicin and different NaCl concentrations at pH 4.5. DLS 
measurements of complexes were conducted immediately after preparation, and 2 h and 4 
h after complex preparation.  Complexes were prepared with 0.3 mg mL-1 of gentamicin in 
water and 10 mM, 500 mM and 2 M NaCl. The standard deviation calculated from three 
replicates is shown. 
 
 
 
 
Figure V-3. a) Intensity plot of size distribution at different times after complex formation 
for PAA-gentamicin complexes prepared in 500 mM NaCl at pH 4.5 with 0.3 mg mL-1 
gentamicin. b) TEM image of complexes 2 h after preparation.  
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2.3.2. Layer-by-Layer assembly of PLL/PAA-gentamicin complexes 
PLL and PAA-gentamicin complexes were alternately deposited on titania films, as 
depicted in Figure V-1B. The complexes are left for 2 h to form, and then are used 
for the PEM assembly and as seen in DLS measurements of the hydrodynamic 
diameter (Table V-1) the size after 2 h keeps constant for the following 2 h at 
around 300 nm in diameter. The assembly of the 4 bilayers of PLL and complexes 
was monitored by the Quartz Crystal Microbalance with dissipation technique 
(QCM-D) (Figure V-4a). With the increase of a material on top of QCM-D sensor the 
frequency shifts to lower values.[343] The deposition of each layer of PLL and 
complexes causes the increase of frequency in the following order 8, 11, 51, 73 Hz 
and 34, 57, 85 and 191 Hz, respectively. Observed frequency changes suggest that 
the LbL assembly follows exponential growth (Figure V-4b).[34],[46–48] Data is fitted 
to the exponential function 𝑦 =  𝑦0 + 𝐴 · 𝑒
𝑅0·𝑥, where 𝑦0is the offset with a value of 
-34.71, 𝐴 is the initial value (42.42) and 𝑅0 the rate 0.67. 𝑦 corresponds to – 𝛥𝑓 and 
𝑥 to each bilayer, the obtained R2 is 0.999. The exponential growth implies an 
increase in the amount of PLL and PAA-gentamicin complexes per layer as the 
number of assembled layers increases. Since complexes can be considered as 
spherical nanoparticle of ~100 nm the deposition of each layer results in an increase 
in the area available for assembly of the next PLL layer. The increase in available 
free area allows for the deposition of more PLL than on a planar surface. This 
situation repeats as the assembly proceeds. Consequently, the top layer will contain 
more complexes and more gentamicin than the layers below, as depicted in Figure 
V-1C. To evaluate the chemical stability of the film, the PEMs immobilized to QCM-
D sensor was exposed to an alkaline environment (pH 13), showing that the 
multilayer film is highly stable in such conditions (Figure V-4c) and thereby suitable 
for biomedical applications.[347] 
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Figure V-4. QCM-D monitoring of layer-by-layer assembly of PLL and PAA-gentamicin 
complexes prepared with 0.3 mg mL-1 gentamicin and film degradation. a) LbL assembly of 
4 bilayers of PLL and PAA-gentamicin (0.3 mg mL-1) complexes in 500 mM NaCl and pH 4.5, 
b) plot of frequency changes after each bilayer is deposited, and c) film degradation in 500 
mM NaCl at pH 13. 
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Detailed SEM analysis PEM cross-section (Figure V-5) revealed an irregular 
topology with the highest measured around 2 μm in height, correlating thus the high 
frequency changes monitored by QCM-D. The surface inhomogeneity was further 
confirmed by AFM analysis. Figure V-6 shows AFM images of height (a, d, e and h), 
phase (b and f) and height profile (c and f) of PLL/PAA-gentamicin complex PEMs. 
The roughness calculated from the height images of the PEM coating is 13.9 and 7.9 
nm for the 15 x 15 µm (Figure V-6a) and 5 x 5 µm (Figure V-6e) scans, respectively. 
The discrepancy in the roughness between the two images from the same sample 
confirms the data obtained from SEM (Figure V-5), that the surface of the PEMs is 
rather inhomogeneous.[348] The inhomogeneity on the surfaces is probably the 
result of the large size dispersion shown by the complexes as observed by TEM and 
DLS. Phase images (Figure V-6b and f) show that the lag in the phase remains 
constant over all scanned regions, suggesting that the LbL assembly is continuous 
without uncovered regions. From the height profile peaks of more than 100 nm can 
be distinguished, as well as regions with peaks of only a few nm and intermediate 
peaks with heights of around 50 nm can also be identified (Figure V-6c and g). 
These images together with the QCM-D monitoring leads to associate the 
exponential growth of the PLL-complex PEM to the ‘Island Model’. This model 
proposes that the first component is adsorbed in the surface forming “islands” and 
after several deposition steps the height and radius of the islands increases making 
the surface more and more heterogeneous and increasing the amount of material 
adsorbed.[110,349,350] 
 
 
Figure V-5. SEM cross-sectional image of the PEM deposited on top of the MTF. The glass 
and the MTF can be distinguished, as well as the PEM grown on top. 
Antibacterial PEMs based on PLL and PAA-gentamicin complexes                                  Chapter 2 
99 
 
 
 
 
 
Figure V-6. AFM images of the assembly of 4 PLL/PAA-gentamicin (0.3 mg mL-1) complex 
bilayers. a) Height, b) phase, c) height of section in a and d) 3D graph of the height of 15 µm 
x 15 µm image and e) height, f) phase, g) height of section in a and h) 3D graph of the height 
of 5 µm x 5 µm image. 
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2.3.3. Gentamicin release from PEMs 
The advantage of encapsulating antibiotics close to the implant-tissue interface is 
the effective antibiotic release that leads to the side effects minimization.[351] Despite 
the PEMs being stable at physiological pH, it is observed a release of gentamicin from 
the films. At physiological pH (7.4), gentamicin is less protonated than at pH 4.5, the 
pH at which the complexes were prepared. The deprotonation of gentamicin should 
weaken the interaction of the antibiotic with PAA, which should trigger gentamicin 
release. On the contrary, PAA has a larger charge at higher pHs. PAA and PLL 
multilayers fabricated with free PAA are stable at physiological pH. Since the 
stability of the film is largely due to the interaction of PLL with PAA, a stable film 
releasing gentamicin is possible. The amount of gentamicin released from the films 
can be monitored by measuring the fluorescence emission at 455 nm of the complex 
formed by gentamicin and the OPA reagent. There is a burst release of gentamicin 
within the first 6 hours, which liberates around 48 % of the total gentamicin (insert 
in Figure V-7). Then, after the burst release, a prolonged release takes place. 
Gentamicin is slowly released in a period from 6 hours to 35 days, after which a 
plateau is reached. This release profile of gentamicin encapsulated in the PEM has 
the characteristics required to avoid infections after a replacement surgery: (1) 
during the critical short-term post-implantation period, which lasts several hours, a 
burst release of gentamicin takes place. This burst release is needed to inhibit the initial 
adhesion of bacteria during the surgery, where there is the largest risk for infection as 
the body is opened and exposed. (2) A continued and slow release takes place beyond 
the initial first hours lasting weeks to avoid bacterial infection during the formation of 
a protective fibrous capsule and tissue integration on the  implant.[308] 
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Figure V-7. Release profile of gentamicin from PEMs formed of 4 bilayers of PLL/PAA-
gentamicin complex on top of titania thin films. Region I shows the burst release (the insert 
is a zoom of region I) and region II the sustainable release. The release is followed up to 35 
days using emission measurements at 455 nm. 
 
 
 
 
 
 
 
 
 
2.3.4. Evaluation of the antibacterial properties of the PEMs 
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To demonstrate the antibacterial activity of the films, an S. aureus strain was seeded 
on top of the PLL/PAA-gentamicin PEMs. Samples were prepared under sterile 
conditions and a glass immersed in gentamicin was used as a control. Approximately 
1,000 CFU of S. aureus were seeded at 37 °C for 24 h on three replicates for each 
sample. Transmission images show very few bacteria adhering to the surface of the 
film, while a larger number of bacteria are observed on the control (Figure V-8a and 
b). This result suggests that the PEM has antibacterial properties. When bacteria 
were detached and incubated for 24 h on agar plates, the CFU for bacteria grown on 
control surfaces was 3 orders of magnitude higher than that for bacteria grown on 
the PEMs (Figure V-8c).  Bacteria were detached from the surfaces and incubated 
for 24 h on agar plates before counting. 
 
Figure V-8. S. aureus growth on PAA-gentamicin PEM coatings and on glass substrates 
immersed in gentamicin. Cell observer images following 24 h of incubation of S. aureus on 
a) PEM coating on top of titania films and b) glass immersed in gentamicin. c) CFU of the 
adhered bacteria on the PEM and glass with gentamicin.  
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2.4. Conclusions and perspectives 
Stable PAA-gentamicin complexes were synthesized by mixing 0.3 mg mL-1 
gentamicin and 1 mg mL-1 PAA in 500 mM NaCl at pH 4.5. Complexes display a 
hydrodynamic diameter ranging from 160 to 300 nm and are stable within 4 hours.  
PEMs were constructed by alternating PLL and PAA-gentamicin complexes by 
adsorption on top of titania up to 4 bilayers. The assembly of the PAA-gentamicin 
complexes with PLL shows an exponential growth and a large number of PAA-
gentamicin complexes are deposited with only a few assembled layers. 
 The PLL/PAA-gentamicin PEMs are stable until pH 13. However, PEMs release 
gentamicin at physiological pH values. Release studies in 10 mM PBS showed an 
initial burst release within the first 6 h followed by a slow release of gentamicin 
lasting up to 5 weeks. The antibacterial properties of the PEMs were tested by 
seeding an S. aureus strain on the LbL films. The CFU counts for bacteria grown on 
the PEMs after 24 h is 3 orders of magnitude smaller than those grown on a glass 
control immersed in gentamicin.  It is important to note that only 4 bilayers of PLL 
and the complex are required to achieve a film with antibacterial properties. 
During surgery and while the body is exposed to the environment, a fast release of 
gentamicin can be crucial for avoiding the attachment of bacteria. At the same time, 
a continuous supply of gentamicin in lower doses is required during the 
osseointegration process until the tissue is reconstituted to ensure that bacteria do 
not attach and proliferate at the site of the implant. The initial burst release of 
gentamicin followed by a long-lasting slow release over weeks makes the PAA-
gentamicin PEMs especially attractive as an antibacterial coating for implants, and 
highlights the potential of these films to prevent nosocomial infections following 
implant surgery. 
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VI. CHAPTER 3 
SrTiO3 mesoporous coating for 
enhanced osseointegration  
 
 
 
3.1. Motivation 
Since the role of an implant is the replacement of the bone, it needs to mimic the 
biological environment and mechanical properties of the bone. Several strategies 
have been proposed to improve interaction between titanium implants and the 
regenerating bone tissue.[79,125,352–354] Topography plays an important role on the 
osseointegration process with cells adhering better to rougher surfaces. Indeed, 
titania with nanoscale surface features has been shown to favour 
osseointegration.[126,127] To increase the bioactivity of titania, growth factors can be 
deposited on top of the implant or the titania can be doped with bioactive 
ions.[352,355–357]   
Several ions present in the human bone mineral apatites like calcium (Ca2+), 
magnesium (Mg2+), niobium (Nb5+), phosphate (PO43–), silicate (Si4–), strontium 
(Sr2+), and zinc (Zn2+) are known to promote osteoblastic precursor cell 
differentiation.[182,185,194,197,199,205,216,218,236,358] The incorporation of some of these 
bioactive ions in titania, in particular strontium, has been shown to induce growth 
factor signaling pathways to osteoblastic precursor cell differentiation.[182]  
Approximately 98 % of the strontium present in our body is localized in bone 
tissue.[237] Strontium has a beneficial effect on the bone metabolism due to its 
anabolic and antiresorptive activity[359] and has been shown to be a promising 
therapeutic agent to heal bone disease, as example, strontium ranelate has been 
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used in clinics for long time.[360] As oral medicament it has been proved to act on 
both the desorption and formation of bone,[361] but currently is not recommended 
due to the side effects it has when is administered orally.[362] Besides, the side effects 
are suppressed when the drug is administered locally.[363] Strontium itself promotes 
osteogenic differentiation of mesenchymal stem cells by up-regulating the 
expression of osteoblast marker genes, such as Runx2, osteocalcin (OCN), 
osteopontin (OPN), bone sialoprotein (BSP), and type 1 collagen, and increasing 
Alkaline Phosphatase (AP) activity and matrix mineralization.[212] 
Strontium incorporated in titania has been shown to lead to an enhanced 
osseointegration and an improved differentiation of pre-osteoblastic cells.[352,364–366] 
The strontium incorporated in titania, however, must be released in the 
environment of the regenerating tissue for a positive action. Besides the amount of 
Sr incorporated in the titania the area available for ion exchange plays an important 
role in the release of Sr as it will only be delivered in the media when it is located on 
the surface.[352,367]  Rougher titania surfaces for example have been shown to deliver 
Sr more effectively than plain titania as a consequence of the larger available 
surface.[182,352,364] A possible mean to increase the surface area for ion delivery is the 
use of mesoporous titania. Mesoporous materials have an ordered, homogenous 
array of pores with highly controlled diameters in the 2-10 nm range.[294]  Titania 
can be synthesized as a mesoporous material without compromising its mechanical 
properties,[301] which is fundamental for bone replacement. Moreover, a 
mesoporous titania film (MTF) can be easily synthesized on top of non-porous 
titania with the same biocompatibility properties as the non-porous titania. 
A  large surface is available in mesoporous films that can be used for the delivery of 
Sr or other bioactive element present in the formulation of the mesoporous 
material.[262] The larger surface results in a larger amount of Sr potentially available 
for delivery in the media if compared with non-porous titania with the same content 
of Sr. Moreover, the mesoporous material can be designed to present interconnected 
pores linked by narrow necks. Once the Sr is released from the surface of the pore it 
will have to escape through the pores, retarding its release from the film. 
Importantly, it is possible to incorporate strontium or calcium into the MTF during 
the synthesis process simply by adding ionic salts to the sol, as demonstrated by 
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Grandfield et al.[243] By this way the ions will be incorporated to the titania matrix, 
up to 0.01 : 1 of Sr : Ti relation in moles.[243] Strontium salts are not very soluble,[368–
370] and depending on the synthetic pathway applied to obtain the mesoporous films 
and the solvents used, the concentration of the strontium salt that can be 
incorporated during the synthesis varies. Grosso et al.[371] also incorporated Sr in 
MTFs and found a 1 : 1    Sr : Ti relation but only in nanocrystals located in the walls 
of the mesoporous structure, being Sr not homogeneously distributed.[371] 
In this chapter strontium titanate mesoporous films (SrTiMFs) are prepared by sol-
gel chemistry employing the evaporation induced self-assembly method (EISA). 
Pore and neck size of the films are measured by Environmental Ellipsometric 
Porosimetry (EEP). Film thickness and surface are visualized by Scanning Electron 
Microscopy (SEM), and pores by Transmission Electron Microscopy (TEM). Small-
angle X-Ray Scattering (SAXS) patterns are obtained to determine the pore ordering 
and mechanical properties of the SrTiMFs are examined by nanoindentation. Sr 
concentration and molar relation to Ti is determined by X-ray Photoelectron 
Spectroscopy (XPS). To assure the Sr is homogeneously distributed in the Ti 
mesoporous structure Energy Dispersive X-Ray (EDX) analysis is performed in 
different points of the film. Sr release is followed by Induced Coupled Mass 
Spectroscopy (ICP-MS). TEM imaging is also performed after the release study to 
evaluate film stability. Cell attachment, proliferation and differentiation studies are 
performed with the MC3T3-E1 pre-osteoblastic cell line showing the enhanced 
bioactivity of the SrTiMFs. 
3.2. Experimental section 
3.2.1. SrTiMF synthesis and characterization 
For the sol preparation Titanium (IV) Chloride (≥ 99.0%, TiCl4), Strontium chloride 
hexahydrate (SrCl2 x 6 H2O), Ethanol Absolute (Synthesis grade, EtOH), Pluronic 
F127® and nanopure water (H2O) were mixed in a molar proportion of TiCl4 : EtOH 
: SrCl2 : F-127 : H2O = 1 : 40 : 0.2 : 0.0056 : 10. The titania precursor was prepared 
first, adding TiCl4 to the EtOH under vigorous stirring and leaving it till drops to 
room temperature.  SrCl2 was homogenized under stirring in water, then the F-127 
was added under stirring and finally the titania precursor is added. The sol is left 
stirring for 10 minutes to obtain a homogenous solution.  
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For the films preparation, 30 μL of the sol were mixed with EtOH in a volume 
proportion of sol : EtOH 2 : 1 and spin coated at 68 rpm for 30 seconds on glass slices. 
Films are placed for 30 minutes in a humidity chamber with a relative humidity of 
50 % and then they are subjected to a thermal treatment: 30 minutes at 60 ˚C and 
another 30 minutes at 130 ˚C. Finally, films are calcinated; first, heating up with a 
ramp of 1 ˚C min-1 and then, keeping them at 350 ˚C for 2 h. As control MTFs were 
synthesized following the same procedure described in Chapter 1.  
Pores were visualized through TEM imaging and field topology was analysed 
through FE-SEM. Ellipsometric and EEP measurements were performed to measure 
film thickness and pore and bottleneck diameters. 2D-SAXS patterns were analysed 
to study pore ordering. The value of the elastic modulus (Er) is extracted from 
nanoindentation tests.  
3.2.2. Strontium detection and release study 
The presence of strontium was confirmed by XPS atomic composition analysis. To 
ensure the strontium was homogeneously distributed in the mesoporous titania a 
Scanning Transmission Scanning Microscope with Energy Dispersive X-Ray detector 
(STEM-EDX) was used for the semi-quantitative analysis of the film composition at 
different positions on the surface.  
To measure the total amount of Sr in the SrTiMF, films were immersed in 5 mL HNO3 
> 99.5 % puriss overnight (around 18 h) to complete dissolution of the film, then 
distilled water was added till 5 % concentration of HNO3 was obtained for ICP-MS 
measurements. As control, MTFs were also dissolved following the same procedure. 
3 samples for each film type were evaluated.  
To study the release of the strontium, samples were placed in wells of 12 multiwell 
dishes with 2 mL 10 mM PBS and the strontium released was measured at 5, 15, 30 
min, 1, 2, 6 h and 1, 2 and 7 days. Samples were prepared in triplicate. TEM images 
were acquired on samples previously immersed in 10 mM PBS for 24 h. 
 
3.2.3. MC3T3-E1 cell bioactivity experiments 
To confirm cell adhesion to the substrates CLSM images were taken after F-actin, 
focal adhesions and nucleus labelling. Cell proliferation was evaluated by 
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colorimetric analysis. Measurements were done by triplicate at 2 h, 1, 2 and 3 days.  
Alkaline phosphatase activity was measured after 5, 10, 15 and 20 days of cell 
culture in osteogenic medium.  
3.3. Results and discussion 
3.3.1. SrTiMF synthesis and functionalization  
SrTiMFs are synthesized by sol-gel chemistry applying the EISA process. The block 
co-polymer Pluronic F127® was used to generate the mesoporous structure.  TEM 
and SEM imaging confirmed the porous structure (Figure VI-1a and b); the pores 
are seen as white spots in TEM and darker spots in SEM images. The pore ordering 
is not well defined, some regions present disordered pores, while other seem to 
present well-ordered pores, with an array compatible with the typical body 
centered cubic array of mesopores typical of F127 templated oxides. The insert in 
Figure VI-1a refers to the 2D-SAXS pattern of the SrTiMF, taken at 90°: a circular 
pattern is observed, compatible with mesoporous thin films in which pores in the xy 
plane are polyoriented, matching what it is observed by electron microscopy.[138] 
The calculated interplanar (-110) distance from the SAXS pattern is 11.1 nm, typical 
of F127 templated mesoporous oxides. [305] From the water adsorption and 
desorption isotherms (Figure VI-1c) a porous volume of 30 % and a pore diameter 
of 5.5 nm is determined. The bottlenecks connecting the pores have a diameter of 
3.2 nm. The SrTiMFs film thickness is 85 nm. These results also confirm that the 
inner porous volume of the film is accessible to water. In these conditions Sr present 
in the walls could get in contact with cell media and be released. Due to the high 
porous volume of the film the surface area largely increases if compared with non-
mesoporous titania films.[372] Then, a larger surface will be in contact with the media 
allowing higher release of Sr from the surface. Sangle el at.[373] have synthesized a 
mesoporous SrTiO3 film by pulse laser deposition and obtained rod-like 
mesoporous structure of 20 nm with a wall thickness of 5 – 7 nm. When films are 
around 100 nm in thickness the surface, compared to a non porous surface of same 
area, is increased in a 2,500 %.[373]  
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Figure VI-1. SrTiMF structural characterization by electron microscopy, SAXS and EEP. a) 
TEM image, insert 2D-SAXS pattern taken at 90°, b) SEM image of the surface and c) water 
adsorption-desorption isotherm, obtained by EEP. 
Nanoindentation measurements showed an elastic modulus of 25 ± 5 GPa for the 
MTF (Figure IV-2 in Chapter 1) and 35 ± 7 GPa for the SrTiMF (Figure VI-2). The 
incorporation of strontium to the mesoporous structure does not affect the Elastic 
modulus of the films; moreover the Elastic module is improved compared with plain 
MTF. However, in any case the value is smaller than for dense titanium surfaces, 
which ranges between 100 and 120 GPa,[31] but at the same time the Elastic modulus 
of SrTiMF is in agreement with the range of elasticity of bone, which lays between 4 
and 30 GPa depending on bone type.[23]  
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Figure VI-2. Nanoindentation study a) Shows the partial-load/unload vs displacement 
curve used for the tests and the results of the analysis of each unload section for Elastic 
modulus (Er) of b) the SrTiMF. 
The Sr : Ti molar relation in the  films synthesis was 0.2 : 1. This relation has been 
the highest possible to obtain an optimal solution for synthesis, since if the 
concentration of SrCl2 was augmented it started to precipitate resulting in an  
inhomogeneous solution. XPS measurements have confirmed that this relation is 
kept after film synthesis, where the resulting relative Sr/Ti atomic percentage is 
around 20.8 ± 0.4 %. Compared with Grandfield et al.[243]  that obtained a 0.01 : 1 of 
Sr : Ti molar relation, the synthesized MTFs have incorporated 20 times more 
strontium in the film, and very importantly in  an homogeneous distribution. 
Figure VI-3a shows the XPS spectra of a SrTiMF, and Figure VI-3b and VI-3c show 
the high resolution spectra of Ti and Sr, respectively. It must be noticed that chlorine, 
which should appear at 199 cm-1, is not detected in the XPS spectra confirming that 
strontium is integrated in the titanium network and not forming SrCl2 crystals. By 
means of ICP-MS the total strontium amount is obtained once the film is digested. 
The total amount of strontium in the SrTiMF resulting from the measurement of 3 
samples is 2.29 ± 0.53 µg.  
Figure VI-4 shows representative STEM and EDX spectra at different spots of the 
SrMTFs. Figure VI-4a and VI-4b correspond to STEM micrographs taken of 
different parts of the film. The spectra shown (Figure VI-4c) are obtained in three 
spots from same region. There are no regions where Ti or Sr bands are missing, 
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meaning that the mesoporous network has a homogeneous distribution of the 
elements and no phase segregation occurs in the mesoporous oxide.  
 
 
 
Figure VI-3. XPS a) Survey spectra and high resolution b) Ti and c) Sr spectra from SrTiMF.  
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Figure VI-4. a) and b) STEM images of SrTiMF and c) EDX analysis of the points in image a 
(white crosses) and area in image b (white rectangle). 
3.3.2. Strontium release  
Figure VI-5 shows the release profile of Sr measured by ICP-MS. After 1 h, 38.58 ± 
1.77 % of Sr is released and after 8 h the percentage of released Sr is 43.76 ± 7.99 %. 
The next measurements at 24 h show a 44.41 ± 6.61 %. of Sr released. The release 
curve shows a fast release within the first 8 h, where the maximum release is 
reached. Then, the release is very slow but continuous. The release characteristics 
of the mesoporous could be further tuned by  modifying pore size, porous structure 
or film thickness.[372] The larger the surface area and thickness of the SrTiMF the 
higher the concentration of ions available for release will be.[372,374] Figure VI-6 is a 
representative TEM image of the SrTiMF after being immersed for 24 h in 10 mM 
PBS for the release experiment. As can be seen, the films do not suffer any noticeable 
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dissolution and the porous structure is maintained without any appreciable 
changes. 
 
 
 
Figure VI-5. Percentage of strontium loss from SrTiMF over time measured with ICP-MS. 
 
 
 
Figure VI-6. TEM representative micrograph of SrTiMTF after being immersed 24 h in 10 
mM PBS. 
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3.3.3. Biocompatibility and bioactivity evaluation  
The MC3T3-E1 osteoblast precursor cell line is used to evaluate adhesion to the 
MTFs (In Chapter 1) and SrTiMFs. Figure IV-7 and VI-8 show CLSM images of the 
cells cultured on the MTFs and SrTiMFs, respectively. The actin filaments (F-actin) 
are stained with phalloidin, which can be appreciated as red fluorescence in the 
images displayed in the second row of the figure. Vinculin is stained with FITC, and 
the staining is shown in green in the first row of images. The nucleus is stained with 
DAPI and is represented in blue in the Merge images (third row), where all the 
labeled cell parts are shown. In the F-actin images it can be seen that cultured cells 
on SrTiMF exhibit a similar size as when cells are grown on MTF and an arranged 
cytoskeleton with distinctive stress fibers inside the cytoplasm, especially at the 
border of the cells. However, cell shape is different after 48 h of culture (third 
column). Compared to cells cultured on top of MTFs, when strontium is incorporated 
in the MTF the cell shape is more elongated and cells show higher filopodia.[312] This 
means that  cells are better interacting with the surface in presence of strontium and 
that they are well attached to the surface.  
Vinculin interconnects signals in the focal adhesions and is a key regulator in the 
environment sensing.[313,314] The first row of images in Figure VI-7 shows the 
vinculin staining in the green channel. Green dots can be distinguished at the end of 
the actin filaments of cells cultured on SrTiMFs. After 2 h of cell incubation on the 
substrates (first column) focal adhesions can be perfectly distinguished, meaning 
cells adhere well to the substrates already at initial times and adhesion will later 
improve cell proliferation.[310,313]  
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Figure VI-7. CLSM images of vinculin (first row), actin (second row), the merge of the actin, 
the vinculin and the nucleus (third row) and the zoom of the merge image (fourth row) at 
2h (first column), 24h (second column) and 48h (third column) of growth of MC3T3-E1 cell 
line on SrTiMF substrates at 63x. 
  
SrTiO3 mesoporous coating for enhanced osseointegration                                               Chapter 3 
117 
 
Figure VI-8 shows results on cell proliferation for MC3T3-E1 cells cultured on top 
of MTFs and SrTiMFs. After 7 days the culture is confluent, meaning that the surface 
is completely full of cells forming a monolayer, and no difference can be 
distinguished between samples.  Within the first day cells proliferate at the same 
rate and cell density is the same for both substrates.  After 2 days of culture on 
SrTiMFs cell proliferation rate is enhanced if compared with cells cultured on MTFs 
(p < 0.05). At day 2, the proliferation on MTF containing Sr is a 64 % higher if 
compared with plane MTFs, and after 3 days of culture the difference is of 52 %. As 
previously seen in Figure VI-8, cells are more expanded and showing higher 
filopodia, as the interaction is better, it is known that proliferation is also 
improved.[310,313]  These results confirm as expected that, strontium enhances pre-
osteoblastic cell proliferation,[375–377] but more importantly how the Sr is released 
from the mesoporous structure makes the substrate a good candidate to enhance 
cell attachment and proliferation at initial times after the implant is placed in the 
human body. 
 
 
Figure VI-8. Proliferation of MC3T3-E1 pre-osteoblasts cultured on MTF and SiTiMF 
substrates for 2 h, 1, 2 and 3 days. * means the difference is statistically significant (p < 0.05). 
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Alkaline phosphatase (AP) is one of the gene markers in the early stage of osteogenic 
differentiation[162] and his activity has also been evaluated. Figure VI-9 shows AP 
activity of the cells cultured on the MTFs and SrTiMFs. After cells reach confluence, 
they are differentiated for 20 days and the AP activity is measured at different 
differentiation times to evaluate differences in the degree of differentiation. 
Differences between both types of substrates (p < 0.05) are observed just after cells 
are cultured in osteogenic medium. Only 5 days after cells are cultured on top of the 
substrates, the AP activity is more than the double on SrTiMFs compared to MTFs. 
Following measurements at 10, 15 and 20 days also confirm enhanced cell 
differentiation on SrTiMF.[375–377]    
 
 
Figure VI-9. Alkaline phosphatase activity after 5, 10, 15 and 20 days of MC3T3-E1 
pre-osteoblastic cell culture in osteogenic medium on MTF and SrTiMF. * means the 
difference is statistically significant (p < 0.05). 
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3.4. Conclusions and perspectives 
SrTiMFs display a porous and accessible mesoporous structure. Around 20 % of 
strontium has been incorporated in the MTFs, which is the highest value for Sr in 
mesoporous titania reported. Moreover, Sr and Ti are homogenously distributed in 
the mesoporous structure without any phase segregation. 
The high porous volume of around 30 % results in a large interface for strontium 
exchange with the media since pores are accessible for water as demonstrated by 
EEP measurements. At physiological pH in 10 mM PBS 44 % of the strontium present 
in the films is released within 8 h. 
SrTiMFs improve MC3T3-E1 cell adhesion and proliferation if compared with MTFs 
resulting in more elongated cells with more defined stress fibers and focal points. 
Cell differentiation is enhanced in a 100 % after 3 days if strontium is present in the 
mesoporous structure. 
This chapter shows that it is possible to synthesize doped mesoporous titania films 
with a high concentration of bioactive ions such as strontium and with a large 
surface area for ion exchange, due the mesoporous structure. Films display 
mechanical properties compatible with bone and can be easily assembled on top of 
titania implants with high potential for increasing osseointegration, specially at 
early stages after implant surgery.  
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VII. CHAPTER 4 
COOH-functionalized Si and Ti 
mesoporous films to complex 
metallic ions 
 
 
4.1. Motivation 
Oxide-based mesoporous hybrid materials (MHMs) display the large surface areas 
and tunable pore sizes of mesoporous materials, the mechanical and thermal 
stabilities of an inorganic support, and are chemically functionalized with organic 
moieties.  Organic molecules included within the oxide provide a mean to tailor the 
pore surface properties, such as hydrophobicity, polarity, catalytic activity as well 
as optical and electronic features. Thus, MHMs carry the potential for many 
applications in catalysis, chemical sensing, adsorption, contaminant immobilization, 
and drug or gene delivery.[137,378,379] MHMs in the form of thin films are particularly 
interesting because they can be easily removed from reaction media and they are 
easily processable, allowing facile production of devices.[380] 
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The incorporation of organic functionalities within porous oxides has attracted the 
increasing attention of the scientific community since the early development in 
mesoporous materials’ synthesis. Two grafting routes are commonly used for 
organic fabrication: post-grafting (post-functionalization) or co-condensation (one-
step approach).[137,380] In the first case, the functionality is grafted to the material 
after consolidation of the mesostructure through vapour deposition or solution 
impregnation. The modification is established through the generation of new bonds 
between Si−OH or M−OH surface groups and the functionalization agent. The co-
condensation method involves the mixing of inorganic precursors with a precursor 
that bears the organic functionality in the presence of the template; organosilanes 
are generally used for this approach. Because the meso-structuration and 
functionalization take place simultaneously, a portion of the introduced organic 
groups remains trapped inside the network, thus hindering their accessibility to the 
medium. The benefit the of co-condensation method is that involves a reduced 
number of processing steps, provides homogeneous distribution of functional 
groups within the inorganic network, and induces minimal pore clogging. 
In this chapter the functionalization of mesoporous titania with organosilanes 
displaying carboxylic groups that can complex Sr has been explored, producing an 
alternative to the incorporation Sr in the titania matrix presented in Chapter 3. In 
this new approach Sr has been complexed through carboxylates that have been 
anchored to the porous walls through post-functionalization. Again, taking 
advantage of the large surface displayed by the mesoporous films compared to the 
non mesoporous titania, the loading of the Sr is increased in a similar way. The 
design of titania with organosilanes displaying carboxylic groups is not direct and 
requires a significant optimization of fabrication protocols.  
Initial work was performed with mesoporous silica films; carboxylated silanes were 
used for functionalization of mesoporous silica films. However, when using titania 
the carboxylic groups are capable to complexes titania, and this difficults the one-
step synthesis of films based on titania.[381,382] Therefore, an alternative fabrication 
route was founded in which the vinylmethoxysilane (VTMS) was first included in 
the mesoporous titania network and modified after films synthesis with carboxylate 
groups through a photoreaction with the silanol.  
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The synthesis of mesoporous silica films functionalized with covalently bonded 
carboxylic groups by co-condensation is shown first. Carboxylic derivatized 
alkoxysilanes are obtained by photochemical radical thiol-ene addition (PRTEA), 
produced by clicking mercaptosuccinic (MSA) or mercaptoacetic thioacids (MAA). 
Different amount of organosilanes are used for the film synthesis. Electron 
microscopy, porosimetry measurements and Small Angle X-ray Scattering with two-
dimensional detection (2D-SAXS) are used for the structural characterization of the 
film and to relate the degree of mesoporous phase ordering and the amount of 
organosilane added to the film. The incorporation of the functional groups is shown 
by X-Ray Photoelectron Spectroscopy (XPS) and Diffuse Reflectance Infrared 
Fourier Transform Spectroscopy (DRIFTS). The availability of the COOH groups for 
further chemical modification is demonstrated by DRIFTS following the changes in 
the typical carbonyl IR bands during proton exchange and Pb2+ metal complexation. 
This simple methodology generates COOH-modified silica thin films in one step, 
without the need of hard reaction conditions or deprotection steps. 
Functionalization with carboxyl groups brings a pH-dependent switch-ability to the 
pore surface that can be used for multifunctional mesoporous materials design. 
Titania based mesoporous films grafted with carboxylates cannot be synthesized in 
one step due to the complexation of the titanium by carboxylic groups, which will 
impact on the mesoporous structure and eventually limit the availability of 
carboxilates.[381,382] VTMS is co-condensed with titanium tetrachloride in order to 
obtain vinyl-functionalized Ti-Si hybrid mesoporous films. By post-grafting the MSA 
is anchored through PRTEA to the vinyl groups functionalizing the surface with 
carboxylic groups. Same methodology is used to study the structure of the films and 
show the incorporation of the functional groups. Sr2+ complexation is assessed by 
XPS and DRIFTS measurements.  
Strontium release is followed by Inductively Coupled Plasma Mass Spectrometry 
(ICP-MS). Cell proliferation and differentiation experiments are carried out using 
MC3T3-E1 pre-osteoblastic cell line, the CCK-8 dehydrogenase activity assay and by 
measuring the alkaline phosphatase (AP) activity at different time periods. Actin 
filaments and vinculin are labelled using the FAK-100 kit. 
4.2. Experimental section 
Chapter 4                   COOH-functionalized Si and Ti mesoporous films to complex metallic ions                                      
124 
 
Reagents Name Abbreviation Chemical structure 
Si precursor 
Tetraethyl 
orthosilicate 
TEOS 
 
Ti precursor 
Titanium 
tetrachloride 
TiCl4 
 
 
 
Si-Vinyl 
precursor 
Vinylmethoxysilane VTMS 
 
 
 
Carboxylic 
Acids 
Mercaptosuccinic 
acid 
MSA 
 
 
 
Mercaptoacetic acid MAA 
 
Photoinitiat
or 
Benzophenone Ph2CO 
 
 
Templates 
Brij 58 B 
 
Pluronic F127 F 
 
 
Table VII-1. Reagents used for the synthesis of mesoporous silica and mesoporous titania 
films functionalized with carboxylic groups. 
 
 
4.2.1. COOH-functionalized mesoporous silica film synthesis 
To synthesize COOH-functionalized mesoporous silica films the carboxylic 
trialkoxysilane precursors were prepared first. 2-((2-(Trimethoxysilyl)ethyl) 
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thio)succinic acid, (MeO)3Si-MSA, and 2-((2-(trimethoxysilyl)ethyl)thio)acetic acid, 
(MeO)3Si-MAA,  precursors were prepared as reported by Bordoni et al.[143] Briefly, 
1 equivalent of vinylmethoxysilane (VTMS) was added to a vial containing methanol 
solution of the desired amount of MSA or MAA (chosen according to the desired 
proportion of organic functions in the final material) and 0.15 equivalents of 
benzophenone (Ph2CO) as  photoinitiatior. Reaction solutions were then irradiated 
under gentle stirring for 16 hours, using a 15 W, 18” long black-light lamp (λmax = 
352 nm). The precursor’s reaction mixture was used in the preparation of the sols 
without any further treatment. 
The sols to produce the functionalized mesoporous silica films were prepared in 
three steps: (1) TEOS, ethanol, and the template (Brij 58 or Pluronic F127) were 
mixed; (2) the reaction mixture of thio-ene addition was added drop wise under 
stirring, the carboxylated precursor added was varied from 5 % up to 20 % in molar 
proportion; and (3) HCl solution was added drop wise under stirring. The films 
synthesized with Pluronic F127® or Brij 58 will be referred as SiF and SiB, 
respectively. The chosen order allows the correct co-condensation reaction between 
the two silanes. The theoretical molar proportions of the sols were TEOS : Si-R : 
template : HCl : EtOH : H2O = 1 – x : x : s : 0.28 : 24 : 5.2, with 0 ≤ x ≤ 0.2, R = MSA or 
MAA, and s = 0.005 for F127 or s = 0.05 for Brij 58. After its preparation, the sol was 
aged for different times in the 1−24 h range. Table VII-2 shows the complete 
information about the studied systems. 
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Carboxylic acid Template 
Nominal % 
of 
functional 
silane 
Aging time 
MSA 
F127 
5 
1 h 
5 h 
24 h 
12.5 
1 h 
24 h 
20 
1 h 
5 h 
24 h 
Brij 58 
5 
1 h 
24 h 
12.5 
1 h 
24 h 
20 
1 h 
24 h 
MAA 
F127 
5 
1 h 
5 h 
24 h 
12.5 
1 h 
24 h 
20 
1 h 
5 h 
24 h 
Brij 58 
5 
1 h 
24 h 
12.5 
1 h 
24 h 
20 
1 h 
24 h 
Table VII-2. Description of explored systems regarding type of carboxylate function, 
surfactant, percentage of silane in the material and sample aging 
Hybrid mesoporous Si1−x(SiR)xO2 films were synthesized by dip coating, applying  
the EISA approach. A withdrawal speed of 3 mm/s was used to deposit the films onto 
glass slides. Immediately after synthesis, the films were placed in a humidity-
controlled chamber at 50% relative humidity (obtained with a saturated Ca(NO3)2 
solution in water) and kept there for 24 h. Afterwards, films were exposed to a gentle 
thermal treatment: 24 h at 60 °C, 24 h at 130 °C, and 2 h at 200 °C. Finally, the 
template was extracted by immersing the films for 2 days in pure grade ethanol. 
4.2.2. COOH-functionalized mesoporous titania film synthesis 
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Mesoporous titania films (MTFs) were functionalized with carboxylic groups by 
post-grafting. The films were first synthesized with VTMS and then the carboxylic 
moiety was anchored to the films through the vinyl groups by click-chemistry. As a 
template Pluronic F127® was used. The fabrication of functionalized hybrid Ti-Si 
films with vinyl groups required the preparation of sols solution in three step 
process: (1) addition of TiCl4 to EtOH (TiCl4 : EtOH = 1 : 40 mol) under vigorous 
stirring at room temperature; (2) mix the TiCl4 solution with ethanol and Pluronic 
F127; and (3) addition of VTMS to H2O under stirring. The theoretical molar 
proportions of the sols were TiCl4 : VTMS : F127 : EtOH : H2O = 1-x : x : 0.005 : 40 : 
10 with x1 = 0.1 and x2 = 0.2.  Films with the vinyl group with x1 = 0.1 and x2 = 0.2 
are referred as V10 and V20, respectively.  
Hybrid mesoporous Ti1−x(Si-Vinyl)xO2 films were synthesized by spin coating. Films 
were prepared in round glass coverslips. A drop of 30 μL of the sol was spin coated 
at 68 rpm for 30 seconds on glass slices. Immediately after synthesis, the films were 
placed in a humidity-controlled chamber at 50% relative humidity (obtained with a 
saturated Ca(NO3)2 solution in water) and kept there for 24 h. Then, they were 
subjected to a thermal treatment: 30 minutes at 60 ˚C, another 30 minutes at 130 ˚C 
and 2 h at 200 °C. Finally, the template was extracted by immersing the films for at 
least 2 days in pure grade ethanol.  
To anchor the carboxylic group by click chemistry, the films are immersed in pure 
ethanol solution containing MSA 23.3 mM (C1) and 33.3 mM (C2) and Ph2CO as 
photoinitiatior in 0.15 equivalents in moles to MSA. Reaction was performed for 1 h 
under irradiation with a 15 W, 18” long black-light lamp (λmax = 352 nm). After the 
reaction films were cleaned by immersing them 1 h in pure grade ethanol, 30 
minutes in distilled water and 1 h in pH 3 aqueous solution adjusted with HCl.  
4.2.3. Films characterization 
Pores were visualized by TEM and 2D-SAXS patterns were obtained at an angle 
between the incident radiation and the sample of 3°. The atomic composition of the 
films was determined by XPS, to calculate the atomic ratio between Sulphur and 
Silicon, three different films for each sample were measured. Ellipsometric and EEP 
measurements gave information about films thickness and pore and bottleneck 
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diameters. Film porosity was obtained from the XRR data. STEM-EDX 
measurements determined Si/Ti relation in films based on titania with Si-Vonyl.  
4.2.4. Pb2+ complexation study 
For metal coordination studies in COOH-functionalized mesoporous silica films, the 
films were put in contact with a 0.4 mM Pb(NO3)2 aqueous solution for 5 min, 
washed with water and ethanol, dried, and then scratched. DRIFTS measurements 
were performed by depositing scratched films onto a KBr-filled sample holder. To 
observe the speciation and accessibility of the COOH group in the inorganic network, 
the films were dried for 10 min in a 130 °C oven and immediately after scratched; 
the spectrum was taken immediately to minimize the water adsorption from the 
environment. In the case of acidic treatment, films were set for 10 min in a chamber 
saturated with HCl vapour. Then, films were dried and scratched in a similar way, as 
with the untreated films.  
4.2.5. Sr2+ complexation and release studies 
To complex Sr ions to the titania films bearing carboxylate groups, 100 mM and 500 
mM aqueous solutions of SrCl2 were prepared by film immersion for 3 h. After one 
immersion in distilled water films were left to dry in air for XPS measurements. As 
controls MTF and hybrid films prior to the photoreaction to attach the organic 
functionalization were used, also immersed in SrCl2 for 3 h. Samples were prepared 
by triplicate. The amount of strontium complexed and adsorbed was measured by 
XPS and atomic composition analysis. To assess ion complexation DRIFTS 
measurements were performed; films were dried at 60 °C after Sr2+ complexation. 
The strontium release was studied by ICP-MS. Briefly, samples were cleaned 
immersing in ethanol, then in water and left to dry in air. They were placed in wells 
of 12 multiwell dishes with 2 mL PBS 10 mM and the strontium release was 
measured at 5, 15, 30 min, 1, 2, 6 h and 1, 2 and 7 days. As controls the release of Sr 
from MTFs was also studied. The released Sr in PBS is diluted to 5 mL in distilled 
water in 5 % HNO3 for ICP-MS measurements. To measure the total amount of 
strontium, films were immersed in 2 mL HNO3 overnight and then distilled water 
has been added til 5 % concentration of HNO3 was obtained for ICP-MS 
measurements.  
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4.2.6. MC3T3-E1 cell biactivity experiments 
Cell experiments were performed in COOH-functionalized hybrid films with 
complexed Sr. As control MTFs and MTFs filled with Sr were used. F-actin, nuclei 
and focal adhesions of the cells were labeled and visualized by CLSM to study cell 
adherence to the substrates. Alkaline Phosphatase Activity Assay Kit and the 
Bradford assay for total protein quantification were performed to study cell 
differentiation process at 5, 10, 15 and 20 days. All samples were evaluated in 
triplicate. 
4.3. Results and discussion 
4.3.1. COOH-functionalized Si mesoporous films 
Two different alkoxysilane bearing carboxylic moieties, one with a short alkyl chain 
and one dicarboxylate, are synthesized by PRTEA; the reaction pathway is presented 
in Figure VII-1.  
 
Figure VII-1. Scheme of the synthetic pathway to obtain alkoxysilanes with MAA 
and MSA.  
In all tested conditions, the obtained materials were porous, as can be seen in the 
TEM images (Figure VII-2 and VII-3). However, only the oxides with lower 
concentration of organic silane showed a high degree of order, as corroborated by 
TEM and 2D-SAXS. In fact, for all samples containing 5 % of organic moiety, 2D-SAXS 
patterns can be assigned to a body centered cubic Im3m pore array, oriented with 
the (110) plane parallel to the substrate. This structure is obtained with F127 and 
Brij 58 as templates, and is similar to the structures obtained without organic 
functional groups.[383] In two cases with 12.5 % of nominal organic silane, the same 
structure is obtained for both SiB MSA and SiF MAA. Further increase in the amount 
of COOH-modified silane to 12.5 % and 20 % impacts on the pore order. For F127 
templated oxides, the 2D-SAXS patterns are ellipses, which correspond to locally 
Chapter 4                   COOH-functionalized Si and Ti mesoporous films to complex metallic ions                                      
130 
 
ordered (wormlike) arrays of mesopores. For Brij 58 templated samples, no pattern 
is observed, meaning that pores are not ordered. These observations agrees with 
previous studies,[384] that showed that the presence of the organic functional groups 
generally limits the organic/metal molar ratio in which order is obtained, being 20 
% the most usual limit.[137,139,140] Aging the film for 24 h has no effect on the 
behaviour of the final structure .[142]  
Regarding the plane’s distances obtained from 2D-SAXS patterns, it is interesting to 
note that the d-110 distance, the distance between the pores for the cubic structure 
in the xy plane, decreases when the amount of organic material in the film is 
increased, as can be seen for the SiF-MSA (Table VII-3).  
 
Nominal  % of 
organosilane 
Aging 
1h 24 h 
0 14.8  
5 13.3 13.5 
12.5 12.6 12.6 
20 11.2 11.4 
Table VII-3. d-110 interplanar distances (in nm) obtained from 2D-SAXS patterns for the SiF-
MSA system. 
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Figure VII-2. TEM micrographs and 2D-SAXS patterns of: a) SiF MSA 5 % 1 h, b) SiF MSA 
12.5 % 24 h, c) SiF MSA 20 % 1 h, d) SiB MSA 5% 1 h, e) SiB MSA 12.5 % 1 h and f) SiB MSA 
20 % 1 h. 
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Figure VII-3. TEM micrographs and 2D-SAXS patterns of: a) SiF MAA 5 % 1 h, b) SiF MAA 
12.5 % 24 h, c) SiF MAA 20 % 24 h, d) SiB MAA 5 % 1 h, e) SiB MAA 12.5 % 1 h and f) SiB 
MAA 20 % 1 h. 
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These results indicate that the diameter of micelles decreases with the increase of 
the concentration of the organic functionalities resulting in smaller interpore 
distances. This tendency suggests concentration-dependent interaction of 
templates and the organic moiety, affecting the size of the micelles and ultimately 
the pores size. A possible explanation is that the COOH moieties interact with the 
hydrophilic part of the templates diminishing the hydration of the formed micelles 
and  decreasing their size.[385]  
Adsorption and desorption isotherms for SiF and SiB MSA 20% with 1 and 24 h of 
sol aging are shown in Figure VII-4 and show the typical hysteresis loop for 
mesoporous materials. From the analyzed isotherms,[262] results shown in Table 
VII-4, it can be concluded that the films presented an accessible porosity of around 
20 % and pore diameters of around 4 nm and  2 nm for F127 and Brij 58, 
respectively. These values are in good agreement with previously obtained results 
for mesoporous thin films that were treated at moderate temperatures, followed by 
template extraction using organic solvents. This kind of treatment results in less 
deformed and interconnected pores than in the case of calcination, with smaller 
pore sizes and lower porosity.[386,387] 
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Figure VII-4. EEP results for a) SiF-MSA 20 % 1 h, b) SiB-MSA 20 % 1 h, c) SiF-MSA 20 % 
24 h and d) SiB-MSA 20 % 24 h thin films. 
 
Sample Thickness (nm) Porosity (%) Pore diameter (nm) 
SiB-MSA 20 % 1 h 254 20 2.7 
SiB-MSA 20 % 24 h 225 19 2.1 
SiF-MSA 20 % 1 h 285 21 3.9 
SiF-MSA 20 % 24 h 295 20 4.7 
Table VII-4. Data obtained from EEP measurements of thickness (nm), porosity (%) and 
pore diameter (nm). 
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The EEP confirms that the obtained films present an accessible porosity of around 
20 % and pore sizes of 4 nm for F127 templated films and 2 nm for Brij 58. These 
values are in good agreement with results for mesoporous thin films treated at 
moderate temperature followed by template extraction using solvents.[386,387] 
To understand the final properties and potentialities of the materials one needs to 
understand chemical composition and speciation of the organic groups 
incorporated within the hybrid films. These results are particularly important for 
the case of mesoporous hybrid materials prepared with the co-condensation 
methodology, since it is highly probable that the organic functionalities will degrade 
due to thermal treatment. The XPS technique is used to characterize the chemistry 
of the film surface. Since the carboxylated precursors used for the hybrid films’ 
synthesis contain thioether bonds, the incorporation of the functionalizing agent 
into the films was quantified by tracking the signal of Sulphur 2p and compared to 
the Silicon 2p signal. Figure VII-5 shows representative XPS spectra of the hybrid 
films, all hybrid films analyzed confirm the presence of Si, O, C, and S, indicating the 
successful incorporation of carboxylated silanes.  
Figure VII-6 and Figure VII-7 show, the high resolution scan spectra for S and Si of 
the SiB-MSA 5, 12.5 and 20 % mesoporous systems of 1 and 24 h of sol aging, 
respectively. All spectra show the Si 2p signal around 103 eV. From the high 
resolution spectra, it can be seen that the samples containing 12.5 and 20 % of the 
carboxylated silanes show the presence of two peaks at 164.2 and 168.6 eV (Figure 
VII-6c and e and Figure VII-7c and e), whereas the films with 5 % show a single 
peak at 168.6 eV (Figure VII-6a and Figure VII-7a). The binding energy at around 
164.2 can be assigned to −C−S− and the one at around 168.6 eV can be associated to 
the oxidized Sulphur species −C−SOx−C−.[388] The oxidation of S was observed for 
every sample. Oxidation could be due to the thermal treatment performed in the 
presence of oxygen. 
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Figure VII-5. XPS spectra wide scan for SiB-MSA 20% 1 h system. 
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Figure VII-6. High resolution spectra of a) S of SiB MSA 5 %, b) Si of SiB MSA 5 %, c) S of SiB 
MSA 12.5 %, d) Si of SiB MSA 12.5 %, e) S of SiB MSA 5 % and f) Si of SiB MSA 5 % of films 
prepared with 1h aged sols.  
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Figure VII-7. High resolution spectra of a) S of SiB MSA 5 %, b) Si of SiB MSA 5 %, c) S of SiB 
MSA 12.5 %, d) Si of SiB MSA 12.5 %, e) S of SiB MSA 5 % and f) Si of SiB MSA 5 % of films 
prepared with 24 h aged sols. 
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The XPS survey also provides the atomic percentage of S and Si in the samples, which 
can be related to the proportion of carboxylated organosilane incorporated into the 
films. Because each carboxylated silane molecule contains one Sulphur atom per 
Silicon the percentage of incorporated silanes can be equalled to the percentage of 
Sulphur. As shown in Table VII-5, increasing the fraction of functionalized silanes 
during film preparation, results in an increase in the final amount of Sulphur in the 
hybrid film. In addition, regardless of the sample considered, the final composition 
of the functionalizing agent in the film corresponds to around the 30 % of the 
nominal composition in the solution. This is presumably due to the degradation of 
the silanes during the thermal treatment at 200 °C and/or the template extraction 
in ethanol. The effect of sol aging is ruled out as a potential cause of degradation, 
because the binding energy for the Sulphur species and the incorporation of 
functional silanes in the final material is equivalent for different aging times, 
indicating that the silane remains stable for at least 24 h.  
Sample S/Si (%)     Sample S/Si (%) 
SiF-MSA 20% 1h 6.0 ± 0.4     SiF-MSA 20% 24 h 6.0 ± 0.7 
SiF-MSA 12.5%  1h 4.5 ± 0.3     SiF-MSA 12.5% 24 h 4.8 ± 0.4 
SiF-MSA 5%  1h 1.7 ± 0.5     SiF-MSA  5% 24 h 2.0 ± 0.1 
SiB-MSA 20% 1h 6.0 ± 0.3     SiB-MSA 20% 24 h 6.2 ± 0.5 
SiB-MSA 12.5% 1h 5.0 ± 0.6     SiB-MSA 12.5% 24 h 4.2 ± 0.5 
SiB-MSA 5%  1h 0.1± 0.1     SiB-MSA 5% 24 h 1.3 ± 0.2 
Table VII-5. Atomic Percentages for S and Si and S/Si Relation calculated from XPS 
spectra of the different systems containing the MSA moiety. 
4.3.2. Pb2+ complexation study 
Infrared spectroscopy was used to qualitatively analyze the presence and reactivity 
of COOH groups. Figure VII-8 shows DRIFTS spectra of selected MSA modified 
samples after template extraction, compared to the spectra of unmodified films. The 
IR spectrum of SiF MSA 20 % 1 h (Figure VI--8b) shows the presence of 
characteristic signals of the carbonyl group, which is absent in the SiF film (Figure 
VII-8a): a shoulder band at 1716 cm−1, associated to the carbonyl group’s 
asymmetric mode of the carboxylic acid (νC=O) protonated form, and another band 
at lower wavenumber (∼ 1578 cm−1).[389] Both bands superimpose with the band of 
adsorbed water (scissoring of OH groups). The lower wavenumber band can be 
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attributed to C=O stretching of the acidic groups that interact by hydrogen bonding 
with chemical species on the oxide surface, as Tsai et al.[390] have previously 
observed in powders by magic angle spinning NMR,[390] or to the ionized form of the 
carboxylic acid.[391] Besides the bands associated to COOH groups, the spectra shows 
the characteristics bands corresponding to the O−Si−O stretching (TO, TO2, and TO3 
modes) of the silica network at 1300−950 and 800 cm−1 zones and the Si−OH band 
at 850 cm−1.[392] Also, the stretching vibration bands corresponding to the aliphatic 
skeleton of silane and some residue of the template (νC−H) are exhibited at 2954, 
2927, and 2858 cm−1. The shift and intensity of C=O bands can be used to evaluate 
the reactivity of COOH/COO− groups toward simple reactions, such as acid−base or 
metal complexation. Note, however, that as the films were obtained by the co-
condensation method, not all carboxylic groups were available on the pore surface. 
When SiF-MSA 20 % film was exposed to HCl vapours (Figure VII-8c), the intensity 
of the band located at 1716 cm−1 increased with the concomitant disappearance of 
the band located at around 1578 cm−1, indicating that a fraction of the COOH groups 
are involved in acid−base equilibrium.[389] Immediately after, this film was 
immersed in 0.4 mM Pb2+ aqueous solution. The spectrum (Figure VII-8d) shows a 
decrease in the intensity of the band located at 1716 cm−1 and the appearance of a 
distinctive band at 1550 cm−1 that is associated with coordinated carboxylic 
groups.[389,391]  Moreover, it can be seen that the 850 cm−1 band associated with 
Si−OH does not suffer any changes after contact with acidic or Pb(II) solutions 
(Figure VII-8c and d). This indicates, as expected on the basis of previous 
results,[143] that the acidity and ion exchange due to the bare silica matrix are 
negligible when compared to those due to the COOH groups, under these 
experimental conditions. Thus, these simple acid−base and coordination 
experiments show that the included carboxylic groups are available for simple 
chemical reactions such as proton interchange or Pb(II) ion trapping. 
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Figure VII-8. DRIFTS spectra of scratched films after extraction: a) SiF, b) SiF-MSA 20 % 1 
h; c) SiF- MSA 20 % 1 h after contact with HCl and d) SiF-MSA 20 % 1 h after contact with 
Pb2+. Left: wide spectra. Right: enlargement of the COOH region. 
4.3.3. COOH-functionalized Ti based mesoporous films 
As previously mentioned, if the COOH-grafted mesoporous film is based on titania, 
is not possible to synthesize the films through the same procedure followed to 
synthesize silica based mesoporous thin films grafted with carboxylic groups in one 
step, through co-condensation. Titanium is complexed by the carboxylic groups, 
which would not be available to complex other ions and they would lose their 
functionality.[381,382] Therefore, a different approach was followed. Silanes were 
incorporated in the film during fabrication as before but bearing a vinyl group. Once 
mesoporous titania films are prepared with vinyl silanes in the pores, the MSA reacts 
with the vinyl groups gifting the pore surface with carboxylic moieties through post-
functionalization in a two-step synthesis. The synthetic pathway is depicted in 
Figure VII-9.  
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Figure VII-9. Scheme of the synthetic pathway to attach MSA to the vinyl groups present in 
the Ti-Si hybrid mesoporous films. 
Samples are prepared with two concentrations of organosilane at concentrations of 
10 and 20 % in moles to the total amount of titanium. Figure VII-10 show two high 
resolution TEM (HRTEM) images and the EDX spectra. The Ti and Si can be detected, 
and as expected, the Si amount present in the film with 20 % of Si-Vinyl (˜ 22.09 %) 
is the double of the Si in films with 10 % (˜ 9.52 %). Then, reactions are performed 
with two concentrations of MSA (C1 = 23.3 mM and C2 = 33.3 mM). Figure VII-11 
shows the high resolutions spectra of Titanium and Sulphur, used to calculate the 
S/Ti molar relations shown in Table VII-6. S/Ti relation is the same in the 4 
different samples, meaning that the amount of MSA, which reacts with the vinyl 
group, remains constant even if the concentration of vinyl groups is increased to the 
double in the mesoporous film. This suggests that the amount of vinyl groups 
available for reaction with MSA is similar regardless the amount of added VTMS. 
Therefore, the films containing 10 % of VTMS are selected for further experiments. 
In the same line, S/Ti ratio remains constant regardless MSA concentration. 
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Figure VII-10. STEM images of MTF with a) 10 % and b) 20 % of Si –Vinyl and c) EDX 
analysis of the images. 
 
Sample S/Ti (%) 
10 % Si-Vinyl C1 9.89 ± 0.43 
10 % Si-Vinyl C2 7.97 ±  1.36 
20 % Si-Vinyl C1 6.47 ± 1.79 
20 % Si-Vinyl C2 10.05 ± 2.30 
Table VII-6. S/Ti atomic relative percentages of mesoporous titania films with 10 % and 20 
% of Si-Vinyl reacted with C1 and C2 of MSA obtained from XPS measurements.  
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Figure VII-11. XPS high resolution spectra of a) Ti and b) S of MTF with 10 % of Si-Vinyl 
reacted with C1 MSA, c) Ti and d) S of MTF with 10 % of Si-Vinyl reacted with C2 MSA, e) Ti 
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and f) S of MTF with 20 % of Si-Vinyl reacted with C1 MSA and g) Ti and h) S of MTF with 
20 % of Si-Vinyl reacted with C2 MSA.  
4.3.4. Sr2+ complexation study 
The incorporation of Sr within MTF containing 10 % Si-Vinyl and C1 MSA is the 
double than Sr in bare MTFs (Table VII-7). Figure VII-12, VII-13 and VII-14 show 
high resolution spectra of Ti and Sr with 100 and 500 mM of SrCl2 of MTFs, MTF with 
10 % Si-Vinyl and MTF with 10 % Si-Vinyl and C1 MSA, respectively. The initial 
concentration of Sr precursor (100 or 500 mM SrCl2) has no effect on the final ratio 
of Sr to Ti in the films. However, the films functionalized with vinyl groups allowed 
for higher incorporation of Sr as compared to MTFs; the Sr/Ti ratio is around 10 and 
15 %, respectively. As calculated in Chapter 2, the porosity of the MTFs is of 33 %, 
lower than the porosity of the MTF with Si-Vinyl, which could be the reason for a 
longer amount of Sr incorporated in the second type of substrates. What is more, if 
the films with Si-Vinyl are subjected to the photoreaction and the COOH groups are 
incorporated, the Sr amount increases by 33 %, and that is due to the complexation 
with carboxylic groups. Changes in the DRIFTS peaks (Figure VII-15) also confirm 
the Sr2+ complexation with carboxylic groups. In the presence of MSA bands appear 
at of 1610 – 1515 cm-1 and 1495 – 1345 cm-1, which correspond to asymmetric and 
symmetric vibrational modes of the coordinated carboxyl groups of the carboxylic 
acid (νC=O).[389,393] As mentioned, carboxylates can complex Ti, which could be the 
reason for the appearance of these bands.[381,382]  When the films are immersed in 
Sr, the maximum peak and the intensities of the asymmetric and symmetric mode of 
the coordinated carboxyl bands change, meaning that the complex is formed27 The 
band ranging from 950 to 650 cm-1 is assigned to Ti-O bonds with a peak at around 
800 cm-1, confirming that the material is formed of titania.[394,395] 
Sample Sr/Ti (%) 
MTF 100 mM SrCl2 9.3 ± 0.6 
MTF 500 mM SrCl2 11.9 ± 0.4 
10 % Si-Vinyl 100 mM SrCl2 16 ± 4 
10 % Si-Vinyl 500 mM SrCl2 15.2 ± 1.3 
10 % Si-Vinyl C1 100 mM SrCl2 19.5 ± 1.1 
10 % Si-Vinyl C1 500 mM SrCl2 19.4 ± 1.3 
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Table VII-7. Sr/Ti atomic relative percentages of MTF with 100 and 500 mM SrCl2, MTF 
with 10 % of Si-Vinyl with 100 and 500 mM SrCl2 and MTF with 10 % of Si-Vinyl reacted 
with C1 MSA with 100 and 500 mM SrCl2 obtained from XPS measurements. 
 
 
 
 
 
 
Figure VII-12. XPS high resolution spectra of a) Ti and b) Sr of MTF with 100 mM 
SrCl2 and c) Ti and b) Sr of MTF with  500 mM SrCl2.   
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Figure VII-13. XPS high resolution spectra of a) Ti and b) Sr of MTF with 10 % of Si-Vinyl 
with 100 mM SrCl2 and c) Ti and d) Sr of MTF with 10 % of Si-Vinyl with 500 mM SrCl2.  
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Figure VII-14. XPS high resolution spectra of a) Ti and b) Sr of MTF with 10 % of Si-vinyl 
reacted with C1 MSA with 100 mM SrCl2 and c) Ti and d) Sr of MTF with 10 % of Si-vinyl 
reacted with C1 MSA with 500 mM SrCl2.  
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Figure VII-15. DRIFTS spectra of scratched films: a) MTF with 10 % Si-Vinyl, b) MTF with 
10 % Si-Vinyl and C1 MSA and c) MTF with 10 % Si-Vinyl and C1 MSA after contact with 
Sr2+. 
Figure VII-16 shows TEM images of the MTF with 10 % of Si-Vinyl (Figure VII-
16a), after the reaction with MSA (Figure 16c) and once the Strontium is complexed 
(Figure VII-16e). The structure and porosity of the films remain unaffected. The X-
Ray Reflectometry (XRR) measurements (Figure VII-16b, d and f) confirmed the 
porosity of 42 % for the three samples, meaning there are no changes in the 
structure of the films. On the other hand, the SAXS pattern of the MTF with 10 % of 
Si-Vinyl (Insert Figure VII-16a) showed a halo without defined dots. The elliptic 
shape of the pattern suggests the presence of multiple domains of locally ordered 
pores.[138] After the photoreaction with UV light, where functionalization of 
mesoporous surface with carboxylic groups takes place, characteristic dots are 
observed (Insert Figure VII-16c).  
The Pluronic F127® template is removed by immersing the film in ethanol. Although 
it is generally agreed that this method is not as efficient as the calcination, it could 
not be applied here because of the possibility of losing the vinyl groups. It is possible 
therefore that not all the surfactant molecules are removed from the mesoporous if 
the ethanol extraction method is used. Besides, during the reaction to attach the MSA 
to the vinyl groups, the film is exposed to UV light, which is another technique to 
remove surfactants from mesoporous films.[396–398] Thus, the appearance of dots in 
the SAXS pattern after the photoreaction may be due to the removal of remaining 
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surfactant upon extraction with ethanol. In Figure VII-15 the C-O-C stretch (1200 – 
1000 cm-1)[394] is identified for the MTF with 10 % of Si-Vinyl, and after the 
photoreaction the intensity of the peaks are reduced.  Calculated interplanar 
distances for MTF with 10 % of Si-Vinyl show an interpore distance of 15.12 nm and 
9 in the (-110) and (110) planes, meaning there is a 40.5 % volume contraction after 
the soft thermal process up to 200 °C.[305] After the click reaction the interpore 
distance decreases to 13.26 (-110 plane) and 7.92 nm (110 plane). No differences in 
the structure of the film are observed after this is exposed to the photoreaction or 
after the complexation with strontium.  
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Figure VII-16. Characterization of MTF with 10 % Si-Vinyl, reacted with C1 MSA and then 
with 100 mM SrCl2. Characterization through TEM (a, c and e), 2D-SAXS patters (insert in a 
and c) and XRR (b, d and f). 
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4.3.5. Sr2+ release study 
After 3h of reaction with 100 mM SrCl2, the total amount of Sr is calculated in MTF 
and MTF with 10 % of Si-Vinyl and MSA C1, which is of 6.06 ± 0.82 µg and 10.99 ± 
0.52 µg, respectively. The release of Strontium in PBS was monitored by ICP-MS 
(Table VII-9, Figure VII-17), showing fast release of the Sr from MTF (Figure VII-
17a). After 2h a plateau is reached at 70 - 80 % of the total Strontium inside the MTF 
being released. Importantly, the Sr release from the COOH-functionalized film is 
more progressive (Figure VII-17b). Initially a fast release takes place (2 hours) 
which is probably due to uncomplexed Sr, followed by a second phase that is much 
slower and over a week time, where a plateau in concentration is reached. The 
amount of Sr that is released after 7 days corresponds to 42 % of the initial Sr within 
the film.  
 
MTF V10 MSA C1 
Time Sr in the films (µg) Released Sr (%) Sr in the films (µg) Released Sr (%) 
0 6.06 ± 0.82 
 
10.99 ± 0.52 
 
15 min 3.80 ± 0.91 62.63 ± 11.58 8.63 ± 0.22 21.45 ± 1.98 
2 h 4.74 ± 0.21 78.24 ± 3.51 8.11 ± 0.15 26.17 ± 1.32 
8 h 4.63 ± 0.32 76.35 ± 5.20 7.89 ± 0.55 28.54 ± 4.96 
2 days 4.75 ± 0.33 78.45 ± 5.47 7.31 ± 0.40 33.52 ± 3.61 
7 days 4.61 ± 0.15 76.01 ± 2.50 6.30 ± 0.35 42.66 ± 3.16 
10 days 4.33 ± 0.52 71.43 ± 8.58 6.33 ± 0.50 42.37 ± 4.51 
Table VII-8. Total amount of Sr present in the substrates and the percentage of 
released Sr over time from MTFs and MTFs with 10 % of Si-Vinyl reacted with C1 
MSA previously immersed in 100 mM SrCl2 for 3 hours measured by ICP-MS. 
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Figure VII-17. Released strontium percentage over time from a) MTFs and b) MTFs with 
10 % of Si-Vinyl reacted with C1 MSA, previously immersed in 100 mM SrCl2 for 3 hours 
measured by ICP-MS. 
4.3.6. Biocompatibility and bioactivity evaluation 
Next, cell adhesion on MTFs was evaluated. The degree of initial adhesion of cells 
determines how fast the proliferation, migration and differentiation will proceed. 
Figure VII-18 and Figure VII-19 show Confocal Laser Scanning Microscopy (CLSM) 
images of MC3T3-E1 pre-osteoblastic cells cultured on MTFs with Sr and MTFs with 
10 % Si-Vinyl and C1 MSA with Sr, respectively. The vinculin is an adapter protein 
that is involved in the interactions between the focal adhesions (FA) of the cells and 
the extracellular matrix (ECM).[310,311,313,314] While, actin filaments (F-actin) are 
stained with phalloidin (shown in red), vinculin is stained with FITC (shown in 
green). The nucleus is stained with DAPI as shown in the merged images. Detailed 
inspection of F-actin filaments suggests that cells have a similar size when cultured 
on different substrates (compare second row in Figure VII-18 and Figure VII-19) 
even if they are compared with cells grown on MTF substrates (Figure IV-7 from 
Chapter 1). It must be noticed that Figure VII-18 and Figure VII-19 show cells with 
higher filopodia,[312] as compared to the cells grown on MTF substrates, although 
there is no significant difference in cell adhesion. The higher filopodia could be a 
consequence of the presence of Sr in the films. It is known that a good interaction of 
cell with a substrate leads to improved proliferation.[310,313] MC3T3-E1 pre-
osteoblastic cell proliferation experiments (Figure VII-20) shows an increased 
proliferation rate after 2 days of cell incubation between the glass substrates and 
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the MTF and MTF with 10 % Si-Vinyl and C1 MSA, both with Sr. After 3 days, there 
is no significant difference (p > 0.05) between the cell proliferation rate on MTFs 
substrates and MTFs with Sr. However, MTF with 10 % Si-Vinyl C1 MSA and Sr show 
a higher proliferation rate of cells (p < 0.05), as the amount of Sr released from the 
COOH-functionalized film is higher (Table VII-8). After one week, cells reach 
confluence, so, no differences are observed (Figure VII-20).  
AP activity after 5 days remains constant for the three substrates (Figure VII-21), 
but after 10 days, the substrates containing Sr exhibited larger number of 
differentiated cell. After 15 days of culturing in osteogenic medium the differences 
between Sr-doped MTF and MTF with 10 % Si-Vinyl and C1 MSA with Sr are more 
pronounced, which is due to higher amount of Sr released from the second 
substrates that also occurs in a more progressive manner. As expected, after 20 days, 
the difference between the two substrates containing Sr is no longer appreciable 
.[399–402] 
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Figure VII-18. CLSM images of vinculin (first row), actin (second row), the merge of the 
actin, the vinculin and the nucleus (third row) and the zoom of the merge image (fourth 
row) at 2 h (first column), 24 h (second column) and 48 h (third column) of growth of 
MC3T3-E1 cell line on MTF with 100 mM SrCl2 substrates at 63x. 
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Figure VII-19. CLSM images of vinculin (first row), actin (second row), the merge of the 
actin, the vinculin and the nucleus (third row) and the zoom of the merge image (fourth 
row) at 2 h (first column), 24 h (second column) and 48 h (third column) of growth of 
MC3T3-E1 cell line on MTF with 10 % of Si-Vinyl reacted with C1 MSA with 100 mM SrCl2 
substrates at 63x. 
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Figure VII-20. Proliferation of MC3T3-E1 pre-osteoblasts cultured on MTF, MTF with 100 
mM SrCl2 and MTFs with 10 % of Si-Vinyl reacted with C1 MSA with 100 mM SrCl2 substrates 
for 1, 2, 3 and 7 days. * means the difference is statistically significant.  
 
 
Figure VII-21. Alkaline phosphatase activity after 5, 10, 15 and 20 days of MC3T3-E1 pre-
osteoblastic cell culture in osteogenic medium on MTF with 100 mM SrCl2 and MTFs with 
10 % of Si-Vinyl reacted with C1 MSA with 100 mM SrCl2 substrates. * and ** mean the 
differences are statistically significant. 
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4.4. Conclusions and perspectives 
In this chapter, direct incorporation of readily available COOH groups to 
mesoporous silica and titania thin films was demonstrated. Two different 
carboxylated organosilanes obtained by PRTEA were used, demonstrating the 
easiness of this reaction and the versatility of the chosen protocol to incorporate 
organic functions. Moreover, the two templates (F127 and Brij 58) used in the 
process showed identical successful results. Structural characterization 
demonstrated the generation of mesoporous phases whose degree of ordering 
depends on the amount of added organosilanes. In particular, low organosilane 
concentrations result in a body-centered cubic mesoporous ordering, whereas 
higher concentrations generate locally ordered structures. The incorporation of 
functional silanes was clearly demonstrated by XPS, showing that around 30 % of 
the nominal organosilane concentration is incorporated within the films. 
The presence of COOH groups on the pore surface is confirmed by infrared 
spectroscopy alongside with its availability for further chemical modification. Clear 
changes in the typical carbonyl signals during proton interchange and metal 
complexation experiments were observed, indicating that chemical reactions can be 
performed on the modified mesoporous structure. 
The proposed simple methodology allows for the synthesis of COOH-modified silica 
thin films in one step, without the need of harsh reaction conditions or deprotection 
steps. Moreover, as the material is obtained as a thin film, it can be easily 
incorporated in reaction media and/or integrated into devices. As COOH groups are 
expected to serve as binding sites for more complex molecules, such as proteins, 
enzymes, or ions, the presented results pave the way toward applications of such 
COOH-modified films, for example, as sensors or drug-delivery devices. 
The synthetic pathway is extended to the functionalization with carboxylic groups 
of mesoporous titania films. A two-step synthesis is followed, with a pre-
functionalization through co-condensation with VTMS, functionalizing the 
mesoporous films with vinyl groups. Films containing 10 and 20 % of organosilane 
have been synthesized. After the click reaction with MSA it has been demonstrated 
that the incorporation of COOH groups is the same for films containing a 10 or a 20 
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% of VTMS, so further experiments were performed with the first ones. Films have 
been shown to have locally ordered mesoporous structure. 
Sr2+ complexation studies have shown that the amount of Sr embedded in the films 
containing COOH groups is the double than in bare MTFs. Moreover, and more 
importantly, the release profile of the Sr is more prolonged during time, which helps 
in the differentiation process. The release also shows an initial burst release which 
would help to enhance pre-osteoblast cell attachment and proliferation processes. 
Even if there are no appreciable differences in cell attachment if results are 
compared with MTFs with Sr, the proliferation rate is improved in the 3rd day of 
culture and the differentiation is also enhanced at day 15.  
If the obtained results are compared to the ones obtained in Chapter 3 for SrTiMFs, 
it can be concluded that this new approach offers a coating with higher Sr amount; 
10.99 µg vs. 2.29 µg. Besides, the synthetic approach followed to obtain SrTiMFs is 
simpler than the one to synthesize COOH-functionalized titania films. 
This chapter shows the possibility to complex bioactive ions in MTFs containing 
larger surface areas that titania surfaces to increase the interaction surface with the 
media and enhance ion release to obtain more effective results in pre-osteoblast 
proliferation and differentiation. 
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VIII. GENERAL CONCLUSIONS 
Overall the research conducted in this thesis is focused on the functionalization of 
mesoporous titania films combining the use of antibiotics, growth factors and 
bioactive ions. Mesoporous films containing strontium and available carboxylic 
groups have been synthesized through spin coating and the EISA method. These 
films charged with antibiotics have demonstrated to be effective against S. aureus 
colonization and have been proven to promote implant osseointegration through 
pre-osteoblastic MC3T3-E1 cell proliferation and differentiation enhancement. 
Summing up the results from each chapter, the following conclusions can be drawn: 
In Chapter 1, mesoporous titania films with a porous volume of 30.7 % were 
synthesized. They were used for the encapsulation of gentamicin and surface 
functionalized with rhBMP-2. Due to the porous structure of the film the gentamicin 
undergoes a progressive release; within the first 6 h the 36 % of the gentamicin was 
released, but then a second release phase lasting weeks took place. This gentamicin 
release kinetics is optimal for antibiotic administration after a surgery; moreover, 
the localized release of gentamicin avoids the problems from a low drug 
concentration at the implant site when antibiotics are administered orally.  
The presence of the gentamicin and rhBMP-2 has been demonstrated with XPS and 
contact angle measurements. The combination of both resulted in an optimal 
coating for titanium implants. The release of gentamicin prevents S. aureus 
proliferation on the film surface, and the rhBMP-2 can enhance implant 
osseointegration and counteract negative side effects of gentamicin on cell 
proliferation.  
In Chapter 2, a PEM based on PLL and PAA-gentamicin complexes has been 
assembled on top MTFs. The complex synthesis has been optimized in order to 
obtain complexes with stable size while the LbL assembly is conducted. Complexes 
for the PEM assembly were prepared in 500 mM NaCl at pH 4.5 by mixing 0.3 mg 
mL-1 gentamicin and 1 mg mL-1 PAA. These complexes were assembled alternatively 
on top of MTFs with PLL. In total 4 bilayers were deposited. The PEM showed an 
exponential growth, which can be related to the ‘island model’ of growth of PEMs 
described in previous works. The PEM is stable till pH 13, but at physiological pH 
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progressively releases the gentamicin. The release mechanism shows an initial burst 
release followed by a progressive release lasting weeks. 
The PEM was effective against S. aureus infection, compared to the control, which 
consisted of a glass coverslip immersed in gentamicin, 3 orders of magnitude less of 
bacteria were able to form colonies. 
In Chapter 3, hybrid mesoporous films have seen prepared by incorporation of 
strontium chloride to the solution used for the synthesis of MTFs. The resulting 
SrTiMTFs had a 20 % of Sr, which was homogeneously distributed in the films 
structure. Due to the presence of pores, the surface area available for the 
interchange of ions is larger, thus, a high amount of Sr can be released to the media 
in contact with the film. The 44 % of the Sr present in the films is release after 8 h, 
and this enhanced MC3T3-E1 pre-osteoblastic cell adhesion to the surface. Cells 
resulted to show higher filopodia with more defined stress fibers, moreover, cell 
differentiation is increased in a 100% compared to cells grown on top of MTFs. 
This chapter demonstrated the possibility to incorporate bioactive ions in the 
mesoporous structure and the effectiveness they have in promoting cellular 
processes. 
In Chapter 4, the surface of pores in MTFs has been functionalized with carboxylate 
groups for complexing and delivering Sr. First, mesoporous silica films containing 
available COOH groups have been synthesized in one-step synthesis. Carboxylated 
organosilanes have been prepared by PRTEA, and have been incorporated to the 
solution containing the silica precursor and the structure directing agent. The 
incorporation of the silanes in the silica films has been demonstrated by XPS 
measurements and the presence of the carboxylates through IR measurements. Pb2+ 
has been proven to be complexed by changes in the carbonyl band signal. 
Then, mesoporous titania films functionalized with COOH groups on the pore 
surface are synthesized in two-step synthesis. VTMS is co-condensed with the Ti 
precursor, and then, after film synthesis, through post-grafting, MSA reacts with the 
vinyl groups by click chemistry. Sr2+ complexation studies and the presence of COOH 
groups have been conducted by IR and XPS measurements. The release of Sr has also 
been followed. The release profile shows an initial burst release at initial times, 
followed by a prolonged release. The release helps in the initial cell adhesion to the 
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implant surface, followed by an enhanced proliferation rate, which is higher 
compared to cells cultured on top of MTF from day 3. This methodology allows the 
synthesis of COOH-modified mesoporous titania films. This COOH groups can serve 
as binding sites for ions or more complex molecules, such as drugs or proteins. 
Overall, the versatility of mesoporous substrates has been demonstrated. It is 
possible to tune the mesoporous structure and pore orientation by changing the 
structure directing agent. Also the thickness can be modified by changing the 
spinning or dipping settings, and lastly, is also possible to synthesize hybrid 
mesoporous films to endow the films with a wide range variety of functionalities. By 
tuning the synthesis of the mesoporous films different amount of molecules can be 
entrapped inside the pore structure and the inner surface area can be enhanced to 
obtain a larger interchangeable surface.  
To conclude, this thesis has highlighted the potential of mesoporous titania films 
functionalized through different approaches to induce a good osseointegration of 
implants and prevent bacterial infections. 
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